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Abstract 
This thesis presents an analysis of the relationship between single nucleotide 
polymorphism (SNPs) and protein–protein interactions. The aim of the thesis is to 
investigate the distribution of non-synonymous single nucleotide polymorphism 
(nsSNPs) in terms of their locations in the protein core, at the protein–protein interface 
sites and on the other areas on the protein surface. The analysis used experimentally 
verified human protein–protein interactions and nsSNPs from the UniProt humsavar 
database. A further investigation was performed on a larger SNP dataset from the 1000 
Genomes Project (1KGP). Both investigations identified a significant preference for 
disease-causing SNPs to occur at the protein interface compared to other areas on the 
protein surface. The three-dimensional structures of protein–protein interfaces were 
examined in order to propose stereo-chemical explanations for the disease-causing 
effect of nsSNPs in the humsavar dataset. In addition, three methodologies (i.e., usage of 
SNP server, structural analysis and usage of GMAF) that could help identify pathogenic 
variants were presented. Structural analysis was also performed on non-disease-
causing SNPs in order to investigate their possible effects on protein–protein 
interactions. The result showed that some of the previously classified non-disease-
causing SNPs could potentially be disease-causing SNPs. The myVARIANT program was 
developed. The program obtains SNPs from 1KGP, maps them to structures, evaluates 
their distribution on structures and performs a structural analysis. In conclusion, the 
thesis demonstrates the important role that protein–protein interactions play in disease 
pathogenesis. 
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1 Introduction  
This thesis describes a study of the relationship between non-synonymous single 
nucleotide polymorphisms (nsSNPs) and protein–protein interactions (PPIs). The 
primary aim of this thesis is to investigate the distribution of nsSNPs in terms of their 
location in the protein core, at protein–protein interfaces and on the protein surface. In 
addition, the thesis also aims to explain, from a structural point of view, how nsSNPs 
that occur at the interface can affect protein–protein interactions.  
In this chapter, relevant previous work on SNPs and PPIs is reviewed. For SNPs, the 
differences between coding SNPs and non-coding SNPs, synonymous SNPs (sSNPs) and 
non-synonymous SNPs (nsSNPs), as well as conservative SNPs and non-conservative 
SNPs are explained. Methods of detecting SNPs and the influence of SNPs studies on 
disease treatment and drug development are discussed. The various SNPs data sources 
are also reviewed. For the PPIs, the different types of PPIs are examined. PPIs detection 
methods, both experimentally and computationally, are reviewed. The various PPIs 
databases are discussed. Furthermore, recent advances in the field of SNPs research are 
discussed in the context of protein structure and protein–protein interactions. Finally, 
the scope of the thesis is presented.  
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1.1 Single Nucleotide Polymorphism (SNPs) 
A single nucleotide polymorphism (SNP) is defined as a single variation in the 
nucleotide sequence of DNA that may or may not affect an organism’s phenotypic 
characteristic. According to Brookes (1999), a working definition of a SNP is that it is a 
single base change in genomic DNA where the sequence alternatives exist in normal 
individuals and the least frequent allele has a frequency of at least 1%. However, as 
pointed out by Cavallo and Martin (2005), often the term SNP is applied in a more 
general context to include any single base variant that is observed and may be 
associated with a disease. In this thesis, the general use of the term SNP will be used. In 
the human population, more than 99% of the DNA is shared and SNPs account for 90% 
of the 1% that differs (Fairweather-Tait et al., 2007). SNPs affect how an individual 
responds to diseases (Wellcome Trust Case Control, 2007), drugs (Ma and Lu, 2011) 
and environmental factors (Bresciani et al., 2013). On average, human DNA consists of a 
SNP for every 300 bases (Nelson et al., 2004). This means that for the whole genome (3 
billion bases) there would be roughly 10 million SNPs. More than 60,000 SNPs are 
located in the coding regions of the genes (Sachidanandam et al., 2001). 
1.1.1 Types of SNPs 
A SNP can be categorised according to its location in the genome: in coding-regions of 
genes, in non-coding regions of genes or in the intergenic regions. The majority of SNPs 
occur in non-coding regions (Syvanen, 2001). However, SNPs that do occur in coding 
region are important because they can affect a variety of important biological and 
molecular activities such as stability (Casadio et al., 2011), expression level (Heinzen et 
al., 2012) and protein function of (Chasman and Adams, 2001). Nonetheless, recent 
studies (Ward and Kellis, 2012, Visel et al., 2010, Prado-Montes de Oca et al., 2009) have 
shown that SNPs in non-coding regions may still affect other activities such as gene 
splicing, gene expression and the sequence of non-coding RNA.  
Out of the estimated 10 million SNPs, only 3–5% are located in the coding region; half of 
these cause amino acid substitutions, termed non-synonymous SNPs (nsSNPs) (Cargill 
et al., 1999). SNPs in coding regions are classified according to their effects. A 
synonymous SNP (sSNP) is a SNP that does not change the amino acid sequence of a 
protein while a non-synonymous SNP (nsSNP) does alter it. It has been suggested that 
20 
 
that 20% of nsSNPs could potentially damage proteins (Sunyaev et al., 2001). An nsSNP 
can be either missense or nonsense. A missense nsSNP results in a different amino acid, 
while a nonsense nsSNP change results in a premature stop codon. A missense nsSNP 
can either be a conservative or non-conservative change. A non-conservative change 
results in a different residue with substantially different physicochemical properties. 
For example, if a DNA sequence codes for lysine, a conservative change may result in 
arginine. However, under a non-conservative change, a protein with neutral side-chain 
charge might be produced.  
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1.1.2 The importance of SNPs  
SNPs are used in a wide range of studies including estimating the predisposition to a 
disease (Voronko et al., 2008), predicting specific genetic traits (Yip and Lange, 2011), 
acting as a biological marker for complex diseases (Stefansson et al., 2009), predicting 
drug efficacy (Giacomini et al., 2007) and tracking ancestral migration (Underhill and 
Kivisild, 2007). 
In a complex disease, a single substitution affects the predisposition that an individual 
has towards a certain disease (Thomas and Kejariwal, 2004). For example, 
apolipoprotein (ApoE) is a gene that has been associated with Alzheimer’s disease. 
There are three SNP alleles for the ApoE gene: E2, E3 and E4. A study (Corder et al., 
1994) has shown that if a person has the E4 allele, the risk of developing this disease is 
higher. However, if a person has the E2 allele, the risk of developing this disease is 
lower.  
Additionally, an earlier study found that SNPs can be used as biological markers since 
they can occur near disease genes (Shastry, 2002). This study also reports that SNPs 
tend to be evolutionary stable, thus helping researcher in mapping the genome for 
disease or traits.  
Association-based studies compare genetic samples of diseased people with unaffected 
people. Once a comparison has been made, researchers can find patterns that exist in 
the diseased patient. This can lead to the development of a SNP profile for a specific 
disease. 
Drug efficacy and toxicity can also be influenced by SNPs (McCarthy and Hilfiker, 2000, 
Ma and Lu, 2011, Deenen et al., 2011, Aithal et al., 1999). Adverse side effects of 
warfarin have been reduced by the identification of SNPs in enzymes involved in 
warfarin drug action (Kim et al., 2009). Aithal et al. (1999) have shown a strong 
association between CYP2C9 variant alleles and warfarin dose requirement. Patients 
carrying the CYP2C9*2 and -*3 alleles have a reduced capacity for metabolizing 
warfarin, resulting in an over-anticoagulation at standard doses. This suggests that if a 
person with SNPs in the CYP2C9 gene is taking warfarin, the person has a higher chance 
of having an adverse drug reaction compared to the population. Similarly, if a person 
carries the 1173T/T allele (VKORC1), the person requires approximately half of the 
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warfarin daily dose compared with patients with an 1173C/C allele (Ma and Lu, 2011). 
In contrast, polymorphisms in the coding regions of VKORC1 often lead to varying 
degrees of warfarin resistance, necessitating high doses of warfarin to reach a desired 
INR value in these patients (Huang et al., 2010).  
Furthermore, Deenen Maarten J, et al. (2011) analysed the relationship between SNPs 
and the toxicity and efficacy of capecitabine in colon cancer patients. Capecitabine is a 
chemotherapeutic agent used in the treatment of colorectal cancer. It is a prodrug, that 
is enzymatically converted to 5-fluorouracil in the tumour, where it inhibits DNA 
synthesis and slows growth of tumour tissue. They explored the effect of 
dihydropyrimidine dehydrogenase (DPYD) SNPs on capecitabine and observed that two 
variants in DPYD (IVS14+1G>A and 2846A>T) affect the toxicity to capecitabine. 
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1.1.3 SNPs identification  
In recent years, different methods have been developed to detect SNPs. Many of these 
methods can be grouped into two categories: scanning a sequence for unknown SNPs or 
genotyping for known SNPs. Examples of the former are denaturing high performance 
liquid chromatography (DHLPC; (Yu et al., 2001) and direct DNA sequencing (Berg et al., 
1995). The methods used for the latter primarily are microarray genotyping (Maskos 
and Southern, 1992) and mass spectrometry (Ross et al., 1998).  
DHLPC uses a modified resin and high-performance liquid chromatography (HPLC) for 
fragment analysis. It is based on DNA heteroduplex formation. At a high temperature, 
the DNA fragments will be separated resulting in partial denaturation. Heteroduplexes 
(mismatches) are separated from their counterpart homoduplexes because of the 
difference in retention time. Although the DHLPC method is fast and has high sensitivity, 
it cannot determine the location where the variation occurs (Teng et al., 2008).  
Another method to identify unknown SNPs is direct DNA sequencing (Kwok and Duan, 
2003). Just like DHLCP, direct DNA sequencing is fast and has high sensitivity (Hattori et 
al., 1992). In addition, it provides complete information for each variant (e.g., location 
and sequence context). Direct DNA sequencing technique uses a DNA sequencer to 
analyse the product of a polymerase chain reaction. The output is a fluorescent peak 
trace, and base-calling software is used to assign the DNA sequence automatically.  
The use of microarrays to detect SNPs is called a SNP array. The principle behind a SNP 
array is simple; complementary nucleotides bind to each other. In general, it involves a 
combination of DNA hybridization, fluorescence microscopy and solid surface DNA 
capture. First, fragments of single stranded DNA (ssDNA) are immobilised to a solid 
surface. Then, this fragment is hybridized with thousands of unique nucleotide probes. 
If the probe and the single-stranded DNA (ssDNA) are complementary, they will bind. 
Once hybridisation is completed, the hybridized probes will have different intensities 
and colours. A specialized machine is then used to capture and measure these 
intensities. The underlying principle is that the signal intensity depends upon the 
amount of target DNA in the sample, as well as the affinity between the target and the 
probe (Laframboise et al., 2007). Then, these measures are processed, analysed and 
output as SNP genotype inferences. 
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Mass spectrometry (MS) is a technique used to measure the molecular weight of 
particles formed. An example of MS is the matrix-assisted laser Desorption-ionisation-
time of Flight (MALDI-TOF; (Karas and Hillenkamp, 1988). Since MS determines this 
fundamental property of a molecule, no labels are needed. A previous study (Ross et al., 
1998) demonstrates that high resolution MS can easily distinguish between DNA 
molecules that differ by one base. The authors also observed that it takes only 
milliseconds to analyse each sample. Furthermore, the authors suggest that by properly 
designing the probes, moderate multiplexing is possible (Ross et al., 1998).  
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1.1.4 SNPs databases  
Currently, there are several SNP databases available, each with different objectives. 
Examples of these are dbSNP (Sherry et al., 2001), UniProt humsavar (Wu et al.) and the 
1000Genome Project (Consortium, 2012). Almost all of the known SNPs data are stored 
in the dbSNP database hosted by the National Center for Biotechnology Information 
(NCBI). The goal of dbSNP is to act as a primary database containing all known genetic 
variations, including the location in the chromosome, the allele frequency, the 
associated literature and the sequencing machine used.  
UniProt humsavar is a manually curated list of SNPs in human protein developed by the 
UniProt consortium. The information comes from the literature, and the SNPs have been 
mapped to protein sequences. This provides researchers working in the proteomics 
field valuable data in allowing investigation into relationship between SNPs and 
proteins. The humsavar list consists of information such as the amino acid changes, the 
variant location in the protein sequence, the associated protein, the dbSNP identifier (if 
it exists) and the variant disease status (whether it is a disease-associated variant or 
not). All of the SNPs in the humsavar list are non-synonymous SNPs (nsSNPs). The 
disease variant status is based on literature reports of disease association from the 
Mendelian Inheritance in Man (OMIM; (Hamosh et al., 2005). The OMIM database 
started as a catalogue of known Mendelian inherited diseases known to occur in human. 
An important aspect of OMIM is that researchers and experts manually curate it 
resulting in a comprehensive catalogue of gene-disease information. The OMIM 
database provides the number of samples used, the sample extraction method, the 
sample background (such as gender and ethnicity) and the position of the mutation. The 
polymorphism status refers to SNPs that do not have disease association information in 
OMIM but have been found to change the amino acid sequence. This information is 
useful for researchers performing variant filtering, for example in exome sequencing. A 
researcher or a clinical geneticist who examines an exome sequencing result can use the 
polymorphism information to filter out SNPs even though their frequency may be low.  
The 1000 Genome Project (1KGP) is an international research collaboration focusing on 
genetic variation in humans (Consortium, 2012). There are two goals of 1KGP. The first 
is to create a comprehensive database of human genetic mutations including 
synonymous SNPs, non-synonymous SNPs, insertion-deletion, copy number variation 
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(CNV) and many other types of human variation. This vast amount of information is 
especially useful for researchers performing genome-wide association studies. The 
project aims to include related information such as population frequencies, variant 
haplotypes and linkage disequilibrium patterns.  
The second goal aims to make improvement to the existing human reference sequence 
(Tsui and Waye, 2005). As shown by Rosenfeld et al (2012), the human reference 
genome, which was based on 13 samples (Henriksen, 2010), did not consider the high 
level of variation between individuals. Because of the 1KGP, genotyping platforms will 
have better SNP and probe selection for future association studies. Furthermore, the 
1KGP database will be a useful tool to study variation in different populations and 
further our understanding of the underlying processes of mutation. Using the latest 
genotyping technologies, the pilot project successfully sequenced 1000 genomes in 
2010. The 1000 Genome Project also contains other types of structural variants such as 
CNVs and microsatellites.  
Other than the above mentioned databases, there also specialized SNP databases that 
look at mutations on a specific gene, such as the IARC TP53 database (Petitjean et al., 
2007), or a specific medical condition, such as the G6PD deficiency database (Kwok et 
al., 2002). The former database compiles all genetic variations that have been reported 
in TP53. The database contains annotations on the functional properties of mutant 
proteins and the functional properties that contribute to the occurrence of mutational 
"hotspots" in different cancer types and to the phenotypes of tumours. The latter is a 
database that provides insights into the molecular aspects of Glucose-6-phosphate 
dehydrogenase (G6PD) deficiency and facilitates the understanding of the structure and 
function relationships of the enzyme. The G6PD gene affects cell growth and 
proliferation (Tian et al., 1998). The G6PD deficiency predisposes individuals to 
haemolysis, which is a spontaneous destruction of red blood cells that results in a 
yellowish pigmentation of the skin and eye in response to a number of triggers, such as 
certain foods, illness or medication. The G6PD database uses mutational and structural 
data from various genetic and structural databases to identify mutations that distort 
secondary structure and destroy hydrogen bonding and electrostatic interactions.  
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1.2 Protein interactions 
PPIs play a critical role in many of the processes inside a cell such as transcription, 
translation, cell cycle control, secretion, and organization of enzymes (Jang et al., 2006). 
Active proteins often interact with partner proteins or bind to other proteins resulting 
in protein complexes. In order to obtain a comprehensive understanding of the 
biological function of proteins, their interactions need to be understood. 
1.2.1 Type of interactions  
A previous study (De Las Rivas and de Luis, 2004) has classified the different types of 
protein–protein interactions into three categories: co-interacting proteins, correlated 
proteins and co-located proteins.  
Co-interacting proteins are defined as two or more proteins that undergo physical 
interactions. The interactions can be divided into two sub-groups, permanent (obligate) 
and transient interactions (De Las Rivas and de Luis, 2004). The former refers to the 
formation of a stable protein complex that carries out a biomolecular role, while the 
latter only carries out a biomolecular function under certain cellular conditions and 
usually the interactions are temporary.  
Correlated proteins do not undergo physical interactions; instead, they are involved in 
the same biomolecular activity. This group can be divided into two sub-groups: 
metabolic and genetic correlations (De Las Rivas and de Luis, 2004). For metabolic 
correlation, proteins are involved in the same metabolic pathway. For genetic 
correlation, proteins are not involved in the same metabolic pathway, but they are 
encoded by co-expressed or co-regulated genes. 
Co-located proteins are proteins that function in the same cellular compartment (De Las 
Rivas and de Luis, 2004). Compartments can be distinguished as either a soluble 
location (same cellular soluble space) or membrane location (same cellular membrane).  
  
28 
 
1.2.3 PPIs detection 
In recent years, many methods have been reported that detect protein–protein 
interactions. The following are some examples.  
One of the most common in vivo methods is the yeast two-hybrid technique (Y2H) by 
Fields and Song (1989). In Y2H, only physical interactions between proteins are 
considered. In the study, they used the GAL4 transcriptional activator in yeast to 
implement this technique. The Y2H technique consists of two distinct domains: a 
binding domain (BD) and an activating domain (AD). The former directs binding to a 
DNA promoter and acts as bait. The latter is involved in the activation of transcription 
and acts as prey. The authors took the protein of interest and fused it to the BD, forming 
a chimeric protein. Then, they cloned the chimeric protein before transfecting it into a 
yeast cell. The same procedures were repeated for another protein of interest but fused 
to the activating domain. If the reporter gene is activated, the two proteins were 
identified as interacting.  
For in vitro experiments, co-immunoprecipitation (Co-IP) is widely used in PPIs to 
determine previously unknown interactions or interacting partners (Phizicky and 
Fields, 1995). The objective of Co-IP is to extract a protein complex of interest from 
solution using an antibody. In solution, a target antigen (i.e., the protein of interest) 
binds with an unknown protein (e.g., ProteinA) forming a complex. An antibody that 
specifically targets the antigen is added to the solution. This makes the antibody bind to 
the antigen-proteinA complex. Through centrifugation, the complex can be removed 
from the solution for further analysis. If an unknown or an associated protein co-
precipitated, this may indicate that the protein has a function related to the target 
antigen. 
Another way to determine if two proteins interact is by predicting PPIs. An example of 
this is gene fusion; two proteins from an organism are predicted to interact if 
orthologous domains are found within a single gene in another organism (Enright et al., 
1999). For example, it is not known if two proteins (protein A and protein B) interact in 
human. However, domain orthologues for protein A (e.g., domain A′) and protein B (e.g., 
domain B′) are part of a single gene from another organism. Thus, the interaction 
between protein A and protein B in human is inferred.  
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1.2.4 Databases of protein-protein interactions (PPIs) 
Several PPI databases have been developed in recent years. Some of them are described 
below. 
The Human Protein Reference Database (HPRD) 
The Human Protein Reference Database (HPRD) is a manually curated protein database 
based on experimental protein–protein interaction results (Peri et al., 2003). The HPRD  
provides details including the proteins involved, the types of interactions they make, 
their association with disease, their location in the cell, tissue expression and their Gene 
Ontology (Ashburner et al., 2000) classification. In addition, for each of the interactions, 
their associated reference is given. Currently, HPRD gives information for each protein 
isoform including the DNA and protein sequences of the isoforms. Each protein is linked 
to GenProt Viewer. a genome browser that allows protein and transcript information to 
be visualized in the context of the relevant gene (Mishra et al., 2006). Each protein is 
also linked to its 3D structure in the Protein Data Bank (PDB) if available (Berman et al., 
2000). Researchers can contribute to the development of HPRD annotation by becoming 
a “Molecule Authority”; they can post comments or corrections on any annotation if they 
consider the annotation to be incorrect. 
IntAct 
The IntAct database contains manually curated protein interaction information derived 
from peer-reviewed publications (Aranda et al., 2009). A researcher can search the 
IntAct database for interactions by using the UniProt protein identifier. The interaction 
information given consists of proteins involved, detection methods, interaction type, 
confidence value and species from which the proteins originated, since it is not limited 
to human protein interactions. When a user searches the IntAct database for a 
particular protein, all the isoforms for that protein will be shown. Currently, six 
manually curated specialized datasets have been created from the original IntAct 
database. These specialized datasets have specific objectives: Alzheimer’s, cancer, 
complexes, cyanobacteria and chromatin. For example, the cancer dataset is a subset 
from the original IntAct dataset consisting of only cancer-related interactions. 
 
30 
 
The Database of Interacting Proteins (DIP) 
The Database of Interacting Proteins (DIP) is a database that derives PPI information 
from manual curation (experimentally determined PPIs) and computational approaches 
(predicted PPIs; (Xenarios et al., 2002, Salwinski et al., 2004). DIP has its own 
visualization tool, JDIP, which provides a graphical representation of the interactions. 
The DIP also accepts submission from predicted PPIs originating from computational 
approaches, which enables the use of high-throughput experiment data. In order to 
evaluate these high-throughput PPIs data, three related services were developed by 
DIP: the paralogous verification method (PVM), expression profile reliability (EPR), and 
domain pair verification (DPV; (Mathivanan et al., 2006). Each service evaluates the 
interaction information differently; PVM uses paralogous interactions, EPR uses 
common expression profiles of interactors and DPV uses domain–domain interaction 
preferences (Mathivanan et al., 2006).  
The Molecular INTeraction database (MINT) 
The molecular interaction database (MINT) consists of experimentally verified PPIs that 
are manually curated from scientific literature (Ceol et al., 2010). It is isoform specific, 
thus different isoforms of the same protein can have a different number of interactions. 
The types of interactions used in MINT are derived from the Proteomics Standards 
Initiative-Molecular Interaction (PSI-MI) standards (Hermjakob et al., 2004): a physical 
interaction, a direct interaction or a co-localization (Ceol et al., 2010). Unlike other PPI 
databases, MINT provides a user with the ability to evaluate the reliability of an 
interaction. This is done using the MINT confidence score (Ceol et al., 2010). A more 
detailed discussion of the MINT scoring system is given in section 1.2.5. A user can 
search the MINT database using a UniProt identifier, a gene name or a PubMed 
identifier. The subsequent results page shows the interacting partners, the PDB 
structure for the protein, the MINT confidence score, type of interactions and OMIM 
links if there are any diseases associated with the query protein. 
The Microbial Protein Interaction Database (MPIDB) 
The microbial protein interaction database (MPIDB) database is a manually curated PPI 
database that is derived from experimentally determined PPI information in 
microorganisms (Goll et al., 2008). The database can be searched either by UniProt 
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protein identifier or by species name. The MPIDB includes information such as the 
proteins involved in the interactions, the methods used in generating the interactions, 
the associated publications and the types of interactions. In the MPIDB, the types of 
interactions can be divided into three categories; these are experimental evidence, 
evidence from interologs and evidence from domain–domain interactions. An interolog 
refers to a conserved interaction between two proteins that have interacting homologs 
in another species (Walhout et al., 2000). 
MatrixDB 
MatrixDB is a manually curated database that focuses on the interactions of 
extracellular proteins and polysaccharides (Chautard et al., 2009). In MatrixDB, the 
multimeric nature of proteins is taken into consideration. It stores experimental data 
from laboratories, literature and other PPI databases. It incorporates interaction data 
from all model organisms. The database can be searched using UniProt identifier, 
protein name or gene name. In the latest version of MatrixDB (Chautard et al., 2011), 
researchers can perform customized queries and build tissue- and disease-specific 
interaction networks that can be visualized and analysed with Cytoscape, a network 
visualization tool (Shannon et al., 2003).  
BioGRID 
BioGRID is a database that consists of comprehensive collections of physical and genetic 
interactions or a combination of the two interactions (Stark et al., 2006). It combines 
interactome data (from all organisms) from both high throughput experiments and 
manual curation of scientific literature. In the BIOGRID database, a physical interaction 
refers to any physical interaction between two proteins or any co-existence in a 
complex. Correspondingly, a genetic interaction refers to how one gene affects another. 
For example, when a gene is over-expressed and causes lethality in conjunction with 
another gene, a genetic interaction is inferred (Stark et al., 2006). The BIOGRID 
database is isoform specific, so different protein isoforms can have a different number 
of interactions.   
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1.2.5 The Human Interactome Database  
Recently, researchers from the Structural Bioinformatics and Network Biology in 
Barcelona developed a Human Interactome Database (Stein et al., 2011). This database 
is composed of experimentally verified interactions reported in the literature and from 
inferred interactions. The database consists of interactions from the seven PPI 
databases described in the previous section (1.2.4). Databases from the IMEx 
consortium (an international collaboration between major public interaction data 
providers who have agreed to share curation efforts) were given priority, owing to their 
common curation standard. In order to avoid duplication of interactions, the 
interactions were chosen on a per publication basis - curation level, references to the 
major protein databases and the controlled vocabulary used.  
According to Ceol et al. (2010), owing to experimental false positives, which often occur 
in high-throughput experiments and different sensitivity or specificity of experimental 
setups, a MINT confidence score (S) was proposed (see Equation 1). The score is used to 
reflect the quality of literature evidence supporting an interaction. This score is 
calculated as a function of the cumulative evidence (x) according to the formula in 
Equation 1. Ceol et al. (2010) argued that, a, determines the initial slope of the curve 
between MINT score and combined experimental evidence . This value was chosen so 
that the function has a suitable dynamic range and only well-supported interactions 
obtain a value close to one (Ceol et al., 2010). A certain confidence threshold is set in 
order to define high quality interactions; in this case, the authors chose the threshold to 
be ≥0.72 (Ceol et al., 2010). 
Equation 1: The equation for the MINT confidence score (S) (the equation is taken 
from (Ceol et al., 2010) 
 
 
 
Equation 2: The equation for the experimental evidence in the MINT score (the 
equation is taken from Ceol et al., 2010) 
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Equation 2 gives the equation for calculating the experimental evidence (x). Ceol et al. 
(2010) calculated the experimental evidence by summing all the experimental evidence 
weighted according to experiment scale (d), the type of interaction (e), the sequence 
similarity of orthologues (h) and the number of publications (n) for each interaction. 
For experiment scale (d), if an article reports more than 50 interactions, the experiment 
in the article is considered large-scale and is assigned a coefficient of 0.5. For a smaller-
scale experiment (less than 50 interactions), it is assigned a coefficient of 1.0. For the 
type of interaction (e), if the interaction is a direct interaction (e.g., yeast two hybrid) it 
is assigned a coefficient of 1.0. However, if the interaction is not a direct interaction (e.g., 
co-immunoprecipitation), it is assigned a coefficient of 0.5. For the sequence similarity 
of orthologues (h), according to Ceol et al. (2010), if the interaction was inferred from 
orthologues in a model organism, the Inparanoid (O'Brien et al., 2005) confidence value 
will be used and multiplied. In cases where there were protein isoforms, the longest 
isoform was chosen. In order to increase the number of interactions, the authors 
included interactions resulting from the inheritance by orthology method. That is, if an 
interaction was detected in an organism, and if each interacting protein has an 
orthologue in the human proteome, the interaction between the two orthologues is 
inferred. In combining the different datasets, Stein et al. (2011) used the MINT scoring 
system in order to evaluate the quality of an interaction. Whenever possible, the cross 
reference system in UniProt and the Picr web service (Côté et al., 2007) were used to 
map protein identifiers to the UniProt knowledge base. The orthology mapping was 
performed using Integr8 (Pruess et al., 2005) and OMA (Schneider et al., 2007). 
  
34 
 
 1.3 SNPs, proteins and interactions 
1.3.1 SNPs and protein structure 
The three-dimensional structure of a protein is determined by its amino acid sequence 
(Sela et al., 1957); therefore a substitution in the amino acid sequence could be 
detrimental to the stability of the structure. Some examples of how SNPs are considered 
to affect the stability of protein structure follow.  
Steric effects 
A study by Zikanova et al. (2010) on adenylosuccinate lyase (ADSL) deficiency identified 
19 ADSL mutant proteins in 16 patients. ADSL is a neuro-metabolic disease. Two SNPs, 
S23R and T450S, were suggested to cause steric changes in the protein core. The S23R 
mutation was shown to cause over-packing and a change in charge at the catalytic sites. 
On the other hand, the T450S mutation was shown to affect the formation of the 
substrate channel in the buried region.  
The reduction of hydrophobic effects 
Kellis and Nyberg (1988) showed the impact of SNPs on hydrophobic interactions. They 
used site-directed mutagenesis on Bacillus amyloliquefaciens to shorten the 
hydrophobic side chains in a ribonuclease. The susceptibility to urea denaturisation was 
used to measure the changes in protein stability. The mutations involved were I96V, 
I96A and F7L. The study found that the stability of the enzyme had decreased upon 
mutation.  
 A more recently Pace et al (2011) measured the changes in conformational stability in 
three different proteins: villin headpiece sub domain (VHP), VlsE, ribonuclease Sa 
(RNase Sa) and ribonuclease T1 (RNase T1). For each of the proteins, a large 
hydrophobic wild type was changed to a smaller hydrophobic mutant (e.g., in RNase T1, 
two isoleucine wild types were mutated to alanine). The results show that for all four 
proteins their stability decreases significantly. These experiments showed that residue 
changes affect the hydrophobic interactions in proteins resulting in a reduction of 
protein stability. 
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A change in side-chain charge 
A study by Akke and Forsén (1990) showed the effect of substituting negatively charged 
residues (the wild type) to positively charged residues (the mutant) in bovine calbindin. 
Most of these wild-type residues were solvent exposed. In this study, they found that 
mutations in the proteins have increased stability of the protein. 
Another study by Sharma et al (2003) on human immunodeficiency virus type 1 reverse 
transcriptase (HIV‐1 RT) showed how changes in charge resulted in the impairment of a 
critical function. Using site‐directed mutagenesis, they mutated lysine (positively 
charged) at position 154 to a glutamic acid (negatively charged). The mutation was 
shown to have severely damaged the polymerase function. In addition, the ability to 
form stable E–TP–dNTP ternary complexes was also disrupted. 
A loss of a disulphide bond 
A loss of a disulphide bond between two proteins can result in the destabilization of a 
complex. When the thiol groups from the cysteine residues between the two proteins 
becomes uncoupled, this causes an increase in entropy for the denatured state. 
(CooperStephen J et al., 1992) examined the effect of removing disulphide bonds on hen 
lysozyme. They performed selective disruption and modification of the disulphide 
between cysteine residues in lysozyme, which resulted in the reduction of the transition 
mid-point (Tm; (CooperStephen J et al., 1992). The modified protein (without disulphide 
bonds) was found to be less stable than the native protein containing disulphide bonds.  
Similarly, Kuroki et al. (1992) demonstrate the consequence of removing disulphide 
bonds on human lysozyme. They found that the native protein was more stable than the 
mutated lysozyme protein; the native protein had a higher Tm compared to the mutated 
protein. They showed that the replacement of the wild type cysteine residue in the 
pocket leads to the destabilization of the pocket in the native structure of the protein. 
 
 
A loss of a salt bridge 
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A salt bridge is a non-covalent interaction between amino acid side-chains of opposite 
charge. Generally, an anionic carboxylate (RCOO-), such as glutamic acid or aspartic acid, 
can form a salt bridge with the cationic ammonium groups of arginine or lysine. Salt 
bridges contribute to the stability of a protein by resisting denaturation by high 
temperature (Anderson et al., 1990) (Chan et al., 2011). An important aspect in 
determining a salt bridge is the distance between participating residues. A cutoff 
distance of 4 Å or less between the oxygen atoms of an acidic residue and the nitrogen 
atoms of a basic residue is generally used (Barlow and Thornton, 1983).  
The congenital factor XIII (FXIII) deficiency is a rare bleeding disorder that is inherited 
in an autosomal recessive manner. Deficiency in FXIII leads to a bleeding diathesis that 
is characterized by delayed haemorrhages in soft tissues after initially successful 
primary clot formation. Mikkola et al. (1996) analysed four mutations in order to 
determine the mutational consequences on the FXIII A-subunit; one of them is a change 
from arginine to isoleucine (R252I). The R252 formed a salt bridge with its neighbour, 
D243. Upon mutation, the salt bridge was destroyed. This disrupts the electrostatic 
balance, which most likely interfere with the proper folding and stability of the affected 
protein. 
Furthermore, Walters et al. (2011) recently analysed the conformational stability of the 
active site of caspase-3 Loop4 (L4). The salt bridge between K242 and E246 was 
destroyed when they mutated the lysine at position 242 to alanine via site-directed 
mutagenesis. This led to a decrease in stability of the dimer. They found that the loss of 
the salt bridge affected not just the two residues (K242 and E246) but also the 
neighbouring residues.  
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General analyses 
A general analysis of the effect of SNPs on the protein structures was performed by 
Wang and Moult (2001). They used a number of factors to develop rules for assigning 
the effects of SNPs. The effects were grouped into protein stability, catalytic binding, 
allosteric regulation, ligand binding and post-translational modification. For protein 
stability, the factors were the following: 
a) Loss of a hydrogen bond 
b) A reduced hydrophobic interaction 
c) The loss of a salt bridge 
d) The introduction of a buried charge 
e) Over-packing 
f) Formation of an internal cavity 
g) Electrostatic repulsion 
h) Causing the burial of a polar residue 
i) The disruption of metal binding 
j) The loss of a disulphide bond 
k) Introduction of backbone strain 
l) The destabilization of a protein multimer 
 
They divided their SNP dataset into two sets, a disease set and a general set. The former 
contained SNPs that were known to be involved in disease while the latter contained 
SNPs that were not involved in disease. For the disease dataset, the SNPs affected the 
protein stability of the protein more than the other factors. In contrast, for the general 
dataset, the majority of the SNPs were found to have no effect on the structure: they 
were normal or neutral polymorphisms, in agreement with an earlier study (Kimura 
and Takahata, 1983). Furthermore, they found that in the disease set, out of the six 
groups (protein stability, ligand binding, catalytic binding, allosteric regulation and 
post-translational modification), protein stability had the largest mutational effects 
(83%). However, in the general set, the majority SNPs were classified as having no 
effects and protein stability came second at 30%. 
Another general analysis was also performed by Martin et al. (2002) where they 
investigated the effect of mutations on the core region of the p53 protein. They 
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examined seven effects of mutations on the p53 crystal structure, 1TSR chain B(Cho et 
al., 1994): 
a) Mutations affecting a hydrogen bond 
b) Mutations to proline 
c) Mutations from glycine 
d) Residue clashes 
e) Mutation at the DNA binding site 
f) Mutation at the zinc-binding site 
g) Mutation in the conserved region 
From 1,729 distinct mutations in the P53 mutation database (Hernandez‐Boussard et 
al., 1999), they selected 882 distinct mutations consisting of amino acid substitution 
that only occur in the core region. A distinct mutation refers to a mutation that was 
observed to occur once or more in the dataset. From 882 distinct mutations, 309 were 
identified to be involved in hydrogen bonding of the wild type. Out of these cases, 16 
were able to compensate for the loss of the hydrogen bond, since their partner amino 
acids were exposed and able to form a new hydrogen bond with water. For mutations to 
proline, the authors determined the allowed region for proline to be -70° ≤ φ ≤ -50° and 
-70° ≤ ψ ≤ -50° or 110° ≤ ψ ≤ 130°. They identified 332 out of 882 mutations as 
involving a substitution to a proline. Out of these, 320 mutations were identified in the 
core region, where 47 of them were found to occur at the disallowed region for proline 
in the Ramachandran plot. For mutations from glycine, 53 out of 70 distinct mutations 
were observed to be involved in a substitution from glycine in the core region. Using a 
list of allowed regions in the Ramachandran plot for non-glycine residues (Martin et al., 
2002), they identified that 32 out of 53 distinct mutations were located in the 
disallowed regions. They identified 68 out of 882 distinct mutations as resulting in 
steric clashes, and 74 out of 882 distinct mutations as occurring in 14 sites affected the 
specificity of DNA binding sites. For zinc binding sites, four sites were affected by 29 
distinct mutations. In their conclusion, Martin et al. (2002) stated that they found 10 
mutations that occurred on the surface where four of them were highly conserved. They 
39 
 
suggested that these residues were probably involved in interactions between the p53 
protein and other proteins.  
 
Subsequently, an integrated pipeline to map single amino acid polymorphisms (SAAPs) 
to structure was developed (Cavallo and Martin, 2005), and this pipeline was used in 
the development of the Single Amino Acid Polymorphism database (SAAPdb; (Hurst et 
al., 2009). The SAAPdb links single nucleotide polymorphisms (SNPs) to phenotype 
alterations. SNP data is linked to a gene sequence, to determine whether the mutation 
occurred in a coding region; if so, the protein sequence and the mutated variations are 
displayed. Whenever possible, mutations are mapped onto protein structures, allowing 
researchers to hypothesize the effect of the mutations on protein structure with the 
clinical phenotype. In order to identify pathogenic mutations, they used general disease 
databases (e.g., OMIM) and specific disease databases (the TP53 mutation, Autosomal 
recessive ZAP70 deficiency, and Adenosine Deaminase Deficiency databases). 
Subsequently, another SNP-structure study was performed by Barešić et al. (2010) that 
also utilized SAAPdb. In this study, the authors perform analysis of structural effects on 
compensated pathogenic deviations (CPDs). A CPD is a variation that is mutant in one 
species but wild type or non-mutant in another species. The authors mapped disease-
causing mutations from OMIM to UNIPROT and dbSNP, and the mutations were divided 
into two data sets, pathogenic deviations (PD) and CPD. They performed two analyses, 
the potential local compensatory mutations analysis, looks at the frequency of mutated 
residues near the disease-associated mutation, and an analysis of the local structural 
effects using structural features in SAAPdb. The results of their analyses show that the 
effects of CPDs are less drastic than uncompensated PDs and that the effects of 
compensation tend to be local. 
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1.3.2 SNPs and protein interactions 
Protein–protein interactions have been combined with SNP datasets in studies to 
predict the effects of mutations on protein–protein interactions in order to suggest 
novel disease genes and identify correlations between diseases. 
Jonsson and Bates (2006) investigated the network position of genes using a human 
cancer genes dataset (Bamford et al., 2004) and interactome data (Jonsson et al., (2006). 
They concluded that cancer proteins tended to have twice as many interaction partners 
as non-cancer proteins. In addition, the authors also found that cancer-related proteins 
tend to reside in large clusters unlike non-cancerous proteins. 
Another study (Oti et al., 2006) observed that proteins that interact with each other 
tend to be involved in similar disease phenotypes. The authors analysed the effect of 
including protein–protein interaction data in predicting disease-causing gene 
candidates. The interaction partners for disease causative gene products were 
compared with gene products from loci (the location of genes on chromosomes) that do 
not have known causative genes. The interaction partners located in such loci were 
considered possible candidates for disease gene predictions. Prediction accuracy was 
tested using a benchmark set of known disease genes. The authors claimed that the 
results suggest the inclusion of interaction data resulted in an improvement in gene 
candidate identification by 10-fold (Oti et al., 2006). 
Goh et al. (2007) created a network of disease-to-gene associations, where each genetic 
disease is connected to the genes known to cause it using the OMIM database. The 
disease-associated genes were shown to have high tendencies to interact with one 
another, and they were often co-expressed. In addition, the authors found that the 
disease-associated genes often have similar classification in all three domains (the 
biological process, the molecular function, and the cellular components) in the Gene 
Ontology (Ashburner et al., 2000). However, the study found evidence for links between 
high numbers of protein–protein interactions and disease associated genes. 
Schuster-Bockler and Bateman (2008) used a combination of SNPs, interactome and 
structural data to create a method for improving the identification of disease genes. 
Using the structural interactome data from iPfam (Finn et al., 2005), Schuster-Bockler 
and Bateman (2008) selected residues that made contacts between distinct polypeptide 
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chains. The authors developed an algorithm based on conservation score and the OMIM 
dataset to identify which residues had disease-causing effects. From 264 proteins, 1,428 
SNPs were predicted to affect protein–protein interactions. 
Teng et al. (2009) used dbSNP, BLAST (Altschul et al., 1990) and the Molecular 
Modelling Database (MMDB) (Chen et al., 2003) to construct 3D models of protein– 
protein complexes with known nsSNPs in their interfaces. They argued that any 
mutation that occurs at the protein interface could affect the binding affinity by 
perturbing a normal interaction. The CHARMM program (Brooks et al., 1983) was used 
to examine if the binding energy of the PPIs was affected by the substitution. The 
nsSNPs were grouped into categories based on how they affected the energetics of PPIs. 
According to Teng et al. (2009), the physicochemical properties of nsSNPs alone were 
not enough to predict their effect on PPIs, because changes in physicochemical 
properties had minimal effects on binding energy. Similarly, substitutions at non-
conserved regions resulted in minimal effects on binding affinity compared to those in 
highly conserved regions. 
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1.3.3 Predicting SNP effects using computational approaches 
Currently, most of SNP servers can be grouped according to the features that they use: 
sequence based, like SIFT (Ng and Henikoff, 2003), MuStab (Teng et al., 2010) and SNAP 
(Bromberg et al., 2008)); structure based, like PoPMuSiC (Dehouck et al., 2009), SDM 
(Worth et al., 2011) and Eris (Yin et al., 2007)) and hybrid based, like Polyphen2 
(Adzhubei et al., 2010), I-Mutant 2.0 (Capriotti et al., 2005) and SNPs3D (Yue et al., 
2006)). 
Sequence based servers  
Ng and Henikoff (2003) developed the Sorting Intolerant From Tolerant (SIFT) 
program, which uses sequence features to predict the effects of SNPs on proteins. The 
program is based on the concept that conserved residues tend to be more intolerant 
towards substitution than non-conserved residues. It estimates positions that will be 
unfavourable to mutation based on tolerated mutations in homologs. When a user 
submits a protein sequence, the SIFT program generates a list of homologous sequences 
using the PSI-BLAST algorithm (Altschul et al., 1997) before aligning them. Next, if the 
user specifies a particular amino acid position, only that position will be scanned. 
However, if the user does not specify the amino acid position, each position will be 
scanned. For each position, the probability for possible amino acid substitutions will be 
calculated and normalized. According to Ng and Henikoff (2003), a user can set the 
threshold value for median conservation of sequence, and the program will use this 
input value to predict if a substitution affects the protein. If the user does not specify a 
specific threshold value, a default value is used instead. 
Statistical potentials based servers 
PoPMuSiC 2.0 (Dehouck et al., 2009) is an example of a statistical-potential-based SNP 
predictor that estimates the stability change caused by a mutation. It is an improvement 
from the first version of the program (Kwasigroch et al., 2002). Prior to the first version 
of the program, most predictors were focused on a limited number of mutations in a 
single protein. According to Dehouck et al (2009), PoPMuSiC 1.0 was the first predictor 
that could be used to detect stability changes on any mutation at any sites on a protein. 
In the newer version, instead of having different energy functions being applied to 
mutations, a single energy function is used, including components that vary with 
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environments such as secondary structure and solvent accessible area. Mutational data 
are extracted from the ProTherm database: a database consisting of thermodynamic 
parameters for mutations that are measured experimentally (Bava et al., 2004). A set of 
statistical potentials is used and the server utilizes a neural network algorithm that 
combines the identities of amino acids, secondary structure, accessibility and the spatial 
distance between amino acids. According to Dehouck et al (2009), the result obtained 
shows a correlation between the predicted and measured Δ Δ G values for 90% of the 
data. In addition, they also showed that the newer version of PoPMuSiC outperforms all 
previously published and freely available structure-based predictors on an independent 
set of more than 300 mutants (Dehouck et al., 2009). 
Hybrid based servers 
PolyPhen2 (Adzhubei et al., 2010) predicts the impact of amino acid substitutions on 
the structure and function of proteins using eight sequence-based and three structure-
based predictive features. Given a protein sequence, PolyPhen2 identifies homologs of 
the input via a BLAST search of UniRef100 (BE Suzek et al., 2007), and a set of hits with 
a sequence identity between 30–94% is selected. Any alignment with less than 75 
residues in length is excluded. Position-specific independent counts (PSIC) (Sunyaev et 
al., 1999) are used on the resulting multiple sequence alignments in order to calculate 
the profile matrix. This profile matrix consists of logarithmic ratios of the probability of 
a given amino acid occurring at a particular position against the probability of this 
amino acid occurring in any position (Adzhubei et al., 2010). If the value between the 
profile scores of two allelic variants are positive, this suggests that the substitution is 
rare in the protein family and thus potentially damaging. Integration of structural 
features is then added by checking the query sequence against the PDB. The Dictionary 
of Secondary Structure in Proteins (DSSP) is then used to extract three parameters for 
further calculations: the phi-psi dihedral angles, the secondary structure and the 
accessible surface area. PolyPhen2 then predicts the amino acid substitution as either 
benign or damaging using a naïve Bayes classifier trained from mutational information 
in the UniProtKB database. 
Table 1 below summarizes the different tools that are being used to predict the 
functional effects. 
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Table 1: Example of tools to predict the functional effect of SNPs 
Software Features Summary of method Reference 
PolyPhen2 Hybrid based Naïve Bayes approach 
coupled with entropy-
based discretization 
Adzhubei et al., 2010 
SIFT Sequence based 
only 
Statistical method 
using PSSM with 
Dirichlet priors 
Ng and Henikoff, 
2003 
PoPMuSiC 2.0 Structure based 
only 
Statistical potentials 
and neural network 
algorithm that 
combines the identity 
of the amino acid, 
secondary structure, 
accessibility and the 
spatial distance 
between amino acids 
Dehouck et al., 2009 
 
1.3.4 Identifying the structural location of SNPs 
In order to understand the structural characteristics of SNPs, Stitziel et al. (2003) 
mapped a set of SNPs from OMIM and dbSNP database to structures. They were 
motivated by Sunyaev et al. (2000), who show a strong correlation between disease-
associated SNPs and solvent inaccessible area. Their objective was to introduce a new 
geometric classification for characterizing disease SNPs. A set of SNPs from OMIM was 
classified as disease causing while another set of SNPs from dbSNP was used as a 
control set; both sets were mapped to protein structures. The geometric locations of 
SNPs were divided into three categories: pocket or void, convex region and completely 
buried. In their study, they found that the majority of disease SNPs occurred in pocket 
or void regions (88%) and that it was less likely that disease SNPs to occur in convex 
regions. Additionally, they found that disease SNPs tend to occur infrequently in 
completely buried regions. According to Stitziel et al. (2003), a mutation is less likely to 
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be observed in the protein core since the core plays a critical role in protein stability; 
therefore, it is more likely that the mutation may be eliminated early in the stages of 
biogenesis. The authors introduced a novel technique that uses hidden Markov models 
(HMMs) for analysing the sequence conservation of the residue position where the SNP 
occurs. They divided the SNPs into four HMM-based classifications: 
a) The SNP is similar to HMM consensus and the SNP is highly conserved 
b) The SNP is similar to HMM consensus and the SNP is not highly conserved 
c) The SNP is not similar to HMM consensus and the SNP is highly conserved 
d) The SNP is not similar to HMM consensus and the SNP if not highly conserved 
The result showed that for disease SNPs in the interior, there was a strong tendency for 
disease causing SNPs to occur in conserved residues. In addition, no strong relationship 
is found between disease SNPs in the pocket and surface regions and highly conserved 
residues. 
Another study by Ye (2006) analysed the structural location of SNPs. In this study, 
homology modelling was used to model the human disease proteins before comparing 
them with SNPs from the UniProt database. The author’s motivation was the lack of 
resources that fully utilized structural information when studying SNPs. Ye (2006) 
argued that while many computational methods have been developed to predict the 
effects of SNP on structures, these methods were limited to experimentally determined 
human proteins. In this study, the author analysed and compared the distribution of 
both disease and non-disease SNPs in protein 3D-structures. Three hundred and sixty-
nine (369) experimentally determined domains from the PDB were used, and 1,484 
domains from 874 proteins were modelled. Ye (2006) used the Fold and Function 
Assignment System (FFAS) program (Jaroszewski et al., 2005) to perform the template 
identification and generate alignments. The alignments were then used by a modelling 
package, Modeller (Fiser and Šali, 2003), to build three-dimensional models. Protein 
structure quality cores (PSQS) (Jaroszewski et al., 1998) were then used to evaluate the 
quality of each model. Six thousands three hundred and fifty-two (6,352) mutations 
were mapped onto structures. The result showed a strong tendency for disease SNPs to 
occur in the core region in patches. Ye (2006) suggested that disease SNPs forming 
these patches could be involved in protein–protein interactions. In order to test this 
hypothesis, eight experimentally determined disease proteins were examined. In most 
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of these experiments, disease mutations were observed to cluster at the interaction 
sites. 
Gong and Blundell (2010) recently catalogued structural and functional features of 
proteins that influence the substitution of amino acids. The motivation behind this 
study was to discover if the factors that restrain the substitution of amino acids in 
evolution also influence the occurrence of SNPs in coding regions. They also argued that 
although previous studies (Ng and Henikoff, 2003, Steward et al., 2003, Ferrer-Costa et 
al., 2002) look at the relationship between different factors (e.g., solvent accessible or 
conserved residue) with SNPs, most of these studies have not taken advantage of the 
rapid growing information in structure and function. In this study, SNPs were compiled 
from three sources: SwissProt, ENSEMBL and COSMIC. These SNPs were divided into 
three categories: Mendelian disease (SVD), neutral polymorphism (SVP & SAP) and 
cancerous mutation (CSM). Doublemap (Gong and Blundell, 2008) was used to align 
UniProt sequence to its corresponding PDB structure. Once the mapping of SNPs to 
structure was completed, the local structural environment of amino acid was examined. 
This examination was based on a previous study (Overington et al., 1992) that defined 
the local structural environments as either secondary structure, solvent accessibility or 
hydrogen bonding between main chains and side chains. JOY (Mizuguchi et al., 1998), a 
program that annotates protein sequence alignments with three-dimensional structural 
features, was used. JOY was used to annotate the secondary structure, solvent 
accessibility and hydrogen bonds. For solvent accessibility, the disease SNPs (SVD) were 
found to have a strong tendency to occur in the solvent inaccessible position compared 
to neutral polymorphisms (SAP & SVP) and cancer mutations (CSM). SVD was reported 
to occur 35% more than expected by chance in solvent inaccessible positions. In 
contrast, for neutral polymorphism, SVP and SAP, occur 40% less often than expected 
by chance in inaccessible positions. Furthermore, SVD was also found to occur more 
often in amino acids making hydrogen bonds, followed by cancerous SNPs and neutral 
polymorphism. Lastly, in terms of the element of secondary structure, SVD was found to 
occur less in alpha helices. This  secondary structure preference result agrees with a 
previous study (Ferrer-Costa et al., 2002). 
With the growing amount of protein–protein interaction information that exists today, 
the effects of disease nsSNPs on interfaces is essential to understanding the molecular 
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origin of disease. Throughout this chapter, we have seen the importance of combining 
structural data to understand the origin of disease. Furthermore, there are some 
suggestions that disease-causing mutations do tend to occur more frequently in not just 
highly conserved regions, but specifically solvent inaccessible regions (i.e., cores of 
proteins). However, many of these studies do not considered the enrichment of SNPs in 
the protein interface compared to the other areas on protein surfaces. It can be 
hypothesised that if the protein surface is further discriminated between non-interface 
and interface categories via an interactome dataset, that we might be able to gain 
insight and shed light on pathogenicity in humans.  
1.4 Overview of the thesis 
In the second chapter, the objective is to examine the distribution of nsSNPs in protein 
complexes. There will be three major steps: identification of the structural interactome, 
identification of nsSNPs and identification of interface residues. Issues relating to 
selecting the structural data, identification of interface and mapping of nsSNPs to the 
protein structures will be discussed. Furthermore, an enrichment analysis will be 
performed to characterize the tendency for SNPs to be found in the protein core, at the 
protein interfaces and on the surface non-interfaces. Finally, a case study involving the 
disease causing SNPs will be presented. 
For the third chapter, the objective is to examine the different methodologies to identify 
potential pathogenic and non-pathogenic nsSNPs. There will be three methodologies: 
SNP server prediction, structural analysis and usage of global minimum allele frequency 
(GMAF). SNP prediction servers (SIFT and Polyphen2) will be evaluated and used to 
predict deleterious SNPs. Then, structural analysis using eight structural features will 
be performed on the predicted deleterious non-disease causing nsSNPs at the interface. 
This is in order to examine the structural consequences of these mutations. Lastly, 
GMAF will be considered. Case studies of the non-dSNPs that passed any of the three 
analyses will be repeated. 
In the fourth chapter, the objective is to examine the distribution of nsSNPs on protein 
complexes using a larger nsSNPs dataset from the 1KGP. Similar methods used in the 
UniProt humsavar study will be used in this examination of the 1KGP data. However, in 
this study, new criteria in determining the protein dataset will be used. The new criteria 
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for proteins will be applied to the old humsavar nsSNPs dataset, and a comparison with 
the old humsavar study will be discussed. Next, the new criteria will be applied to the 
1KGP nsSNPs dataset. Comparison and similarities between the 1KGP study and the 
humsavar study using the new criteria will be discussed.  
Finally, in the fifth chapter, a summary for each of the studies will be presented. The 
impact of this thesis on the field will be discussed. Also in this chapter, future studies to 
probe the relationship between PPIs and SNPs will be presented. 
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2 The UniProt humsavar analysis 
2.1 Introduction 
Since proteins do not function in isolation, it is vital to consider the effect of any nsSNP 
in the context of the mechanism by which the mutated protein interacts with others 
(Ideker and Sharan, 2008). 
In this chapter, SNPs from the UniProt humsavar list are mapped to the experimental 
protein interaction data. The methods involved in identifying the interface sites, 
organizing the list of SNPs, mapping SNPs to structures and calculating the enrichment 
of SNPs will each be explained in detail.  
The result of the enrichment analysis of nsSNPs at interfaces described in this chapter 
was recently published in Human Mutation (David et al., 2012). The study of humsavar 
nsSNPs was initiated and analysed by me. This includes the identification of interfaces 
and nsSNPs, mapping nsSNPs onto the structures, enrichment analysis, the 
identification of which disease mutants to present in detail, the generation of the figures 
and the structural analysis. As part of a complementary analysis started after I initiated 
this study, Dr Alessia David and Dr Mark Wass obtained similar results but used slightly 
different criteria for defining the interface, the accessible surface area and which 
proteins to remove from the analysis due to incomplete coverage. Their data were 
presented in David et al. (2012). The results presented here use my definitions of 
interface and accessible surface and additionally include a consideration of the 
biological unit.  
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2.2 Identification of the human interactome dataset 
The human interactome dataset, developed by the Structural Bioinformatics and 
Network Biology group at the Institute for Research in Biomedicine, Barcelona, Spain 
(Stein et al., 2011), was used in this research. In outline, the interactome dataset 
contains two sets of interactions. The first set contains interactions that were obtained 
from experimentally derived human protein–protein interactions from major PPI 
databases. For the second set, the interactions were inferred from experimentally 
observed interactions between orthologous proteins. Orthologous proteins are proteins 
resulting from speciation event (when a species diverges into two separate species) and 
generally share the same function. Figure 1 illustrates how the inferred interactions 
were selected. 
 
Figure 1: A prediction of an interaction from yeast to human. The hexagons 
represent protein A (in human and coloured in red) and protein A’ (in yeast and 
coloured in gradient red). Protein A and protein A’ are orthologous. Similarly, the 
triangle represents protein B (in light green) and its orthologues in yeast, B’ (in gradient 
light green). In human, there was no information to suggest that an interaction occurs. 
However, in yeast, the orthologues were found to be interacting. Consequently, an 
interaction between protein A and protein B in human is inferred.  
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The experimentally verified interactions from the major databases came from literature 
evidence. Each interaction was weighted using a scoring system proposed by the MINT 
database where the score reflects both the quantity and quality of the evidence 
supporting an interaction. For more information on how the MINT score was used to 
verify the interactions, see section 1.2.4. 
Figure 2 shows the number of protein–protein interactions in the structural 
interactome database. In total, there were 84,649 PPIs corresponding to 13,300 unique 
proteins; 53,305 PPIs (63%) were experimentally verified human interactions, while 
31,344 PPIs (37%) were inferred from the orthologous interactions. For all of the 
interactions (84,649 PPIs), the median number of the interactions was five and the 
highest frequency class (2,601 proteins) was for proteins with a single interaction (see 
Figure 3).  
 
 
Figure 2: The number of protein-protein interactions in the structural human 
interactome dataset.  
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Figure 3: A histogram of the numbers of protein-protein interactions. The figure 
shows the histogram from the human interactome database. There are 84,649 
interactions corresponding to 13,300 proteins. The maximum number of interactions 
was 450 interactions and the median number of interactions is five. 
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2.2.1 Removing redundant sets 
For every protein in the interactome dataset (13,300 proteins from 84,649 PPIs), the 
sequence was searched against the PDB. If human structures for the proteins were not 
available, homologous complexes were used instead. This resulted in 227,395 structural 
interactions corresponding to 3,518 proteins. This means that for a single protein there 
could be multiple structures available.  
In order to ensure the reliability of these homologous models, the threshold sequence 
identity between the sequence in the PDB and UniProt was set to >30%. Furthermore, 
to ensure the entire domain in a protein chain was included, a cutoff of 80% for the 
UniProt sequence to PDB (and vice-versa) coverage was applied. This resulted in the 
number of interaction records being reduced to 130,357 interactions represented by 
2,371 proteins. 
The records were further filtered to remove redundancies that occur due to having 
multiple templates for the same complex, e.g., threonyl-tRNA ligase (UniProt ID: 
A2RTX5) was reported to interact with another aminoacyl-tRNA synthetase protein 
(UniProt ID: P26639) in five different PDB codes (1FYF, 1KOG, 1EVL, 1NYQ and 1NYR). 
For such redundancies, the PDB entry having the longest coverage and then the highest 
sequence identity for both chains were chosen. The chain coverage was restricted to a 
cutoff value of 80%.  
In selecting a representative structure for each protein, the longest sequence coverage 
and the sequence identity were used for the selection process. For example, in complex 
2QTS, protein Q9UHC3 interacts with protein Q16515. In another complex 1AD3, 
protein P51648 interacts with protein Q16515. In this case, 2QTS was selected as the 
representative structure for Q16515 since it has the longest PDB-UniProt coverage and 
the highest sequence identity. However, if two or more complexes have the same 
sequence identity and coverage, any of the complexes can be used. 
The status of the protein in UniProt (both reviewed and non-reviewed) was examined. A 
reviewed entry in UniProt suggests that the record is of high quality, because it has been 
manually curated. In contrast, a non-reviewed entry is computer-generated by TrEMBL 
and may contain only fragments of the full sequence. The output from this filtering 
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process was 38,332 interactions with 1,027 representative protein structures. Figure 4 
describes the filtering process involved.  
Interacting partners were assigned for all proteins. Other related information regarding 
proteins such as protein name, amino acid length, function, disease associated, family, 
subunit, pathway and tissue specificity were obtained from UniProt. 
 
 
Figure 4: The process of filtering the interactome dataset. The process started with 
227, 395 interactions corresponding to 3518 proteins. Cut-off values were used for 
length of coverage and sequence identity. Next, multiple copies of PDB codes for the 
same interactions were removed. Finally, based on the UniProt ID attached to every 
protein, non-reviewed proteins were removed by comparing against the reviewed 
protein list from UniProt. 
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2.3 Identification of SNPs 
The SNP database was downloaded from the UniProt humsavar (Wu et al., 2006) list 
(version October 2010). The database consists of a list of all non-synonymous variants 
that have been identified in human proteins. There are three justifications for using 
UniProt humsavar. First, although dbSNP has a larger number of nsSNPs, dbSNP does 
not provide disease-to-SNP relationships (however, after the analyses was been 
concluded, dbSNP did begin to include clinical significance attributes in its online 
database). Secondly, dbSNP considers multiple transcripts, which means that for a 
single nsSNP, the position or the substitution may differ between different transcripts. 
This is different from humsavar where the amino acid position and substitution is based 
on the default transcript. Lastly, the UniProt humsavar dataset was chosen because of 
its comprehensiveness in term of disease to SNP annotation. Previous to this study, Yip 
et al. (2008), Bauer-Mehren et al. (2009), (Gong and Blundell, 2010) and (Huang et al., 
2010) also used humsavar to classify their nsSNPs. 
More recently, the ClinVar database (Landrum et al., 2014) was developed to provide 
relationships among medically important variants and phenotypes. It contains a more 
exhaustive list than UNIPROT humsavar. In addition, ClinVar is a manually curated list. 
However,  ClinVar was not used in this thesis, since it was released after the completion 
of the experiment.  
The SNPs were classified into three different groups: disease-causing SNPs (dSNPs), 
polymorphic SNPs (pSNPs) and unclassified SNPs (uSNPs). Figure 5 gives an overview 
of the SNPs dataset. 
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Figure 5: The nsSNP dataset.  
 
 
The disease causing SNPs (dSNPs) group is based on the manually curated disease 
annotation in UniProt, and a majority of dSNPs also have an entry in OMIM. 
Furthermore, the minor allele frequency (MAF) of these nsSNPs was further examined 
using the dbSNP database, and any nsSNPs with a frequency above 10% were removed. 
Additionally, any nsSNP that is statistically associated with a disease but does not 
represent a direct cause to the disease was removed. An example is the tag “SNP 
identified in GWAS”. The MAF was used because pathogenic nsSNPs that result in 
serious consequences are expected to occur with low frequency in the population.  
The neutral polymorphism SNPs (pSNPs) group refers to any nsSNP that is not found to 
be directly related to disease, i.e., it is not present in OMIM. However, since OMIM does 
not provide a complete list of disease-causing variants, some of these pSNPs may still 
actually be disease causing.  
The unclassified SNPs (uSNPs) group refers to any nsSNP identified in a pathological 
sample. However, due to the lack of both statistical and experimental evidence, it is 
regarded as not having a disease-causing effect. Similar to pSNPs, uSNPs are not covered 
in OMIM, thus some of these uSNPs could potentially be disease causing. 
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In the version of humsavar analysed, there were 61,538 nsSNPs in the database and 
36,480 were pSNPs (59%), 19,670 were dSNPs (32%) and 5,388 were uSNPs (9%). The 
total number of proteins with SNPs in the database was 12,260 proteins. 
Further investigation was undertaken by examining the substitution score for the 
different categories of SNPs. BLOSUM (Block Substitution Matrix) gives a substitution 
matrix score, the observed frequency rate of an amino acid in a sequence to change to 
another amino acid. Due to strong selective pressures, amino acids tend to be 
substituted by amino acids with similar physicochemical properties. This is because a 
different residue with substantially different physicochemical properties can affect the 
folding and activity of a protein. In this study, the BLOSUM62 matrix (Henikoff and 
Henikoff, 1992) was employed due to its ability to detect similarities in both divergent 
and less divergent sequences. The substitution score is based on amino acid 
substitutions in amino acid sequences that share more than 62% identity. A positive 
score indicates substitutions that occur frequently, while a negative score indicates 
unfavourable substitutions that occur infrequently. For BLOSUM62, the substitution 
score ranges from -4 to 4.  
Out of 19,670 dSNPs, 12,784 (65%) have a negative score, while 6,886 (35%) have a 
positive score. For pSNPs, out of 36,480 SNPs, 15,136 (42%) have a negative score, 
while 21,344 (58%) have a positive score. Lastly, for uSNPs, out of 5,388 nsSNPs, 2,832 
(53%) have a negative score, while 2,556 (47%) have a positive score. The dataset was 
re-run using other types of BLOSUM matrix, BLOSUM80 and BLOSUM45, and the results 
show a trend similar to the one seen in BLOSUM62; a majority of the dSNP and uSNP 
variants have negative scores, while a majority of the pSNP variants have positive 
scores. In conclusion, there was no significant difference between the three BLOSUM 
matrices (p = 0.345) according to a chi-squared statistics. 
It was not surprising that the majority of the dSNPs have a negative score. However, for 
the other 6,886 dSNPs, a positive score could be due to a conservative change still 
having an effect on the structure, function or interaction of the protein. For pSNPs, one 
would expect positive BLOSUM scores. However, major changes that yield a negative 
score (e.g., a hydrophobic residue changed to hydrophilic) could occur on the protein 
surface and may not be as severe as destroying the protein fold.  
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2.1 Mapping SNPs to structure 
Prior to mapping SNPs to structures, the amino acid sequences from the PDB file and 
UniProt sequences had to be aligned. This was performed in order to avoid potential 
differences in residue numbering between PDB and UniProt. Although the Multiple 
Sequence Comparison by Log-Expectation (MUSCLE) program version 3.5 (Edgar, 2004) 
is used primarily for multiple sequence alignments, in this case, we used it to align the 
two sequences. The MUSCLE program involves three procedures: k-mer clustering, 
progressive alignment and refinement. An alternative approach would have been to use 
the PDBSWS resource, but I was unaware of it at the time the work was performed. 
The MUSCLE program generated an output file consisting of an alignment between the 
two input sequences from PDB and UniProt. The output file was used to map each 
variant in the humsavar dataset to their respective proteins.  
The structure to sequence match was performed via the UNIRPOT accession identifier. 
There were two issues in mapping nsSNPs to structures: differences in the amino acid 
sequences and variants that were located outside of the alignment between the PDB and 
UniProt sequences. . To solve the first issue, the physicochemical properties of the 
mutation were identified; only conservative amino acid changes were accepted. A 
conservative change here refers to a change from one amino acid to a different amino 
acid that has similar physicochemical properties such as hydrophobicity and side-chain 
polarity. This action was taken in order to make sure that the change to the “substituted 
amino acid” would result in a similar change. The second issue was handled by 
excluding nsSNPs that were located outside of the alignment from the study.  
Out of 61,538 nsSNPs, 4,532 nsSNPs from 537 proteins were mapped to structures. The 
537 proteins studied had at least one nsSNP. The median number of nsSNPs per protein 
was two and ranged from 1 to 127. There were 217 nsSNPs that were located outside of 
the alignments between PDB and UniProt sequences; thus, they were excluded. Out of 
the 4,315 nsSNPs, 2,071 nsSNPs (48%) had similar residue numbering, while 2,244 
nsSNPs (52%) did not. In terms of differences in residue type, 3,366 nsSNPs (78%) had 
similar residue type, while 949 nsSNPs (22%) differed in residue type. Out of 937 
nsSNPs that differ, all were found to have similar physicochemical properties.  
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Each nsSNP category was examined. Of the 4,315 nsSNPs mapped, 2,420 were dSNPs 
(56%), 1,133 were pSNPs (26%) and 762 were uSNPs (18%).  
In conclusion, a chi-squared test shows that there is a higher percentage of dSNPs 
observed in the study population (mapped to structures) than in the UniProt population 
(original humsavar dataset of 61,538 nsSNPs; p ≤ 0.01). In contrast, there was a lower 
percentage of pSNPs observed in the study population compared to the UniProt 
population (p < 0.01). The differences may result from more structural studies being 
performed on proteins that were associated with diseases compared to those that were 
not. 
 
Figure 6: A comparison of nsSNPs type between study population and UniProt.  
 
 
Next, the substitution scores of the nsSNPs mapped to the structures (study population) 
were examined. Out of 2,420 dSNPs, 1,478 (61%) had a negative BLOSUM62 score (i.e., 
non-conservative change) while 942 (39%) had a positive score (conservative change). 
For pSNPs, 489 (43%) out of 1,133 pSNPs had a negative score while 644 (57%) had a 
positive score. Lastly, for uSNPs, out of 762 uSNPs, 444 (58%) had a negative score, 
while 318 (42 %) had a positive score. Chi-squared analysis shows that all three groups 
are statistically different in terms of the substitution score from the original UNIPROT 
population (p < 0.01). 
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Figure 7 shows the comparison of conservative substitutions between the study group 
and the population group. In the study population, 1,931 SNPs (45%) were non-
conservative changes and 2,384 SNPs (55%) were conservative changes. Compared to 
the UniProt population, 25,846 SNPs (42%) were non-conservative changes and 35,692 
(58%) were conservative changes. Figure 8 shows the differences between different 
SNP groups in conservative and non-conservative substitutions. In conclusion, there is a 
significant difference between the UniProt population and the study population in the 
types of substitutions (p < 0.01). 
 
 
Figure 7: A comparison between different types of substitutions. The type of 
substitution is divided into two categories: conservative substitution and non-
conservative substitution. 
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Figure 8: A comparison of substitution score for nsSNPs type between study 
population and UniProt. The graph on the left shows the distribution for all three 
nsSNPs types where the BLOSUM62 score is lower than or equal to -1. The graph on the 
right shows the distribution for all three nsSNPs type where their BLOSUM62 score is 
zero or more (x≥0). 
2.5 Analysis of interface sites 
2.5.1 Identification of interface, core and surface residues 
A biological unit is a macromolecular assembly that is considered to represent the 
functional form of a molecule. Since this study focuses primarily on nsSNPs on the 
interface, utilizing the biological unit provides the best representation of nsSNPs on the 
interface. If a non-biological unit, such as an asymmetric unit in the PDB, were used 
instead, potential interface sites would be limited. This would affect the number of 
nsSNPs in the interface region for proteins and could result in Type I error. Figure 9 
shows the differences between a biological unit and a non-biological unit. Certain areas 
on the protein surface could potentially be interface sites if the biological unit of a 
protein is used. However, if only an asymmetric unit was used, these potential sites will 
not be identified.  
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Figure 9: A representation of a biological unit and a non-biological unit. In the non-
biological unit only chain B is interacting with chain A while in the biological unit, 
another two chains are interacting with chain A.  
 
To the best of my knowledge, this study is the first to exploit the biological unit to 
understand the relationship between PPIs and nsSNPs. When a crystal structure is 
deposited in the PDB, only the asymmetric unit is deposited. The asymmetric unit can 
be identical to the whole or a portion of the biological unit, or it may contain multiple 
biological units. In order to obtain a complete biological assembly, symmetry operations 
have to be performed on the asymmetric unit. This is usually shown in the PDB file 
(REMARK 350). Other than the RCSB PDB databank, programs such as Protein 
Interfaces, Surfaces and Assemblies Server (PISA) (Krissinel and Henrick, 2007) and 
Probable Quaternary Structure Server (Henrick and Thornton, 1998) can also be used 
to predict the biological unit of proteins. 
The biological units for all of the 537 proteins associated with SNPs were downloaded 
from PDB database. The coordinates of each protein were analysed and if atoms in 
different chains were within a cutoff value of less than 5 Å, they were considered to be 
interacting. The usage of ≤5 Å to identify an interaction was consistent with previous 
studies (Méndez et al., 2003, Han et al., 2004). The nearest atom-to-atom contacts were 
chosen. If there was more than a single atom contact for a residue, this was still 
considered as one interaction. A minimum of five residues in a chain involved in an 
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interaction was required for defining an interface. This cutoff was chosen because some 
protein–protein interactions were found to be mediated by very few contacts by Kinjo 
and Nakamura (2010). The authors suggested 8,000 biologically relevant interfaces 
consist of less than 30 atoms. Figure 10 shows the histogram for interface residues. This 
methodology identified 43,381 residues as being interface residues. The largest number 
of interface residues for a protein was 496 residues while the smallest was seven 
residues. The median number of interface residues was 75. In order to confirm the 
interactions between interface residues, a sample of structures was selected and 
manual observation was performed using PyMOL program (DeLano, 2002) see Figure 
11). 
 
Figure 10: A histogram of the interface residue. The histogram shows a positively 
skewed histogram of interface residues. The largest number of interface residues for a 
protein was 496 residues (RNA polymerase II subunit B1) while the smallest number of 
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interfaces was seven residues (trafficking protein particle complex). The median was 75 
residues. 
 
 
Figure 11: A diagram of TRAPP I complex interfaces. The figure shows TRAPP I 
complex 2J3T (Kim et al., 2006), in a cartoon model. The diagram shows two chains 
(chain D coloured in yellow and chain A coloured in green) and their interface residues 
on both sides are represented in sticks. 
 
Once the identification of interface residues was completed, Define Secondary Structure 
of Proteins (DSSP), (Kabsch and Sander, 1983) was used to differentiate residues on the 
surface and in the protein core via the accessible surface area (ASA). The DSSP 
algorithm uses the atomic coordinates of a protein to assign secondary structure to 
amino acid residues. ASA measures the exposure of an amino acid towards a solvent 
(usually water) that surrounds the protein. A cutoff ASA ≤ 5 Å2 was used to define a 
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residue as buried (Lee and Richards, 1971). The total number of residues for 537 
proteins was 198,528. The number of buried residues was 42,342 (21%), while 43,381 
(22%) were identified as interface residues, and 112,805 (57%) were surface non-
interface residues. Figure 12 and Figure 13 show the histograms for residues in the core 
and on the surface respectively. Similar to interface residues, the histograms for core 
and surface show a skewed distribution. The medians for core and surface residues 
were 72 and 252, respectively.  
 
Figure 12: A histogram of buried residues where the median for buried residues 
is 72. 
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Figure 13: A histogram of surface non-interface residues. 
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2.5.2 The nsSNPs and their location on protein structure 
Table 2 summarises the location of nsSNPs in protein complexes, while Figure 14 shows 
the distribution of observed and expected nsSNPs. Each of the 4,315 nsSNPs (537 
proteins) was assigned to its position in a structure as either interface, core or surface 
non-interface. Out of 4,315 nsSNPs, 1,251 nsSNPs (29%) were interface residues, 1,079 
nsSNPs (25%) were core residues and 1,985 (46%) were surface non-interface 
residues. Since few of these proteins have a complete structure for all of their 
interactions, it can be assumed that some areas on the surface non-interface could 
potentially be interface sites, as suggested by Schuster-Bockler and Bateman (2008). 
 
Figure 14: The distribution of observed nsSNPs across three groups. The blue bar 
represents the number of nsSNPs in the core, the red bar represents nsSNPs at the 
interfaces, and the green bar represents nsSNPs on surface non-interface. The gradient 
colours represent the observed number of nsSNPs for each type while the solid colours 
represent the expected number of nsSNPs by chance.  
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Table 2: The location of nsSNPs on protein complexes 
 dSNPs pSNPs uSNPs 
Position Buried Interface Surface 
non-
interface 
Buried Interface Surface 
non-
interface 
Buried Interface Surface 
non-
interface 
Total 
residues 
42,342 43,381 112,805 42,342 43,381 112,805 42,342 43,381 112,805 
Observed  781 620 1019 175 294 664 115 350 297 
Expected  516 529 1375 242 248 644 163 167 433 
Observed 
/ 
Expected 
ratio 
1.5 1.2 0.7 0.7 1.2 1.0 0.7 2.1 0.7 
 
The ratio of observed to expected dSNPs shows that they were over-represented in the 
core and interface regions. The expected number of nsSNPs of type I by chance was 
calculated with Equations 3 and 4. 
Equation 3: The equation for calculating the expected number Eij of nsSNP of type 
i (Ei) in region j 
Eij = Si × Fi 
Si is the total number of nsSNPs of type ‘i’ in all the proteins, and Fj is defined by 
Equation 4. 
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Equation 4: The equation for obtaining the total number of residues in all regions 
 
Here, ni is the total number of residues (in all proteins) in region j, and N is the total 
number of residues in all protein (in all regions).  
For 2,420 dSNPs mapped to structures, 781 (32%) were in the core, 620 (26%) in the 
interface and 1,019 (42%) on the surface. Based on a random distribution of residues, 
the observed number of dSNPs in the core region (781) was higher than that expected 
by chance (516). For dSNPs in the interface region, the observed number (620) was 
more than expected (529), while on the surface non-interface region the number 
observed (1019) was less than expected (1375). In conclusion, a chi-squared test 
indicates that there were more dSNPs found in the buried regions than all types of 
surface (surface non-interface and interface combined) regions (p < 0.01). In addition, 
interface regions tend to have more dSNPs compared to surface non-interface regions 
(p < 0.01). Most non-synonymous changes in the core region were expected to cause 
damage to the stability of the structure (Kellis and Kerstin Nyberg, 1988, Eriksson et al., 
1992) , therefore it was not unexpected to see the high number of dSNPs in the core 
when compared to chance.  However, the high number of dSNPs at the interface site 
compared to chance has (to my knowledge) never been quantified before. The high 
number of dSNPs in the interface region compared to chance indicates the important 
role that PPIs play in the pathogenesis of disease. 
Additionally, of the 1,133 pSNPs, 175 (15%) were in the core, 294 (26%) were at the 
interface and 664 (59%) were on the surface non-interface sites.  
For the 762 uSNPs, 115 (15%) were in the core, 350 (46%) were in the interface, and 
the remaining 297 (39%) were found to be surface non-interfaces. In contrast to dSNPs 
and pSNPs, a chi-squared test shows there was a higher percentage of occurrence at the 
interface compared to all other regions (p < 0.01). By chance, the number of uSNPs 
expected in the interface region was 167. Since most of these uSNPs were found from 
pathological samples, the high number of observed uSNPs compared to the number 
expected in the interface suggests that the majority of these uSNPs could potentially be 
Fj = 
nj 
N 
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affecting PPIs. Upon further investigation of the uSNPs, it was found that out of 762 
uSNPs, 725 (95%) of them were identified in cancerous sample cells. Although there 
was no confirmation of direct causation due to the lack of experimental data, it does 
highlight the potentially important role PPIs have in cancer. One possible explanation 
could be that many of these uSNPs are passenger mutations in cancer samples. For 
example, in cancer samples, there are two types of mutations, driver mutations and the 
neutral passenger mutations. One goal of cancer research is to distinguish between the 
two. In Chapter 3, a further investigation was performed on these uSNPs to understand 
the reason behind this high prevalence. 
It could be argued that the above results need corrections for multiple hypothesis 
testing; accordingly, a correction to the significance value should be applied. However, 
for dSNPs and pSNPs we have prior hypotheses; that dSNPs will preferentially occur in 
the core rather than the surface, and thus a multiple testing correction need not be 
applied. For uSNPs, there was no prior hypothesis but as the observation without 
correction was significant at the 1% level, it would still be significant at a 5% 
significance level after a Bonferroni correction. 
 
2.5.3 The enrichment analysis 
An enrichment analysis was performed to find the likelihood of having certain types of 
nsSNPs in one type of region of a protein compared to another type of nsSNPs. Equation 
5 shows the odds ratio calculation. For each type of SNPs (disease, polymorphic and 
unclassified), the preference to occur in one type of region rather than the other (e.g., 
core, interface and surface) was quantified with an Odds Ratio (OR) calculation. 
An odd is defined as the probability of observing SNPs in a region over the probability of 
not observing SNPs in that region. An odds ratio (OR) is the ratio of the odds for having 
SNPs in the target group relative to the odds in favour of having SNPs in the other 
group. An OR is expressed by the following formula. 
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Equation 5: The equation for the odds ratio (OR) calculation 
 
A1 and A2 here refer to the probability of having an nsSNP in region 1 and 2. For 
example, the probability of observing a nsSNP at the interface site was represented by 
the following equation.  
Equation 6: The equation to calculate the probability of having nsSNPs 
 
 
Nx is the number of observed nsSNPs in the region of interest, while Ny refers to the total 
number of residues that can be found within that region of interest. For this study, a 
two-tailed p-value of 0.05 was used for indicating statistical significance.  
Table 3: The odds ratio between different nsSNPs classes in the humsavar study 
 dSNPs pSNPs uSNPs 
Type Core-
Surface 
Core-
Interface 
Interface-
SNI 
Core-
Surface 
Core-
Interface 
Interface-
SNI 
Core-
Surface 
Core-
Interface 
Interface-
SNI 
Odds ratio  
(OR) 
1.77 1.30 1.59 0.67 0.61 1.15 0.65 0.33 3.08 
p-value 0.0001 0.0018 0.0001 0.0018 0.0002 0.1730 0.001 0.0001 0.000003 
95%  
confidence 
interval 
1.62–
1.93 
1.10–1.51 1.44–1.76 0.57–
0.79 
0.50–0.73 0.94–1.41 0.54–
0.80 
0.25–0.45 2.64–3.60 
The table shows the odds ratio for each SNP type (dSNPs, pSNPs and uSNPs). For each type of nsSNP, a 
comparison was made between buried and surface (Core vs. Surface), buried and interface (Core vs. 
Interface) and interface and surface non-interface (Interface vs. SNI). 
OR 
 
= 
= 
A
1
/1-A
1
 
Nx 
A
2
/1-A
2
 
Ny 
Aregion 
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Table 3 gives the results of the enrichment analysis. The results show that dSNPs were 
significantly more likely to occur in the buried region than the non-buried region, 
consisting of surface non-interface and interface (OR 1.77). This result agrees with 
previous studies (Wang and Moult, 2001, Burke et al., 2007) that have shown that a 
nsSNP change in the buried region tends to be more deleterious. When a comparison is 
made between the buried region and the interface region, dSNPs were significantly 
more likely to occur in the buried region (OR 1.30), although the OR was lower than the 
buried versus non-buried comparison. For the OR comparing the interface region with 
surface non-interface region, the interface region was observed to be significantly more 
likely to have dSNPs (OR 1.59). 
The OR between the buried region and the non-buried region shows pSNPs were 
significantly less likely to occur in the core (OR 0.67). This is because the non-buried 
region can accommodate far greater changes compared to the buried region. Thus, 
changes to the non-buried region were less likely to affect the stability and integrity of 
proteins. The OR between the buried region and the interface region showed that pSNPs 
were less likely to occur in the buried region (0.61). The OR also shows no significant 
differences between nsSNPs being at the interface region and surface non-interface 
region (OR 1.15). This result is significant at 5% but not 1% significance. A reason for 
this surprising result may be that some of these pSNPs might be misclassified regarding 
their disease status. Further analysis of the deleterious nature of pSNPs at the interface 
will be performed in Chapter 3. 
The uSNPs were found to be significantly less likely to occur in the buried region than 
the non-buried region (OR 0.65). Similar conclusions can also be made between being in 
the buried region and at the interface region (OR 0.33). Interestingly, for the OR 
between the interface and surface non-interface, there was a strong significant tendency 
for uSNPs to occur in the interface (OR 3.08). Since the majority of the uSNPs came from 
cancerous samples, a possible explanation is that the PPIs are heavily involved in the 
pathogenesis of cancer related disease. Similar to pSNPs, further analysis on the 
deleterious nature of uSNPs at the interface will be investigated in Chapter 3.  
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2.6 Case studies of dSNPs on the interface 
Four case studies showing dSNPs and their respective proteins are presented in this 
section. These case studies were also reported in the publication that resulted from this 
study (David et al., 2012). For each case study, the PyMOL program was used to 
generate the images. PyMOL was used to mutate the residues and the SCWRL program 
(Krivov et al., 2009) was used to predict the side chains of protein backbones using a 
library of backbone-dependent rotamers. SCWRL was used, because the PyMOL 
program mutates a residue without considering the effects on the surrounding side-
chains. SCWRL on the other hand, maintains the backbone conformations but re-orders 
the side chains to obtain the optimal conformation. 
 
Cardiac troponin I protein (UniProt ID: P19429 | FTID: VAR_019874) 
Figure 15 shows troponin I (TrI) as a part of the troponin complex that confers calcium-
sensitivity to striated muscle actomyosin ATPase activity. The troponin complex 
consists of troponin T (TrI) and troponin C (TrC). The analysis shows that a dSNP, 
R162P, occurs at residue 162, the interface between TrI and TrC. The R162P 
substitution could cause the loss of a salt bridge with glutamic acid at position 19 of the 
TrC. In addition, the substitution to a proline could affect the backbone angle since the φ 
and ψ for arginine (φ = -145°, ψ = 360°) was incompatible with proline. Studies 
(Richard et al., 2003) (Ingles et al., 2005) have shown that this substitution leads to 
hypertrophic cardiomyopathy (MIM 191044). 
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Figure 15: A diagram of the interface for human cardiac. The complex was obtained 
from the PDB structure 1J1E (Takeda et al., 2003). The figure shows both pre-mutation 
state and post-mutation state. The interface is between cardiac troponin I protein (TnI) 
represented in grey colour interacting with troponin C (TnC) represented in light yellow 
colour. The wild-type SNP (R162) of TnI is represented in a grey coloured stick while 
the interacting residue from TnC, represented in light yellow coloured stick. The post-
mutational substitution is also shown where the mutated residue, a proline, causes 
backbone constraint and a lost of salt bridge. 
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Gap junction beta-2 protein (UniProt ID: P29033 | FTID: VAR_009969) 
Figure 16 illustrates the gap junction beta-2 protein (GJB2). It is a protein in the 
connexin family. A connexon is a cluster of closely packed pairs of transmembrane 
channels. They are involved in coordinated depolarization of cardiac muscle and proper 
embryonic development. The analysis shows the substitution of R184W, a dSNP, is at 
residue 184, the interface between GJB2 and GJC3 (gap junction gamma-3 protein). This 
substitution probably causes instability in the complex GJB2-GJC3 connexon complex. 
This is due to the loss of a salt bridge between arginine at position 184 of GJB2 with 
glutamic acid at position 47 of GJC3. Furthermore, the substitution could also result in a 
steric clash with nearby interacting residues in GJC3. This analysis explains in structural 
terms the relationship between the R184W substitution and the disease, which results 
in a loss of hearing (Wilcox et al., 2000).   
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Figure 16: A diagram of nsSNPs at the interface for gap junction beta-2 protein 
(GJB2). The structure was obtained from PDB structure 2ZW3 (Maeda et al., 2009). The 
figure shows both pre-mutation state and post-mutation state. The interface is between 
gap junction beta-2 protein (GJB2) represented in grey colour and gap junction gamma-
3 protein (GJC3) represented in light yellow colour. The wild-type SNP (R184) is 
represented by a grey coloured stick in the pre-mutation state. The mutated SNP, a 
tryptophan, is shown in the post-mutation state causing a lost of a salt birdge and 
potential steric clashes with nearby interacting residues in GJC3. 
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Integrin beta-2 (UniProt ID: P05107 | dbSNP ID: rs137852614) 
Figure 17 shows integrin beta-2 (CD18), which is involved in the human immune 
system. It interacts with integrin alpha L (CD11a) forming lymphocyte function-
associated antigen-1, a receptor found on T-cells, and functions as an adhesion 
molecule. In the analysis, the P178L substitution could cause instability to the formation 
of a stable lymphocyte function-associated antigen-1. This is in line with previous 
studies that showed the relationship of this substitution could cause diseases (Back et 
al., 1992, Ohashi et al., 1993). The substitution occurs at the interface between CD18 
and CD11a. The possible structural effect is the introduction of a steric clash between 
the mutated leucine at position 178 of CD18 and a nearby interacting residue, CD11a. 
Another explanation is the loss of the ability to form an interaction with aromatic side 
chains that exist for proline but not leucine (Bhattacharyya and Chakrabarti, 2003). 
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Figure 17: A diagram of nsSNPs at the interface for integrin beta-2. The complex 
was obtained from the structure of an integrin with an alpha I domain, complement 
receptor type 4 (PDB entry 3K6S) (Xie et al., 2010). The figure shows both pre-mutation 
state and post-mutation state. The figure demonstrates the interface between integrin 
beta-2 (CD18) and integrin, alpha L (CD11a). CD18 and CD11a are represented in 
cartoon format and coloured in grey and light yellow respectively. The wild-type SNP 
(P178) in CD18 is represented as a grey coloured stick, and the yellow coloured stick, 
shows the residue where a clash could occur. 
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Electron transfer flavoprotein subunit alpha, mitochondrial (UniProt ID: P13804 | 
FTID: VAR_002367) 
Electron transfer flavoprotein subunit alpha (ETFA) plays a role in catalysing the initial 
step of mitochondrial fatty acid beta-oxidation. It dimerises with the electron transfer 
flavoprotein subunit beta (ETFB) protein to form the mature electron transfer 
flavoprotein, a protein required for the transfer of electrons to dehydrogenases in the 
main mitochondrial respiratory chain. The substitution V157G, is at residue 157, the 
interface between ETFA and ETFB, and was shown to cause high levels of the mutant 
ETFA precursor, resulting in barely detectable ETFB levels (Indo et al., 1991). This could 
potentially lead to the instability of the ETFA-ETFB complex. This instability can be 
explained from the analysis of the structure. The V157G substitution results in a loss of 
hydrophobic effect due to the change from a medium sized and hydrophobic residue to 
a smaller sized residue. 
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Figure 18: A diagram of nsSNPs at the interface of electron transfer flavoprotein 
subunit alpha (ETFA). The complex was obtained from the human MCAD: ETF complex 
(PDB entry: 1T9G). The figure shows both pre-mutation state and post-mutation state. 
The figure shows the wild-type SNP, (V157) represented as a grey coloured stick, at the 
interface between electron transfer flavoprotein subunit alpha (ETFA), coloured in grey, 
and electron transfer flavoprotein subunit beta (ETFB), coloured in yellow. 
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2.7 Conclusion 
This chapter discussed the methods to identify the interface and SNP datasets using 
1,027 representative proteins selected from the structural interactome dataset. The 
interfaces were identified from their biological units. The SNP dataset came from the 
UniProt humsavar database. The mapping between the proteins from the interface 
dataset and nsSNPs from the SNP dataset resulted in 537 proteins with 4,315 nsSNPs. 
In this chapter, an enrichment analysis was also presented. The result from the 
enrichment analysis showed that disease-causing nsSNPs (dSNPs) that do not occur in 
the protein core are more likely to be located at the interface region rather than on the 
surface non-interface region. The enrichment analysis also showed that there were 
more pSNPs and uSNPs at the interface region than the buried region or the surface 
non-interface region. Further analysis of the uSNPs revealed that the majority of them 
came from cancerous samples. It was suggested that some of these uSNPs at the 
interface could actually be disease causing but this has yet to be experimentally verified.  
Lastly, in this study of nsSNPs from humsavar, four examples were given that showed 
how nsSNPs at the interface could potentially affect the stability of protein complexes.  
In the next chapter, Chapter 3, further studies will be performed on the results obtained 
in Chapter 2. Three methodologies to assist in the identification and classification of 
nsSNPs into disease causing and non-disease causing are presented. The result of these 
methodologies on uSNPs will also be examined. 
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3 Identification of disease causing 
and non-disease causing nsSNPs 
3.1 Introduction 
Over the last few years, sequencing platforms have undergone a massive 
transformation, where many are now able to produce high-throughput data in a short 
period of time (Loman et al., 2012). Therefore, an automated mechanism is needed to 
assist in the identification of disease-causing and non-disease-causing nsSNPs produced 
by these sequencing platforms. 
In this chapter, we describe three methodologies that can be used to assist in the 
classification of nsSNPs as disease causing or non-disease causing. First, we describe the 
usage of nsSNP server to determine the pathogenicity of an nsSNP. Second, an analysis 
of the structural features was performed to identify the most useful predictor of 
pathogenicity. The analysis of the structural features include loss of a salt bridge, loss of 
a hydrogen bond, loss of a disulphide bond, a steric clash, backbone strains, a change in 
polarity and a change of inside-chain charge. Third, we demonstrate the application of 
global minor allele frequency (GMAF) in assisting in the identification of a pathogenic 
nsSNP. Finally, four case studies of non-disease-causing nsSNPs were examined. 
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3.2 Identifying pathogenic nsSNPs using SNP Servers 
There are many servers available that predict the effect of nsSNPs such as SIFT(Ng and 
Henikoff, 2003), SNAP(Bromberg et al., 2008), Polyphen2 (Adzhubei et al., 2010), 
PoPMuSiC (Dehouck et al., 2009), I-Mutant (Capriotti et al., 2005) and SNPs3D (Yue et 
al., 2006). 
Recently, a range of consensus-based SNP servers, such as Condel (González-Pérez and 
López-Bigas, 2011), Meta-SNP (Capriotti et al., 2013) and PredictSNP (Bendl et al., 
2014), were developed. However, these consensus-based servers were not considered 
because they were unavailable at the time of the analyses.  
In this study, Polyphen2 was chosen because of its well-publicised performance and 
usability compared to alternatives. Previous studies (Xi et al., 2004) (Savas et al., 2004) 
have suggested that Polyphen (Ramensky et al., 2002) was able to correctly predict 
more than 80% of SNP substitutions. Polyphen2, which is a newer version of Polyphen, 
has been shown to improve the prediction rate compared to the earlier version 
(Adzhubei et al., 2010). 
Polyphen2 uses a hybrid-based approach that considers both sequence and structure to 
distinguish between deleterious and non-deleterious nsSNPs. This is in contrast with 
SIFT (sequence based) or PoPMuSiC (structure based). Polyphen2 has an additional 
three structure-based predictive features that it uses in its scoring system, the phi-psi 
dihedral angles, secondary structure and accessible surface area. It also provides both 
quantitative and qualitative scoring mechanisms. If the score is <0.5 it is classified as 
benign (non-deleterious), and if the score is ≥0.5 it is considered deleterious. 
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The performance of both servers was compared using two statistical measures, 
specificity and sensitivity. Sensitivity reports the proportion of actual positives that are 
correctly identified, while specificity reports the proportion of negatives that are 
correctly identified. Specificity and sensitivity were calculated using the formulae in 
Equation 7. 
Equation 7: The formulae for obtaining sensitivity 
 
Equation 8: The formulae for obtaining specificity 
 
 
A true positive (TP) is a positive result correctly identified (i.e., a nsSNP that is identified 
to be disease causing by humsavar and predicted to be deleterious by a SNP server). A 
true negative (TN) is a negative result correctly identified (i.e., a nsSNP that is identified 
to be non-disease causing by humsavar and predicted to be benign by a SNP server). A 
false positive (FP) occurs when a positive prediction is wrong (i.e., a nsSNP that is 
identified to be non-disease causing by humsavar but predicted to be deleterious by a 
SNP server). A false negative (FN) occurs when a negative prediction is wrong (i.e., a 
nsSNP that is identified to be disease causing by humsavar but predicted to be benign 
by a SNP server). 
 
86 
 
The UniProt humsavar SNP dataset (61,471 nsSNPs) was used as a benchmark to test 
the performance between these servers. Polyphen version 2.0.9 and SIFT version 2010 
were used for analysis. 
Table 4 shows the higher sensitivity and specificity of Polyphen2 compared to SIFT. 
This result corroborates previous studies by Hicks et al. (2011) and Rodrigues et al. 
(2011), which showed the superior performance of Polyphen2 compared to SIFT. In 
fact, the result shown in the study by Rodrigues et al. (2011) was similar to the result 
shown in Table 4. The lower sensitivity and specificity for SIFT compared to Polyphen2 
could be due to the lack of structural features consideration in SIFT. In Polyphen2, three 
structural features, the phi-psi dihedral angles, secondary structure and the accessible 
surface area, were considered in the algorithm. Additionally, the result also shows that 
Ployphen2 has a higher false positive rate than false negative rate. The set tested in 
Table 4 included disease-causing SNPs and polymorphisms, hence the negative and 
false positives. 
Table 4: A comparison of statistical measures between Polyphen2 and SIFT using 
humsavar dataset (n = 61,471) 
 Polyphen2 SIFT 
True Positive 15,368 25% 21,515 35% 
True Negative 29,506 48% 14,753 24% 
False Positive 12,909 21% 14,138 23% 
False Negative 3,688 6% 11,065 18% 
Sensitivity 0.81 0.66 
Specificity 0.69 0.51 
 
87 
 
The result is encouraging since both servers did not use the humsavar dataset as their 
training set. This is important since a proper evaluation of the comparative 
performances of these programs requires testing on data not used in training. For 
Polyphen2, the training dataset was from humdiv and humvar, while for SIFT, a handful 
of proteins were used for manual optimization of the parameters. Based on the result, 
Polyphen2 was selected as the program to perform the nsSNP phenotype predictions. 
Additionally, both Polyphen2 and SIFT share a similar disadvantage, they cover only 
amino acid substitutions, which means variation in the intronic and intergenic regions 
are not taken into account. Recent studies (Chen et al., 2013, Almada et al., 2013) and 
the publication of the ENCODE project (Consortium, 2012a) have shown that genomic 
regions formerly known as ‘junk DNA’ is actually very much functional.  Despite this, 
there are some studies that have rejected this notion such as Graur et al. (2013). 
However, since the scope of the thesis is on the relationship between nsSNPs and 
protein interfaces, the disadvantage of having no prediction on intergenic and intronic 
regions is not really an issue. 
3.2.1 Predicting the deleterious nature of dSNPs 
Table 5 shows the statistical measures for dSNPs in all three types of region. Buried and 
surface regions exhibited high sensitivity and specificity values. In contrast, the 
sensitivity and specificity for the interface region is lower. This suggests that although 
the Polyphen2 server can predict disease-causing nsSNPs with high confidence in 
buried regions, the prediction for disease-causing nsSNPs at the interface is lacking. As 
shown in Chapter 2, disease-causing nsSNPs at the interface could cause detrimental 
effects on proteins. We hypothesize that the reason for the lower detected sensitivity at 
the interface region could be  the limited consideration of structural features that affect 
protein–protein interactions as was explained in the previous section. Thorough 
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analysis of different structural features at the interface could reveal more insights to 
this low sensitivity value. Additionally, the false positive and false negative rate in non-
interface regions was similar to observations in Table 4.  
Table 5: Polyphen2 prediction on dSNPs at all regions 
 Buried 
(n = 781) 
Surface 
(n = 1,019) 
Interface 
(n = 620) 
True Positive 509 65% 393 39% 136  22% 
True Negative 164 21% 472 46% 198  32% 
False Positive 55 7% 92 9% 112 18% 
False Negative 53 7% 62 6% 174 28% 
Sensitivity 0.91 0.86 0.44 
Specificity 0.75 0.84 0.64 
 
As uSNPs are unclassified, Polyphen2 predictions could suggest which uSNPs are likely 
to be disease associated and which are benign. Table 6 gives the Polyphen2 predictions 
of uSNPs broken down by location. A predicted deleterious uSNP refers to an uSNP that 
was predicted to be damaging by Polyphen2. Similarly, a predicted benign uSNP refers 
to an uSNP that was predicted to be benign by Polyphen2. A chi-squared test on this 
contingency table shows the observations are very significantly different from random 
(p < 0.0001).  
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Table 6: The Polyphen2 prediction for uSNPs based on regions 
 uSNPs (n = 762) 
Interface Surface non-interface Buried 
 Observed Expected Observed Expected Observed Expected 
Predicted 
deleterious 
(395) 
166 181.4 46 98.5 183 115.1 
Predicted 
benign (367) 
184 168.6 144 91.5 39 106.9 
Total 350 190 222 
 
Table 7 gives the results of tests using 2 × 2 contingency tables to determine whether 
each entry is significantly different from the rest of the matrix. The table gives the chi-
squared p-values for each entry in the table being significantly different from the 
remainder via 2 × 2 contingency tables. It shows highly significant enrichments of 
predicted deleterious uSNPs in the buried regions and of predicted benign uSNPs in the 
surface regions. 
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Table 7: Chi-squared p-value comparing each element against rest 
 Interface Surface  
non-interface 
Buried 
Predicted deleterious p > 0.1 p < 10-7 p < 10-11 
Predicted benign p > 0.1 p < 10-7 p < 10-11 
 
Note that the observations are so strongly significant that applying a multiple testing 
correction will not alter any conclusions. These observations are consistent with the 
results for deleterious and benign nsSNPs made from the humsavar dataset (in Chapter 
2). There was no significant enrichment of either predicted deleterious or predicted 
benign uSNPs at the interface. 
The results in this section show that Polyphen2 can be used to predict the pathogenicity 
of nsSNPs, but there is room for improvement for Polyphen2, especially concerning its 
prediction of nsSNPs at the interface. In the next section, we demonstrate that structural 
features might increase the performance of Polyphen2, especially at the interface. 
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3.3 Identifying pathogenicity using structural features 
In the previous section, Polyphen2 SNP server was used to predict pathogenic nsSNPs. 
The results suggest that Polyphen2 might not thoroughly consider all the structural 
features that could affect a protein–protein interaction. An examination of the structural 
aspects of PPIs might give some insights to this question.  
In this second, followup methodology, eight structural features were examined in order 
to find the most useful predictor for pathogenicity. In addition, by performing this 
analysis, we identified which structural features may help improve the prediction 
mechanism of Polyphen2, especially within protein interfaces. 
First, the effects of the eight structural features on dSNPs were examined. This gives an 
overview of which structural features are the most useful predictors of pathogenicity. 
Next, the uSNPs were examined to see if any of them show patterns similar to those 
seen in dSNPs. This is of interest because in the previous section some uSNPs were 
observed to be pathogenic. Two analyses of uSNPs will be performed, analysis of the 
general interface uSNPs and those that were predicted to be pathogenic by Polyphen2. 
The eight structural features that were analysed are as follows: 
a) The loss of a salt bridge 
A salt bridge is defined as an anionic carboxylate (RCOO-) forming a non-covalent 
bond with a cationic ammonium. Salt bridges have been shown to contribute to 
the stability of a protein by resisting denaturation by high temperature 
(Anderson et al., 1990; Chan et al., 2011). 
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A cut-off distance of 4 Å or less (≤4 Å) between the oxygen atoms of an acidic 
residue and the nitrogen atoms of a basic residue is used to identify salt bridges 
(Barlow and Thornton, (1983).  
b) The loss of a disulphide bond 
A disulphide bond is a covalent bond, which occurs due to the oxidation of the 
thiol groups of two nearby cysteine residues. It is usually around 2.05 Å in 
length. A disulphide bond plays an important role in the stability and folding of a 
protein by destabilizing the unfolded state by lowering its entropy, thus making 
a folded state more energetically favourable (Poland and Scheraga, 1965; Lin et 
al., 1984; Pace et al., 1988). 
c) The loss of a hydrogen bond 
A hydrogen bond is defined as a hydrogen donor to acceptor distance ≤2.5 Å at 
an angle of ≥90.0°(Wang and Moult, 2001). Most of the hydrogen bonds in 
proteins have a length of approximately 2.5 Å (Jeffrey, 1997). A study (Jiang and 
Lai, 2002) showed that hydrogen bonds play an important role at protein 
interfaces and in the stability of protein complexes.  
d) Steric clashes 
A steric clash is defined as the overlapping of any two non-bonding atoms in a 
protein structure. A mutation which results in a steric clash can affect the 
formation of the substrate channel due to creation of a cavity in the buried 
region as shown Zikanova et al. (2010). In this analysis, an interaction with an 
arbitrary length of ≤2.0 Å is considered a potential candidate for steric clash. The 
reason for this cutoff is based on the van der Waals radius of the alanine methyl 
group, which is 1.9 ± 0.5 Å.  
e) A change in polarity 
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Introduction of changes in polarity at the interface region 
f) A change in side-chain charge 
Since these nsSNPs are located at the interface, any increase in positively 
charged residues on the surfaces prevents normal assemblies with non-native 
interfaces (Berezovsky, 2011). 
g) Loss of the hydrophobic effect 
The loss of the hydrophobic effect is defined as a reduction of solvent accessible 
area ≥50 Å2 caused by a hydrophobic side chain at the interface region. 
h) Backbone strain 
 Glycine -> X (Any amino acid except glycine) 
A nsSNPs change from glycine (wild) to any other amino acid residue 
(mutant) where the mutant residue φ and ψ values are not located within 
the allowed region of the Ramachandran plot for non-glycine residues is 
particularly disruptive. A list of all the φ and ψ values (Appendix A) was 
obtained from Professor George D. Rose’s website at the Department of 
Biophysics, Johns Hopkins University.  
 X (Any amino acid except proline)->proline 
A nsSNPs change from any amino acid residue (wild) to a proline residue 
(mutant) where the mutant main chain angle (φ and ψ) value is not 
compatible with proline is also very disruptive. 
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The nsSNPs were mutated computationally using the mutagenesis feature in PyMOL and 
scripted in Perl. In analysing the post-mutated state of the structures, the SCWRL 
program (Krivov et al., 2009) was used. 
Table 8: A structure-based analysis of dSNPs at the interface region. 
 dSNPs 
Class A (n = 620) Class B (n = 248) Class C (n = 372) 
Loss of a salt bridge 77 12% 10 5% 67 18% 
Loss of a H-bond 35 6% 16 6% 19 5% 
Loss of a disulphide bond 54 9% 36 15%  18 5% 
Loss of a hydrophobic effect 57 9% 42 17% 15 4% 
Steric clash 103 17% 17 7% 86 23% 
Backbone strain: X->Pro 51 8% 47 19% 4 1% 
Backbone strain: Gly->X 50 8% 50 20% 0 0% 
Change in polarity 142 23% 97 39% 45 12% 
Change in side-chain charge 139 22% 102 41% 37 10% 
Class A refers to all the dSNPs in humsavar, Class B refers to the dSNPs that were predicted to be deleterious 
by Polyphen2 and Class C refers to the dSNPs that were predicted to be benign by Polyphen2. The sum for the 
entire percentages in a group does not equal 100% because an nsSNP can affect more than one feature or it 
may not affect any of the features listed. 
Table 8 shows that for Class A, the changes in polarity and side-chain charges, steric 
clash and loss of salt bridge are the most frequent structural features identified. For 
Class B (predicted deleterious), the changes in polarity and side-chain charges, 
backbone strains and loss of hydrophobic effect are the top structural features 
identified. This suggests that Polyphen2 underestimates the effect of loss of a salt 
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bridges and steric clash on protein stability and function. Furthermore, Class C 
(predicted benign) exhibits an abundance of loss of salt bridge and steric clash 
mutations, which could be related to the high false negative rate observed in Table 5. 
This result supports the hypothesis that Polyphen2 may have misclassified some 
variants due to the limited consideration of structural features. This is because 
Polyphen2 only includes three structural features: phi-psi dihedral angles, secondary 
structure and accessible surface area. By including two other structural features, steric 
clash and loss of salt bridge, the sensitivity of the prediction server could be improved. 
Another observation that can be derived from Table 8 was that a majority of the dSNPs 
destabilize proteins by affecting multiple structural features. Table 9 shows the number 
of structural features for Class A, Class B and Class C. The table shows that for Class A, 
the associated proteins were destabilized by one or more structural features 86% of the 
time. For Class B, this was 73%, and a majority of the associated proteins in Class C are 
affected by factors other than protein stability. 
Table 9: The number of structural features for dSNPs at the interface region 
 Number of 
nsSNPs 
Number of features 
= 0 
Number of features = 
1 
Number of features 
≥1 
Class A 620 12 2% 74 12% 533 86% 
Class B 248 47 19% 20 8% 181 73% 
Class C 372 201 54%  375 10% 134 36% 
As in Table 8, Class A refers to all the dSNPs in humsavar, Class B refers to the dSNPs that were predicted to 
be deleterious by Polyphen2 and Class C refers to the dSNPs that were predicted to be benign by Polyphen2. 
The findings are similar to a previous study that looked at the effect of disease SNPs and 
protein stability by Wang and Moult (2001). The authors observed that the 
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destabilization of proteins was the major effect of dSNPs. However, the main difference 
between this result and that of Wang and Moult (2001) or Martin et al. (2002) is in 
regard to the location of the SNPs. In this thesis, the emphasis is on the nsSNPs at the 
interface. In contrast, Wang and Moult (2001) were more general while Martin et al. 
(2002) focused primarily on the core domain of the p53 protein. The findings related to 
the multiple structural features corroborates a recently published study by Hurst et al. 
(2009), in which they had observed a percentage, of approximately 88%. They 
considered a similar number of structural features with the addition of sequence 
conservation. Although Hurst et al. (2009) did analyse the disruption to quaternary 
structure, the authors did not observe the same findings as we did in regards to the 
pathogenic SNPs at the occurring at interfaces. Instead, they found that pathogenic SNPs 
tend to occur at the core, which is not the focus of this thesis.  
For the dSNPs that were not assigned any feature, their disease state could be due to 
their involvement in non-stability-related activities. For example, a mutation from a 
protein might not be assigned any structural feature because it occurs at a ligand-
binding site. Other than involvement in ligand-binding sites, some of the unassigned 
dSNPs could also be involved in catalytic sites, involvement in allosteric regulation or 
post-translational modification. 
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Table 10: A structure-based analysis of pSNPs at the interface 
 pSNPs 
Class A 
(n = 294) 
Class B 
(n = 162) 
Class C 
(n = 132) 
Loss of a salt bridge 12 4% 5 3% 7 5% 
Loss of a H-bond 13 4% 8 5% 5 4% 
Loss of a disulphide bond 0 0% 0 0% 0 0% 
Loss of hydrophobic effect 0 0% 0 0% 0 0% 
Steric clash 8 3% 3 2% 5 4% 
Backbone strain: X->Pro 23 8% 19 12% 4 3% 
Backbone strain: Gly->X 19 6% 16 10% 3 2% 
Change in polarity 45 15% 32 20% 13 10% 
Change in side-chain 
charge 
49 17% 39 24% 17 13% 
As in Tables 8 and 9, Class A refers to all the pSNPs in humsavar, Class B refers to the pSNPs that were 
predicted to be deleterious by Polyphen2 and Class C refers to the pSNPs that were predicted to be benign by 
Polyphen2. The sum for the entire percentages in a group does not equal 100% because a nsSNP can affect 
more than one feature or it may not affect any of the features listed. 
Table 10 describes the distribution of structural features affected by pSNPs in interface 
regions. 
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Table 11: A structure-based analysis of uSNPs at the interface 
 All uSNPs 
(n = 350) 
Class B 
(n = 266) 
Class C 
(n = 84) 
Loss of a salt bridge 39 11% 12 5% 27 32% 
Loss of a H-bond 14 4% 11 4% 3 4% 
Loss of a disulphide bond 5 1% 5 2% 0 0% 
Loss of hydrophobic effect 3 1% 3 1% 0 0% 
Steric clash 35 10% 10 4% 25 30% 
Backbone strain: X->Pro 28 8% 26 10% 2 2% 
Backbone strain: Gly->X 21 6% 21 10% 0 0% 
Change in polarity 134 38% 122 46% 12 14% 
Change in side-chain 
charge 
142 41% 125 47% 8 10% 
As in Tables 8–10, Class A refers to all the uSNPs in humsavar, Class B refers to the uSNPs that were 
predicted to be deleterious by Polyphen2 and Class C refers to the uSNPs that were predicted to be benign by 
Polyphen2. The sum for the entire percentages in a group does not equal to 100% because an nsSNP can 
affect more than one feature or it may not affect any of the features listed. 
Table 11 shows the results from the structural analysis of uSNPs at the interface. The 
result for the predicted deleterious uSNPs reveals a similar pattern to what was 
observed for Class B (correctly predicted dSNPs by Polyphen2) in Table 8. For predicted 
benign uSNPs, a spike in percentage was observed for both loss of a salt bridge and 
steric clash. Since Polyphen2 does not consider these two features in its algorithm, 
some of the uSNPs that were predicted to be benign could actually be pathogenic. 
However, not many of the predicted benign uSNPs resulted in backbone strain, 
although, again, this feature is not explicitly included in the algorithm. However, this 
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feature may be indirectly included via consideration of allowed residues at that position 
since a residue leading to steric strain would not be (or just rarely) observed in close 
homologues.  
 There is also the possibility that the uSNPs could potentially apply stabilization 
mechanisms. Previous studies have shown how proteins can tolerate most neutral 
polymorphic effects by introducing a stabilization mechanism (Nagata et al., 1999, 
Silverman et al., 2001, Kunichika et al., 2002, Guo et al., 2004). 
The objective of the structural analysis was to provide a structure-based explanation for 
the effect of dSNPs and non-dSNPs at the protein interface. The dSNPs were observed to 
destabilize protein via a combination of multiple structural features. Similarly, 
predicted deleterious uSNPs at the interface also tend to destabilize protein via multiple 
structural features. Another observation was the important role that deleterious nsSNPs 
at the interface play in protein stability. This result confirms a previous study (Yue et al., 
2005), which showed that the majority of nsSNPs affect protein stability. Destabilizing a 
protein indirectly affects the interaction capability of the protein as well, as has been 
shown by a number of studies (Bonet et al., 2005) (Jelesarov and Karshikoff, 2009) 
(Byrum et al., 2012). 
While some of the predicted deleterious uSNPs may disturb protein stability, it is 
important to consider conformational rearrangement in negating nsSNP changes, as 
shown by Zhang et al.(2010). The authors used energy calculations to model the 
energetic changes due to a mutation. They found that the mutations had very little effect 
on energy because of the ability of proteins to undergo structural relaxation. This would 
therefore minimize any steric clashes and unfilled cavities. 
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3.4 Global minor allele frequency (GMAF) of non-disease 
causing SNPs (non-dSNPs) 
In this third analysis, the global minor allele frequencies (GMAF) for predicted 
deleterious non-dSNPs was examined. Because a deleterious nsSNP may harm the 
stability or function of a protein, such nsSNPs are expected to be rare in a population. 
An allele refers to a specific DNA polymorphism at a specified position in a 
chromosome. In a diploid organism, such as human, each chromosome will have one 
copy of each allele, one allele from the mother and another allele from the father. If the 
two alleles are the same, the individual’s genotype is homozygous for that locus. If the 
alleles are different, the individual genotype is heterozygous. When the alleles are 
heterozygous, one allele may be dominant to the other. In a heterozygote, the 
expression of a dominant allele masks the recessive allele. In this case, the dominance is 
identified as a complete dominance. There are two other types of dominance, partial 
dominance and co-dominance. The former refers to the production of an intermediate 
phenotype in individuals heterozygous for a given gene, and the latter refers to the 
production of a phenotype that results from both alleles being expressed when neither 
allele is recessive. 
The minor allele frequency is the proportion of all chromosomes in a population that 
bear the less common allele. Minor allele frequencies generally differ between 
populations. For example, an allele might be less common in a Chinese population than 
in an African population. In this section, since the thesis is not focused on any one 
particular population, the global minor allele frequency is used. One would expect that a 
SNP that causes damaging effects would be rare in population. In contrast, a 
polymorphism that does not cause damage would be expected to be common in a 
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population. A number of recently published studies have indeed shown that rare and 
disease SNPs tend to have low GMAF (Tennessen et al., 2012) (Verde et al., 2012) (Casto 
and Feldman, 2011) (McClellan and King, 2010). 
Currently, the main issue regarding the application of GMAF to this topic is determining 
a standard threshold at which a SNP is too rare to make any significant contribution to 
mutational studies. This problem occurs due to insufficient statistical power when a 
frequency is too low. Generally, the power of a statistical test depends on the size of the 
dataset—the larger the dataset, the more reliable the result is. If a researcher were 
studying a rare nsSNP that affects a population, they would need a large dataset in order 
to obtain a significant association. In the past, it was impossible for a researcher to do 
this, but nowadays, with the development of various sequencing technologies (Levy et 
al., 2007); (Wheeler et al., 2008); (Bentley et al., 2008) this is no longer a problem. 
The HapMap project, a project undertaken to find and identify patterns in human 
genetic variation, only analysed variants that have a GMAF ≥ 5% (Gibbs et al., 2003). 
Similarly, the 1000 Genome Project also focuses on variants with a GMAF ≥ 5% 
(Altshuler et al., 2010). However two recent studies (Tennessen et al., 2012) (Verde et 
al., 2012) have shown that a GMAF < 10% can be used to identify rare variants. 
Therefore, in this study, a GMAF threshold of <10% is used to identify a variant as rare. 
In order to make the study as general as possible (i.e., not population specific) this 
GMAF value was used because different populations may have a different or similar 
MAF value. The GMAF reports the minor allele frequency for each dbSNP identifier 
included in a default global population. The default global population at the time of 
writing is the 1000 Genome Project (Phase 1) genotype data from 1094 worldwide 
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individuals, released in the May 2011 dataset. The list of GMAF values was downloaded 
from the NCBI dbSNP website. 
The GMAF results are shown in Table 12, and in order to analyse the result, we 
compared the observations to the null model of an equal number ≤10% and >10%. The 
table shows that a majority of the dSNPs have a frequency less than or equal to 10% (χ2 
= 597.026, p-value < 0.001). Similarly, the same pattern holds for a majority of the 
uSNPs (χ2 = 68.220, p-value < 0.001). In contrast, a majority of pSNPs were observed to 
have a frequency of more than 10% (χ2 = 463.923, p-value < 0.001). These findings are 
consistent with previously published findings (Tennessen et al., 2012) (McClellan and 
King, 2010) that showed that the rarer a variant is the higher the likelihood that it is 
unfavourable, potentially indicating pathogenicity. 
Next, each type of nsSNP was considered (dSNPs, pSNPs and uSNPs). To my knowledge, 
this is the first study that looks at the relationship between interface and rare nsSNPs. 
The study evaluated, using χ2 tests, whether the distribution of GMAF ≤10% (low GMAF) 
and >10% (high GMAF) with a particular type of region was significantly different from 
the distribution in the other two types of regions. The results are shown in Table 12, 
where ‘*’ next to a number denotes a significant enrichment. All results are significant at 
0.01% level of significance, so the conclusions would not be altered by a Bonferroni 
correction.  
Table 12: The GMAF result for all nsSNPs mapped to structures 
 dSNPs 
(n = 2,420) 
pSNPs 
(n = 1,133) 
uSNPs 
(n = 762) 
≤10% >10% ≤10% >10% ≤10% >10% 
Interface 554* 66 50 244 278* 72 
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Surface 
non-
interface 
499 520* 109 555* 134 163* 
Buried 758* 23 45* 130 83 32 
Total 1811 609 204 929 495 267 
Each nsSNPs group is divided into three columns: nsSNPs for which GMAF is less than or equal to 10% 
(≤10%), nsSNPs with GMAF values more than 10% and nsSNPs where there is no GMAF value for (≤10%). A 
‘*’ denotes a significant (p < 0.01, without a Bonferroni correction) enrichment between GMAF SNPs ≤10% 
and < 10% for that region compared to the totals in the other two regions for a given type of nsSNP. 
For dSNPs, both buried regions and interfaces are enriched in low GMAF nsSNPs, whilst 
the surface is enriched in high GMAF nsSNPs. For pSNPs, the buried regions are 
enriched in low GMAF nsSNPs, whilst the surface is enriched in high GMAF nsSNPs; 
however, there was no enrichment of low GMAF nsSNPs at the interface. For uSNPs, the 
interface is enriched in low GMAF nsSNPs, whilst the surface is enriched in high GMAF 
nsSNPs. Thus the enrichment of uSNPs at the interface is the same (in favour of low 
GMAF) for dSNPs, but different to pSNPs. This suggests that many uSNPs at interfaces 
might be disease causing. 
In conclusion, we have shown that GMAF can be a good indicator for identifying and 
discriminating between deleterious and non-deleterious nsSNPs. The limiting factor in 
this study could be the bias towards Caucasian data in the GMAF calculation. However, 
with the expansion of the 1000Genome project, it is hoped that the GMAF will be more 
representative of the global population. At the time of the experiment, none of the major 
SNP servers considered GMAF as a factor in their algorithms.   
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3.5 Case studies of predicted deleterious non-disease causing 
SNPs (non-dSNPs) 
In the previous analyses, the GMAF value was used in order to examine the relationship 
between SNP rarity and pathogenicity. In order to verify the result of the structural 
analysis, manual examination of their structures was performed using the PyMOL 
program. Similar to the case studies for dSNPs presented in Chapter 2, PyMOL was used 
to mutate the residues, and SCWRL was used to re-build the side chains. Four non-
dSNPs occurring at the interface were chosen for the case studies. The case studies were 
selected from uSNPs and pSNPs that were predicted to be deleterious by Polyphen2, 
affect protein stability and have GMAF values less than 10%. 
Pyruvate dehydrogenase E1 component subunit alpha, testis-specific form, 
mitochondrial (UniProt ID: P29803 | dbSNP ID: rs17024795) 
Pyruvate dehydrogenase E1 component subunit alpha (PDHA2) E1 is the first 
component in the pyruvate dehydrogenase complex (PDC). The other two components 
are dihydrolipoamide acetyltransferase (E2) and lipoamide dehydrogenase (E3). The 
pyruvate dehydrogenase complex catalyses the conversion of pyruvate to acetyl-CoA 
and CO2 (Dahl et al., 1990). E1 performs decarboxylation of pyruvate and reductive 
acetylation of lipoic acid, which is bound to E2. The E1 alpha subunit regulates the 
activity of E1 by phosphorylation and dephosphorylation (Dahl et al., 1990). A study has 
shown that mutation of the E1 alpha subunit (PDHA2) can cause a congenital 
degenerative metabolic disease called pyruvate dehydrogenase (PDH) deficiency (Frye 
and Benke, 2007). 
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Figure 19 shows the wild type of the nsSNP (R349G) located in the interface between 
PDHA2 and PDCE2-R349G. The nsSNP is predicted to be deleterious by Polyphen2. It 
also has a minor allele frequency of less than 10%. Analysis suggests that the R349G 
substitution would abolish a salt bridge with E281 in PDCE2. This could result in a 
weaker affinity for interactions between the two chains. Since the R349 substitution 
occurs in the pocket region, the specificity of the enzyme could be affected. 
 
Figure 19: A diagram of the interface of death-associated protein kinase 2 
(DAPK2) represented in cartoon figure from human pyruvate dehydrogenase 
S264E variant complex - PDB entry 2OZL - (Seifert et al., 2007). The figure shows 
both pre-mutation state and post-mutation state. The two chains, PDHA2 and PDCE2, 
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are represented in light red coloured chain and in light blue coloured chain respectively. 
The wild-type SNP (R349) represented as a red stick in the pre-mutation state, makes a 
salt bridge with the interacting chain of PDCE2 at E281 (pre-mutation state). The 
mutant SNP, a glycine, is shown in the post-mutation state resulting in the loss of the 
salt bridge. 
 
Death-associated protein kinase 2 (UniProt ID: Q9UIK4 | dbSNP_ID: rs56047843) 
Death-associated protein kinase 2 (DAPK2) is part of the serine/threonine protein 
kinase family. It is involved in multiple cellular signalling pathways that trigger cell 
survival, apoptosis and autophagy. It regulates both type I apoptotic and type II 
autophagic cell death signals, depending on the cellular setting. The former is caspase-
dependent, while the latter is caspase-independent and is characterised by the 
accumulation of autophagic vesicles. In addition, it may also play a role in granulocytic 
maturation. 
Figure 20 shows the wild-type variant, R50W, located in the interface, which is 
predicted to be deleterious by Polyphen2. A study (Greenman et al., 2007) that 
examined 1000 somatic mutations (mutations occurring on non-germ cells), including 
the R50W substitution, showed that many of the somatic mutations are not directly 
involved in cancer; however, they might contribute to the development of cancer. The 
authors made this conclusion from the enrichment of non-synonymous SNPs compared 
to synonymous SNPs and by looking at the conservation of substitutions. The R50W 
substitution causes the loss of a salt bridge between the arginine at residue 50 and the 
aspartic acid at residue 220 in the interacting chain. In addition, the substitution also 
results in steric clash with leucine at position 218 of the interacting chain. 
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Figure 20: A diagram of death-associated protein kinase 2 (DAPK2)represented 
above in a cartoon figure from the human death-associated protein kinase 
complex (PDB entry 2A2A) (Tereshko et al., 2001). The figure shows both pre-
mutation state and post-mutation state. The figure shows the interface between chain A 
(light red coloured chain) and chain B (light blue coloured chain).The wild type SNP 
(R50) is represented as a red stick and it occurs at the loop region in the pre-mutation 
state. The mutant SNP, a tryptophan represented by a white stick in the post mutation 
state, is shown causing a lost of salt bridge and a potential steric clash with residues 
from the interacting chain. 
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Adenylate kinase isoenzyme 1 (UniProt ID: P00568| FTid: VAR_055338) 
Adenylate kinase isoenzyme 1 (AK1) is part of the adenylate kinase family enzyme. 
Adenylate kinase catalyses the reversible transfer of the terminal phosphate group 
between ATP and AMP. It is involved in energy metabolism by modulating the inter-
conversion of adenine nucleotides 2ADP ⇔ AMP + ATP. AK1 is an isozyme of AK and, in 
mammals, it is found in abundance in skeletal muscle. 
Figure 21 shows the wild-type variant, G67, which is located in the interface. G67R is 
predicted to be deleterious by Polyphen2. Since the G67R substitution occurs in the 
AMP binding domain of adenylate kinase, it may affect the AMP binding affinity. The 
analysis shows that the G67R substitution may result in a steric clash with valine at 
position 75 of the interacting chain. In addition, the G67R substitution could cause a 
backbone strain due to the φ and ψ backbone angle of arginine being outside of the 
Ramachandran sterically allowed region (74.7° φ & 16.5° ψ). 
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Figure 21: A diagram of adenylate kinase isoenzyme 1 (AK1) represented above 
in a cartoon figure from the complex of adenylate kinase 5 (PDB entry 2BWJ). The 
figure shows both pre-mutation state and post-mutation state. The interface is between 
chain F (represented by light red coloured chain) and chain C (represented in light cyan 
coloured chain). The wild type SNP (G67), represented as a red coloured stick, occurs at 
the loop position of helix-loop-helix region in the pre-mutation state. The mutant SNP, 
an arginine represented by a white coloured stick in the post mutation state, is shown 
causing steric clash with residues from the interacting chain. 
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Haemoglobin subunit alpha (UniProt ID: P69905 | FTid: VAR_002855) 
Haemoglobin is involved in transporting oxygen from the lung to the various peripheral 
tissues. It is a hetero tetramer complex of two alpha chains and two beta chains. Figure 
18 shows the 1bz1 complex that consists of two alpha and two beta chains. The alpha 
chains form the haemoglobin subunit alpha (HBA) protein while the two beta chains 
forms the haemoglobin subunit beta (HBB). 
Figure 18 shows the wild type variant, R142P, which is located in the interface between 
HBA and HBB. The nsSNP is predicted to be deleterious by Polyphen2. The salt bridge 
between arginine at position 142 and aspartic acid at position 127 is disrupted when 
the arginine is substituted with a proline. In addition, the substitution of proline causes 
backbone strain due to the φ and ψ main chain angle of the wild nsSNP (arginine) not 
being compatible with proline (74.7° φ). This is because in the Ramachandran plot, 
proline has a very limited allowed region (see Appendix A). 
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Figure 22: A diagram of haemoglobin subunit alpha (HBA)represented above in a 
cartoon figure from the haemoglobin (alpha+met) variant complex (PDB entry 
1BZ1) (Hui et al., 1999). The figure shows both pre-mutation state and post-mutation 
state. The interface is between HBA represented by a light red coloured chain and HBB 
represented by light cyan coloured chain. The wild type SNP (R142) occurs at the 
terminal end of the chain and represented by a red coloured stick in the pre-mutation 
state. The mutant SNP, a proline represented as a white stick in the post-mutation state, 
is shown in the figure causing backbone strains. 
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3.7 Conclusion 
This chapter has described three methodologies, prediction of deleterious status, 
analysis of structural features and consideration of GMAF values, which can be 
performed in order to investigate the pathogenicity of nsSNPs. In addition, it was also 
shown that some of the uSNPs could potentially be pathogenic nsSNP (i.e., dSNPs).  
In the first method, the Polyphen2 SNP server was chosen to predict the deleterious 
nature of the nsSNPs. This study showed that 52% (395 out of 762) uSNPs are predicted 
to be damaging. Several of the predicted deleterious uSNPs were at the interface, 
supporting the notion of the importance of the interface region in regard to disease 
pathogenesis as mentioned in Chapter 2 and in our paper (David et al., 2012). 
In the second methodology, the predicted deleterious nsSNPs at the interface were 
examined from a structural perspective by considering eight structural features. A 
majority of these nsSNPs affect protein interactions by destabilizing the protein via 
multiple features. It was also observed that many of the dSNPs that Polyphen2 identifies 
to be benign are not (i.e., false negative) and affect changes, such as loss of a salt bridge 
and causing a steric clash. We hypothesized that this is due to the exclusion of these two 
structural features in the Polyphen2 algorithm. 
For the last methodology, the GMAF values were assigned and examined. A cutoff of less 
than 10% was used to categorize a variant as rare. The result showed a majority of the 
dSNPs and uSNPs have a GMAF value below the cutoff, which indicates that they tend to 
be rare variants. The results also suggest that many uSNPs at the interface tend to be 
rare variants, which suggests that they may be disease causing. 
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4 The 1000 Genomes project 
4.1 Introduction 
In the second chapter, disease nsSNPs (dSNPs) were found to be more likely at the 
interface region compared to the other areas on the protein surface. A larger dataset of 
nsSNPs would give more insight as to whether this observation is correct. Accordingly, 
in this chapter, nsSNPs from the 1000 Genomes Project (Consortium, 2012) were 
examined. 
The 1000Genome Project (1KGP) is an international research collaboration focusing on 
genetic variation in humans (Consortium, 2012). There are two goals of the 1KGP. The 
primary goal is to create a comprehensive catalogue of human genetic variation. 
Additionally, the aim is to estimate the population frequencies, haplotypes and linkage 
disequilibrium patterns. The second goal is to support better SNP and probe selection 
for genotyping platforms in future studies and for the improvement of the human 
reference sequence. The overarching aim is to create a useful database for researchers 
studying all types of human mutation. 
Previously, the human reference genome was used as a standard in identifying variants 
in the human genome. However, studies since the establishment of the reference human 
genome in 2003 have shown that a different population may have a different tendency 
towards different diseases. In the 1KGP, individuals from different populations across 
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the world were sequenced, and the result should be more informative than the 
reference human genome. 
In this 1KGP study, the same structural interactome dataset from Chapter 2 will be used 
in mapping SNPs to structure. 
4.2 Changes to the previous methodology 
Changes were made since the publication described in the UniProt humsavar study (see 
Chapter 2). These changes were in response to the feedback received during the 
publication of the journal paper (David et al., 2012) detailing the result from the 
humsavar study. 
The first change was regarding the size in identifying the interface region (minimum of 
5 residues). Although it was shown in the work by Kinjo & Nakamura (2010) that even 
less than 30 atoms was sufficient to identify an interface, the feedback showed 
disagreement. Thus, in the 1KGP study, a new set of interface definitions was proposed.  
The size of an interface is defined as the loss of accessible surface area upon complexion 
(from a monomeric state to a dimeric state), denoted by the symbol ΔASA. A study on 
the principles of protein–protein interactions by Jones and Thornton (1996) 
demonstrated that the ΔASA per recognition patch for homodimers and heterodimers 
were from 368 Å2 to 4746 Å2 and 639 Å2 to 3228 Å2, respectively. Subsequently in 
another study (Chakrabarti and Janin, 2002) that analysed the recognition sites of 70 
pair-wise protein–protein complexes from known three-dimensional structures found 
that the interface size is on average 800 Å2 per recognition patch. Similarly, in a study 
by Bahadur et al. (2003) that used 122 homodimers of known three-dimensional 
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structures, interface size per recognition patch was found to range from 498 Å2 to 
7149Å2.  
In the humsavar study, although the minimum number of interface residues per chain 
required for identification of an interface was five residues, the smallest number of 
interface residues in a chain was seven. The protein with seven interface residues was 
trafficking protein particle complex subunit 2 (TRAPPC2), a protein that prevents the 
repression of transcription and aids vesicular transport from endoplasmic reticulum to 
Golgi. In the humsavar analysis, TRAPPC2 had the lowest interface area, 222 Å2. The 
protein with the highest number of interface residues, as well as the largest interface 
area, was DNA-directed RNA polymerase II subunit RPB1 (POLR2A). The enzyme has 
496 interface residues out of 1,970 total residues and an interface area of 12,116 Å2. 
To determine the minimum surface area required, the original dataset of 1,027 proteins 
(see Figure 4) was analysed. Figure 23 shows a scatter plot between numbers of 
interface residues and size of interface area for all the proteins, while Figure 24 shows a 
subset of the scatter plot (interface area ≤ 1600 Å2). 
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Figure 23: A scatter plot showing the number of interface residues against the 
interface area. The data consist of 1,027 proteins that were obtained from the original 
interactome dataset. 
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Figure 24: The scatter plot from the subset of 1,027 proteins in the structural 
interactome dataset. The subset contains protein that has an interface area ≤1600Å2. 
The scatter plot shows there were a few proteins below having interface residues below 
10. 
 
Figure 24 shows that the 1,027 proteins confirm the results of Jones and Thornton 
(1996) and Bahadur et al. (2003) in regard to the size of interface area. However, from 
the scatter plot it can be assumed that a small increase in the minimum number of 
interface residues per chain would not have any significant effect on the overall protein 
dataset.  
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Therefore, the parameters used to identify an interface residue and interface patch were 
as follow: 
a) A residue was defined as an interface residue if any of its atoms were within ≤5 Å of 
an interacting atom in another chain. 
b) A residue was defined as an interface residue when its ΔASA > 1 Å2 upon forming a 
complex. 
c) An interface patch was defined as having a minimum contact of five residues per 
chain. 
d) An interface patch was defined as having an interface area ≥400 Å2. 
The second type of feedback was regarding the resolution quality of the PDB files, which 
was also addressed. The PDB website describes the resolution as follows: 
“Resolution in the PDB file is defined as a measure of quality of that has been 
collected on the crystal containing the protein or nucleic acid. If all of the 
proteins in the crystal are aligned in an identical way, forming a perfect crystal, 
then all of the proteins will scatter X-rays the same way, and the diffraction 
pattern will show the fine details of crystal. On the other hand, if the proteins in 
the crystal are all slightly different, due to local flexibility or motion, the 
diffraction pattern will not contain as much fine information.” 
http://www.rcsb.org/pdb/101/static101.do?p=education_discussion/Looking-
at-Structures/resolution.html 
Figure 25 shows a histogram of PDB resolution from the 1,027 proteins dataset (822 
PDB structures). As shown in Figure 25, the majority of the structures (80% or 658 
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structures) have a resolution below 2.75 Å. Therefore, only structures resolved at a 
scale better than 2.75Å were considered. This is to reduce the possibility of having 
substantial errors in coordinates. 
The two changes made to the previous methodology result in a new protein dataset 
consisting of 830 proteins. This was a reduction of 19% from the original dataset of 
1,027 proteins. 
 
Figure 25: The histogram of PDB resolution from 822 structures. The graph shows 
that majority of the data were between 1.75 Å -2.75Å. The line in the graph shows the 
limit at 2.75Å, where ≥80% of the data was observed. 
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4.2.1 Reassessment of the UniProt humsavar study 
In order to examine the effects of the changes, the protein dataset from the humsavar 
study was reassessed. In the previous humsavar study, 4,315 nsSNPs from 537 proteins 
were observed. From these 4,315 nsSNPs, 1,251 nsSNPs (29%) were located in 
interface regions, 1,079 nsSNPs (25%) in buried regions, and 1,985 (46%) on the 
surface non-interface regions. 
The new definitions for interface and PDB resolution were applied to the humsavar 
protein dataset. From 537 proteins, 348 proteins met the new criteria. The total number 
of residues was 115,106, where 27,282 were buried residues (24%), 28,673 were 
interface residues (25%) and 59,151 were surface non-interface residues (51%). Of the 
total number of SNPs, 1,499 were identified as dSNPs, 816 were identified as pSNPs and 
461 were identified as uSNPs. In order to differentiate the humsavar study in Chapter 2 
with the reassessed humsavar study, the former is given the HSVRO abbreviation while 
the latter is abbreviated as HSVRN. 
Table 13: The location of nsSNPs on protein complexes in the HSVRN study 
 dSNPs pSNPs uSNPs 
Position Buried Interface Surface 
non-
interface 
Buried Interface Surface 
non-
interface 
Buried Interface Surface 
non-
interface 
Total residues 27,282 28,673 59,151 27,282 28,673 59,151 27,282 28,673 59,151 
Observed 530 429 540 133 205 478 74 172 215 
Expected 355 373 770 193 203 419 109 115 237 
Observed:Expected 
ratio 
1.5 1.1 0.7 0.7 1.0 1.1 0.7 1.5 0.9 
 
121 
 
 
Table 14: The location of nsSNPs on protein complexes in the HSVRO study 
 dSNPs pSNPs uSNPs 
Position Buried Interface Surface 
non-
interface 
Buried Interface Surface 
non-
interface 
Buried Interface Surface 
non-
interface 
Total residues 42,342 43,381 112,805 42,342 43,381 112,805 42,342 43,381 112,805 
Observed 781 620 1019 175 294 664 115 350 297 
Expected 516 529 1375 242 248 644 163 167 433 
Observed:Expected 
ratio 
1.5 1.2 0.7 0.7 1.2 1.0 0.7 2.1 0.7 
 
Table 13 and Table 14 show the number of observed and expected SNPs for each 
nsSNPs class within different protein regions for HSVRN and HSVRO. A comparison 
between the two datasets was performed. Although in general there was no significant 
difference between the numbers of interface and surface non-interface nsSNPs in the 
two datasets (χ2 = 0.145, p-value = 0.703), a 2 × 2 contingency table shows a significant 
difference between the numbers of interface dSNPs and surface non-interface dSNPs (χ2 
= 10.253, p-value = 0.001) in the two datasets. In addition, a similar observation was 
observed in a comparison of the numbers of interface uSNPs and surface non-interface 
uSNPs (χ2 = 8.642, p-value = 0.003). No significant difference was detected between 
interface pSNPs and surface non-interface pSNPs (χ2 = 0.057, p-value = 0.811) in the 
two datasets. This could be explain by the relatively few pSNPs occurring at the 
interface. Additionally, there was also no significant difference detected between buried 
and interface in all three groups (χ2 = 1.268, p-value = 0.260).  
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Table 15 and Table 16 show the results of the enrichment analysis on the HSVRN and 
HSVRO datasets, respectively. In the dSNPs group, all three comparisons (Core-Surface, 
Core-Interface and Interface-Surface) show similar patterns for both datasets. In 
addition, the odds ratio for the dSNPs Interface-Surface class increased from 1.59 
(HSVRO) to 1.64 (HSVRN). In the earlier study using HSVRO, it was observed that the 
OR for pSNPs between interface and surface non-interface (Interface-Surface) was 
significantly greater than 1.0 (OR = 1.15, CI = 1.00-1.32, p-value = 0.04). In the newer 
HSVRN dataset, the OR for finding more pSNPs at the interface compared to surface 
non-interface was not significantly greater than 1.0 (OR = 0.89, CI = 0.70-1.12, p-value = 
0.312). The significance of the difference of two odds ratios can be tested using the 
method described by (Altman and Bland, 2003). The test shows that the difference in 
the ORs is not significant (p = 0.07, two-tailed test) Nevertheless, this result based on 
HSVRN suggests that using the new definitions with further observations we may be 
able to obtain significant results that neutral polymorphism (pSNPs) would be found 
more often on the surface non-interface than in the interface region. This would be 
more consistent with what one would have expected, since at the interface, pSNPs are 
more likely to affect protein interactions 
Table 15: The odds ratio between different nsSNPs classes for HSVRN proteins 
 dSNPs pSNPs uSNPs 
Type Core-
Surface 
Core-
Interface 
Interface-
Surface 
Core-
Surface 
Core-
Interface 
Interface-
Surface 
Core-
Surface 
Core-
Interface 
Interface-
Surface 
Odds ratio 
(OR) 
1.66 1.30 1.64 0.63 0.68 0.89 0.62 0.45 1.65 
Bonferroni 
corrected p-
< 0.001 < 0.01 < 0.001 < 0.001 < 0.05 > 0.5  < 0.05 < 0.001 < 0.01 
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value 
95%  
confidence 
interval 
1.42–
1.95 
1.08–1.55 1.37–1.98 0.49–
0.80 
0.50–0.92 0.70–1.12 0.45–
0.86 
0.31–0.65 1.24–2.22 
This table shows the odds ratio for each SNP type (dSNPs, pSNPs and uSNPs). For each type of SNP, a 
comparison was made between buried and surface (Core-Surface), buried and interface (Core-Interface) and 
interface and surface non-interface (Interface-SNI). 
 
Table 16: The odds ratio between different nsSNPs classes for HSVRO proteins 
 dSNPs pSNPs uSNPs 
Type Core-
Surface 
Core-
Interface 
Interface-
SNI 
Core-
Surface 
Core-
Interface 
Interface-
SNI 
Core-
Surface 
Core-
Interface 
Interface-
SNI 
Odds ratio 
(OR) 
1.77 1.30 1.59 0.67 0.61 1.15 0.65 0.33 3.08 
Bonferroni 
corrected 
p-value 
< 0.001 < 0.02 < 0.001 < 0.02 < 0.005 > 0.5 < 0.01 < 0.001 < 0.001 
95% 
confidence 
interval 
1.62–
1.93 
1.10–1.51 1.44–1.76 0.57–
0.79 
0.50–0.73 0.94–1.41 0.54–
0.80 
0.25–0.45 2.64–3.60 
The table shows the odds ratio for each SNP type (dSNPs, pSNPs, and uSNPs). For each type of SNP, 
comparison was made between buried and surface (Core-Surface), buried and interface (Core-Interface) and 
interface and surface non-interface (Interface-SNI). 
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The other main difference between the HSVRN and HSVRO studies was the OR for 
uSNPs. In the HSVRO, the OR for uSNPs was 3.08 (see Table 16), while in the HSVRN 
study it was 1.65 (see Table 15). The difference in ORs is significant at the 1% level 
(two-tailed test) Although there was this was this significant reduction, the OR for uSNPs in 
the HSVRN remains significantly greater than 1.0 (p-value<0.05).  
Three general observations can be made. Similar to the HSVRO study, the HSVRN study 
found that dSNPs had significant preference to occur at the interface compared to surface 
non-interface. The uSNPs in the HSVRN study were more likely to be at the interface 
compared to all other protein regions, similar to whatas was seen in the HSVRO study. The 
pSNPs in the HSVRN study just failed (at the 5% level) to have a significantly different OR 
compared to pSNPs in the HSVRO. In conclusion, the reassessment of the humsavar dataset 
suggests that applying the new definitions of interface regions and resolution cutoff had 
resulted in the enrichment analysis of non-dSNPs being more consistent with biologically 
based expectations. This was achieved by re-identifying the position of nsSNPs that were 
previously identified to occur at the interface and by removing proteins that had a low 
resolution or small interface area. 
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4.3 The 1000 Genomes Project (1KGP) dataset 
The 1KGP variants dataset was downloaded from the NCBI FTP site. The FTP site 
includes all variants (including copy-number variations, SNPs, indels and others) for all 
chromosomes from all populations around the world. However, the 1KGP SNP variant 
dataset can also be downloaded directly from the dbSNP website. This is because since 
September 2010 (build 132), SNP variants from the 1KGP are automatically added to 
the dbSNP database. For this study, the dbSNP build 135 was used, which contains 
21,247,880 SNPs. 
However, since the study only focuses on nsSNPs that were associated with proteins 
from the structural interactome dataset described in Chapter 2, an automated system 
for retrieving the list of associated SNPs was developed. Given a protein UniProt 
identifier, the ENSEMBL Gene identifier (ENSG) and ENSEMBL Transcript identifier 
(ENST) were captured from the UniProt website. These identifiers were developed by 
the ENSEMBL project (Hubbard et al., 2002), a project aiming to annotate genomes of 
various eukaryote organisms. The difference between ENSEMBL and other genome 
annotation services such as NCBI is that they store the mRNA transcripts of each gene. 
Therefore, in the ENSEMBL database, a gene may have more than a single instance of 
each protein (due to the different mRNA transcripts). 
Figure 26 illustrates how a splicing event could result in different transcripts. A splicing 
event occurs after the process of transcription. When introns (non-coding regions 
imbedded into coding regions) are removed through the process of alternative splicing, 
the exons (coding sequences) are integrated with each other. This integration will result 
in different forms of amino acid sequences.  
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Figure 26: A diagram of a splicing event. The diagram illustrates how a splicing event 
could result in two different transcripts – either transcript 1 or transcript 2 in the figure 
above. The blue coloured rectangles represent exons while the red coloured rectangles 
represent introns. In the diagram, a single gene can have two transcripts depending on 
the order of the exons (A-D). These two transcripts result in two protein isoforms.  
 
In the 1KGP, the ENSEMBL identifier is used to determine if a sequence is a DNA or 
amino acid sequence. For DNA sequences, the identifier starts with ENSG, but for amino 
acids, the identifier starts with ENSP. In addition, transcripts are represented with the 
ENST identifier. The ENSEMBL identifiers were obtained using the UniProt identifier for 
all proteins using the cross-link function in UniProt. The two identifiers were then used 
to obtain the protein sequence from the ENSEMBL database. When there was more than 
a single transcript, the resultant protein sequences for each of these transcripts were 
compared against the PDB sequence. If the PDB to ENSEMBL protein sequence coverage 
was less than 90%, the transcript was rejected. Then, the ENSEMBL protein sequences 
were validated against the Consensus CDS database (Pruitt et al., 2009). The Consensus 
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CDS (CCDS) database consists of protein-coding regions that have been regularly 
annotated and are of high quality. If the protein sequence was not available in the CCDS 
database, it was excluded from the study. 
In the 1KGP database, the variants are classified using the Sequence Ontology (SO) 
classification (Eilbeck and Lewis, 2004). SO provides a controlled vocabulary for 
annotating or describing sequences. Since there are many types of variations, a SO 
provides an easy way to differentiate between different variations in terms of their 
location. Figure 27 shows the comparison between how SO classifies synonymous 
variants, non-synonymous variants and intergenic variants. The use of the SO identifier 
enables all non-synonymous variants for a protein to be captured and stored in an 
internal database. 
 
Figure 27: A subset of vocabulary used in Sequence Ontology (SO). The diagram 
shows the vocabulary used by the 1000 Genomes Project (1KGP) to classify variants.  
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4.3.1Protein dataset in 1000 Genomes Project (1KGP) 
Figure 28 describes data used in the 1KGP study. Out of the 21,247,880 SNPs that were 
downloaded, 509,181 were identified as missense (nsSNPs). This corresponds to 20,197 
genes. In this study, instead of all the proteins for the 20,197 genes, the focus was only 
on proteins that have structural interactome data. The nsSNPs were matched to the 
protein dataset consisting of 830 proteins using the UniProt identifier. From 509,181 
nsSNPs, 7,741 nsSNPs were successfully mapped to structures that correspond to 718 
proteins. Initially, there were 830 proteins but 112 of them did not have any nsSNPs 
that were associated with them, so they were excluded from the 1KGP study. 
 
Figure 28: An overview of the 1KGP nsSNPs and protein dataset. The dbSNP build 
135 was used to represent the 1KGP SNPs. The process of mapping nsSNPs to structure 
results in 7,741 nsSNPs and 718 proteins.  
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The number of 1KGP nsSNPs mapped to structures was 7,741 nsSNPs (718 proteins), 
while in the HSVRN dataset, it was 2,776 nsSNPs (348 proteins). If the protein dataset 
was excluded, the number of nsSNPs in the 1KGP dataset is 509,181 nsSNPs compared 
to 56,083 nsSNPs in the original UniProt humsavar data (excluding 5,388 for uSNPs). 
Clearly, the limiting factor in this study is the number of well-studied proteins, not 
polymorphism. However, since the focus of the thesis is the structural effects of nsSNPs 
on protein interactions, the quantity of the nsSNPs is not vital to the study.  
Figure 29 shows the distribution of nsSNPs on proteins using the HSVRN dataset 
compared to proteins using the 1KGP dataset. In the former, there were 348 proteins 
with nsSNPs mapped to structures, while in the latter there were 718 proteins. All 
proteins in the HSVRN dataset were included in this 1KGP study and their nsSNPs were 
compared. The comparison showed that 296 proteins (85%) had more nsSNPs in the 
1KGP dataset, 45 proteins (13%) had more nsSNPs in the HSVRN dataset and seven 
proteins (2%) have an equal number of nsSNPs in the two nsSNPs datasets. The median 
for 1KGP was 10 nsSNPs per protein compared to three nsSNPs for HSVRN. For 1KGP, 
the number of nsSNPs ranges 1–273 nsSNPs, while for HSVRN it was 1–257 nsSNPs. The 
increase in the number of nsSNPs per protein indicates that the 1KGP nsSNPs dataset 
provides better coverage of nsSNP per protein than the HSVRN dataset. 
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Figure 29: The nsSNPs comparison between the same proteins in HSVRN and 1KGP datasets. The graph shows the 348-shared 
proteins that were both in the HSVRN and in the 1KGP datasets. The graph also indicates that on average, there were more nsSNPs per 
protein in the 1KGP study compared to HSVRN. 
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4.3.2 Identify deleterious nsSNPs 
In the humsavar dataset, disease-associated nsSNPs were defined as variants that have 
been clinically proven to cause a disease and have an entry in the OMIM database. This 
is because unlike 1KGP, humsavar was manually curated. However, since the 1KGP 
dataset comes from high-throughput experiments from around the world, identification 
of the disease SNPs has to be performed. Currently, two SNP prediction servers on the 
1KGP website were used to predict the effects of SNP variants, Polyphen2 and SIFT (see 
Chapters 1 and 3 for background on these two servers). These prediction servers were 
used specifically on SNP variants and not on other type of variants such as copy number 
variation (CNV).  
Table 17: The list of data sources used to increase disease annotation 
Type 
 
Name Reference Description 
Server Polyphen2 (Adzhubei et al., 
2010) 
tool which predicts possible impact of an amino 
acid substitution on protein function 
SNP 
database 
SNPedia (Cariaso and 
Lennon, 2012) 
wiki-styled website focusing on SNP variants 
 OMIM (Hamosh et al., 
2005) 
manually curated database of Mendelian based 
disorder in human. 
Disease 
database 
COSMIC (cancer) (Bamford et al., 
2004) 
database listing all known cancer related variants 
GWAS NHGRI Catalogue (Hindorff et al., 
2010) 
catalogue of published genome wide association 
studies 
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In an attempt to improve the annotation of nsSNPs in the 1KGP study, publicly available 
databases containing SNP annotation were queried and downloaded. Table 17 shows all 
the resources used to identify the deleterious nsSNPs from the 1KGP dataset. All 
databases were searched using the dbSNP identifier. First, the nsSNPs were queried 
against the OMIM database. This resulted in 124 matches. Next, the SNPedia database 
was queried. SNPedia policy allows the inclusion of any SNP that has any medical or 
genealogical consequences as long as it is published in a peer-reviewed paper. The 
difference between SNPedia and OMIM is that the former targets a wider audience and 
the annotation of variants is easier compared to the later due to its collaborative nature. 
In SNPedia, as long as the SNP variant is uploaded together with a peer-reviewed 
publication (minimum of 500 patients) and a short description of the paper, it is 
accepted. This makes the process of sharing variant information (especially newer 
ones) easier. The query against the SNPedia database resulted in 335 matches, 17 of 
which overlapped with the OMIM matches. The process to annotate nsSNP disease 
status was continued by downloading and querying the COSMIC database, a database of 
all known cancer-related variants. The COSMIC query results in 303 matches, and 18 
and 8 nsSNPs overlapped with SNPedia and OMIM, respectively. 
The other sources that were examined were the genome wide association studies 
(GWAS) databases. Some GWAS studies are included in OMIM, some are not in OMIM 
but publicly available, and some are private. In this study, the National Human Genome 
Research Institute (NHGRI) was used to annotate disease in 1KGP but no annotations 
were found. 
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Next, Polyphen2 was used to improve the disease annotation. Polyphen2 was chosen 
over SIFT because of the higher recall rate compared to SIFT identified in the previous 
chapter (Chapter 3). If the prediction score was ≥0.5 (i.e., possibly damaging and 
probably damaging), the nsSNPs were classified as damaging. The Polyphen2 program 
predicted 4,495 out of 7,741 nsSNPs to be deleterious. Prior to Polyphen2 prediction, 
the number of disease nsSNPs was 736 dSNPs.  
Figure 30 shows the Venn diagram between the different disease annotation sources. A 
total of 4,804 deleterious nsSNPs (dSNPs) were identified; 308 dSNPs (6%) of the 
dSNPs from OMIM, SNPedia and COSMIC were not identified as deleterious by 
Polyphen2. In the 1KGP dataset, the Polyphen2 disease prediction together with OMIM, 
SNPedia and COSMIC were grouped into a new classification, predicted deleterious 
nsSNPs (pdSNPs). This was to differentiate the group from the verified disease causing 
nsSNPs (dSNPs) in the HSVRN study (Chapter 2). Neutral polymorphism nsSNPs in 
1KGP were called predicted polymorphism nsSNPs (ppSNPs). Although the nsSNPs from 
OMIM, SNPedia and COSMIC were verified to be disease causing, the majority of the 
1KGP disease dataset consisted of predictions from Polyphen2 (4082 nsSNPs or 85%), 
and these nsSNPs have no entries in OMIM, SNPedia or COSMIC. 
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Figure 30: A Venn diagram of pdSNPs from the 1KGP study. The diagram shows the 
number of pdSNPs search source has and the overlapping pdSNPs between each of 
them. 
 
For this 1KGP study, 4,804 pdSNPs (62%) and ppSNPs, 2,937 (38%) were successfully 
mapped to protein structures. In the HSVRN study, from 2,315 nsSNPs (excluding 
uSNPs), 1,499 dSNPs (65%) and 816 pSNPs (35%) were identified. Figure 30 shows the 
Venn diagram comparing the two nsSNPs datasets. Compared to dSNPs from the HSVRN 
dataset that were mapped to structures, the percentage of pdSNPs is slightly lower for 
the 1KGP dataset. However, this difference was found to be significant at the 5% but not 
the 1% level (χ2 = 5.408, p-value = 0.02).  
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4.4 Analysis of 1KGP interfaces 
4.4.1 Identification and mapping of 1KGP nsSNPs on the interface 
The DSSP program was used to differentiate between residues on the surface and in the 
core. The same cutoff value of 5 Å2 that was used in Chapter 2 was applied in this study. 
The total number of interface residues identified from 718 proteins was 56,575 
residues (see Appendix B). The average number of interface residues per protein 
decreased slightly to 79 residues per protein compared to the HSVRN dataset (80 
residues per protein). The median was 69 residues, and the range was 10–301 residues. 
Figure 31 shows the histogram for number of interface residues. 
 
Figure 31: A histogram of the number of interface residues. 
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In the 1KGP dataset of 718 proteins, 212,461 residues were considered; this total is 
comprised of 59,935 buried residues (28%), 56,575 interface residues (27%) and 
95,951 surface non-interface residues (45%). Similarly, in the HSVRN study, 115,106 
residues were considered, consisting of 27,282 buried residues (24%) 28,673 interface 
residues (25%) and 59,151 residues (51%) surface non-interface residues. A chi-square 
test shows the distribution of sequence residues between interface residues in 1KGP 
and HSVRN is significantly different (χ2 = 1265.537, p-value = 0). 
 
Figure 32: A comparison of the nsSNPs distribution across three regions between 
1KGP, and HSVRN datasets. 
A total of 7,741 nsSNPs were mapped onto the protein structures where 2,026 nsSNPs 
(26%) were identified to be located at the interface regions, 2,045 nsSNPs (26%) were 
in the buried regions and the remaining 3,669 nsSNPs (48%) were on the surface non-
interface regions. In general, a majority of the nsSNPs in the 1KGP were identified to be 
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on the surface non-interface region. A chi-square test reveals a significant difference 
between 1KGP and HSVRN datasets (χ2 = 11.196, p-value = 0.003).  
4.4.3 Enrichment analysis on 1KGP nsSNPs 
Table 18 and Table 19 describe the number of nsSNPs for each region in the 1KGP and 
HSVRN studies, respectively. In the 1KGP study, 4,803 nsSNPs were identified to be 
pdSNPs (62%) and 2,938 were identified to be ppSNPs (38%). For interface nsSNPs 
(2,026 nsSNPs), there were more pdSNPs identified (72%) compared to ppSNPs (28%). 
This was higher than in the HSVRN dataset, where 65% were dSNPs and 35% for pSNPs.  
The pdSNPs for the interface region in the 1KGP dataset showed a similar pattern to the 
dSNPs in the HSVRN dataset; it was more likely to find a pdSNP at the interface than 
expected by chance (χ2 = 4.326, p-value = 0.038). 
Table 18: The location of pdSNPs and ppSNPs in the 1KGP study 
 pdSNPs ppSNPs 
Position Buried Interface Surface 
non-
interface 
Buried Interface Surface 
non-
interface 
Total residues 59,935 56,575 95,951 59,935 56,575 95,951 
Observed 1,839 1460 1,504 206 566 2,166 
Expected 1355 1279 2169 829 782 1326 
Observed:Expected 
ratio 
1.4 1.1 0.7 0.2 0.7 1.6 
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Table 19: The location of dSNPs and pSNPs in the HSVRN study 
 dSNPs pSNPs 
Position Buried Interface Surface 
non-
interface 
Buried Interface Surface 
non-
interface 
Total residues 27,282 28,673 59,151 27,282 28,673 59,151 
Observed 530 429 540 133 205 478 
Expected  355 373 770 193 203 419 
Observed:Expecte
d ratio 
1.5 1.1 0.7 0.7 1.0 1.1 
 
However, there were differences between the two datasets in terms of ppSNPs or pSNPs 
at the interface and on the surface non-interface. In the 1KGP study, compared to 
chance, it is less likely for ppSNPs to occur at the interface (observed 566, expected 
782). This was significantly different from the pSNPs at the interface for the HSVRN 
dataset, where the observed number of pSNPs was 205 while expected was 203 (χ2 = 
8.338, p-value = 0.003).  
Additionally, in the 1KGP dataset, the ratio between observed and expected for surface 
non-interface ppSNPs was 1.6. In the HSVRN dataset, the ratio between observed and 
expected for surface non-interface pSNPs was lower, at 1.1. The result for ppSNPs 
showed a significant difference between the two datasets (χ2 = 22.391, p-value = 2 × 10-
6). Since most mutations in the buried region or at the interface have deleterious 
consequences, mutations that do not cause deleterious effects (i.e., neutral 
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polymorphisms) are more likely to occur on the surface non-interface. The enrichment 
analysis on ppSNPs at the surface non-interface in the 1KGP dataset corroborates this.  
For pdSNPs in the buried region in the 1KGP dataset, the ratio between observed and 
expected shows a similar pattern to the HSVRN dataset (χ2 = 1.426, p-value = 0.232). 
This suggests that unlike the interface, there were no changes made to the buried 
residues. The same cutoff (≤5 Å2 accessible surface area) used to identify buried 
residues in the HSVRN study was also implemented in the 1KGP study. 
Table 20 and Table 21 show the odds ratios (ORs) determined from the 1KGP dataset 
and the HSVRN dataset, respectively. As in the enrichment analysis in Chapter 2, a two-
tailed p-value < 0.05 was considered as the significance cutoff for nsSNPs to be in one 
region over another. For pdSNPs or dSNPs, the 1KGP enrichment analysis shows a 
similar observation to the HSVRN enrichment analysis result. The ORs in the 1KGP 
dataset are similar and located within the 95% confidence interval of the ORs from the 
HSVRN dataset, suggesting there is no significant difference in term of ORs. In 
particular, in the HSVRN enrichment analysis, it was observed that compared to the 
other areas on the protein surface, the interface region had a higher tendency for a 
dSNP to occur (OR = 1.64, p-value < 0.05). A similar pattern was observed in the larger 
1KGP dataset (OR = 1.65, p-value < 0.05). 
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Table 20: The odds ratio between different nsSNPs in the 1KGP 
 pdSNPs ppSNPs 
Type Core-
Surface 
Core-
Interface 
Interface-
SNI 
Core-
Surface 
Core-
Interface 
Interface-
SNI 
Odds ratio 1.58 1.19 1.65 0.53 0.34 0.44 
p-value < 0.05 < 0.05 < 0.05 < 0.05 < 0.05 < 0.05 
95%  
confidence 
interval 
1.45–1.72 1.08–1.31 1.49–1.83 0.4–0.60 0.28–0.43 0.39–0.50 
This table shows the odds ratio for each SNP type (pdSNPs and ppSNPs). For each type of SNP, a comparison 
was made between buried and surface (Core-Surface), buried and interface (Core-Interface) and interface 
and surface non-interface (Interface-SNI). 
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Table 21: The odds ratio between different nsSNPs in the HGVRN 
 dSNPs pSNPs 
Type Core-
Surface 
Core-
Interface 
Interface-
SNI 
Core-
Surface 
Core-
Interface 
Interface-
SNI 
Odds ratio 1.66 1.30 1.64 0.63 0.68 0.89 
p-value < 0.05 < 0.05 < 0.05 < 0.05 < 0.05 = 0.312 
95%  
confidence 
interval 
1.42–1.95 1.08–1.55 1.37–1.98 0.49–0.80 0.50–0.92 0.70–1.12 
This table shows the odds ratio for each SNP type (dSNPs and pSNPs). For each type of SNP, a comparison 
was made between buried and surface (Core-Surface), buried and interface (Core-Interface) and interface 
and surface non-interface (Interface-SNI). 
In contrast, there were substantial differences for the ORs for ppSNPs from 1KGP data 
and the pSNPs from the HSVRN datasets. All pairs were significantly different at the 1% 
(two-tailed) level using the method of Altman and Bland (2003). However, the three 
tendencies for comparisons between structural regions remained the same across the 
two datasets. 
This analysis is limited by the accuracies of the assignments of an nsSNP into the 
disease or polymorphism categories. It is not known whether some of the neutral 
polymorphisms in HSVRN are in fact disease causing. This is because unless all the 
pSNPs were clinically verified not to cause disease, we will never absolutely know if 
they are deleterious or not. However, a comparison between the different versions of 
HSVRN can be performed. For the HSVRN dataset, 205 out of 816 proteins occur at the 
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interface. For each of these 205 pSNPs, the disease status was checked against the latest 
humsavar database (October 2012). The result showed that 15 nsSNPs previously 
classified as neutral polymorphisms at the interface had been changed to disease 
causing. Although the number of changes was small, the fact that the disease status 
changed over time shows that some a small percentage of pSNPs in the humsavar 
dataset could be misclassified due to limited information regarding specific variations. 
The analysis of the 1KGP dataset was primarily based on predictions by Polyphen2, 
which are not fully accurate. However, the aim is to find general trends and the 
conclusion from the enrichment analysis of nsSNPs from the 1KGP study corroborates 
with those observed in the HSVRO and HSVRN study—that there is a higher tendency 
for dSNPs to occur at the interface compared to the rest of the area of the protein 
surface.  
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4.5 Development of myVARIANT 
As a result from the 1KGP study, an automated system called myVARIANT was 
developed. The myVARIANT program was built from the integration of various Perl 
scripts and the internal MySQL database that was used in the 1KGP study. 
Currently, given a protein sequence, a UniProt identifier or a PDB code, myVARIANT 
identifies and retrieves all relevant nsSNP variants from the 1000 Genomes Project. In 
the future, insertions and deletions will also be included. Once the nsSNPs identification 
is completed, the nsSNPs are annotated with disease status. For each nsSNP identified, 
the disease status is determined using the amino acid position of the variation. 
Annotation of the disease status is performed using NCBI ClinVar and the COSMIC 
database. If an nsSNP status is novel or unknown, a consensus prediction using CONDEL 
is performed. Next, the nsSNP is mapped to structure. If no suitable PDB structure is 
available, a protein model is generated using the Phyre2 (Kelley and Sternberg, 2009) 
program. Once the nsSNPs have been mapped, identification of the buried and surface 
regions is performed using DSSP. Then, the structural interactome data from the 
Structural Bioinformatics and Network Biology group at the Institute for Research in 
Biomedicine, Barcelona, Spain (Stein et al., 2011) is used to identify the interface sites. 
Next, the enrichment analysis is performed in order to identify the frequency of each 
nsSNP groups (i.e., disease or predicted disease and benign) in each region. Later, an 
automated structural analysis using the eight structural features described in Chapter 3 
is performed. Finally, the output is a detailed report of all the steps involved, including 
an option to generate JPEG or PYMOL images for the nsSNPs. 
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The myVARIANT tool has also been designed to be compatible with output from next 
generation sequencing machine (i.e., FASTQ or VCF format files). For a VCF format file, 
the myVARIANT tool employs ENSEMBL Variant Effect Predictor to first annotate the 
variants in the VCF file. Once an annotated VCF has been generated, myVARIANT 
identifies all the ENSEMBL protein identifiers with their corresponding variants and 
groups them together. Since myVARIANT uses the unique ENSEMBL protein identifier 
(protein specific instead of variant specific), variation that maps to more than one 
transcript is not an issue. The rest of the pipeline is similar to the one mention 
previously. For a FASTQ format file, myVARIANT employs two extra methods. First, 
BWA is used to align the sequencing reads to the reference human genome. Secondly, 
the output of the alignment (i.e., BAM) is processed using the Genome Analysis Tool Kit 
(GATK), which filters and identifies potential variants. The output of the second method 
is a pre-filtered VCF. 
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4.6 Conclusion 
In the second chapter, it was observed that dSNPs tend to occur more at the protein 
interface than other areas on the protein surface. In this chapter, a comparison between 
the new humsavar nsSNPs dataset (HSVRN) and the old humsavar nsSNPs dataset from 
Chapter 2 (HSVRO) was examined. In general, the trends observed in the HSVRN dataset 
were also seen in the HSVRO dataset, although there were some observations in the 
HSVRN dataset that were more consistent with our expectations based on biology than 
in the HSVRO dataset. In particular, the OR for pSNPs between interface and surface 
non-interface regions was 0.89 in the HSVRN dataset as compared to 1.15 in the HSVRO 
dataset. This difference just failed to be significant at the 5% level. However, this still 
suggests that the new criteria used to establish the HSVRN dataset is superior to those 
used in the HSVRO dataset. More data is required to validate this supposition. 
The conclusion shows broadly similar results for pdSNPs in the 1KGP dataset and dSNPs 
in the HSVRN and HSVRO datasets; the OR for a disease SNP to be at the interface 
compared to surface non-interface is significantly greater than one.  
Finally, the study of the 1KGP data led to the development of an automated SNP 
program called myVARIANT. In the next chapter, Chapter 5, a summary from each 
chapter will be presented and recommended future work will be discussed. 
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5 Conclusion 
The previous chapters have shown the important role that nsSNPs can have in affecting 
protein–protein interactions. In this chapter, summaries of each of the studies in the 
thesis will be presented, and their contributions to the field will be discussed. 
Suggestions of possible future work that could be carried out will be described.  
5.1 The humsavar study 
In the humsavar study, the objective was to examine the distribution of nsSNPs on 
protein complexes. Experimentally verified structural interactome data and the 
UNIPROT humsavar list of nsSNPs were used in this study. From the structural 
interactome data, the interfaces for each protein were identified. For each protein, their 
associated nsSNPs were mapped to structures and an enrichment analysis was 
performed to find the tendency for each type of nsSNPs to occur either at the interface, 
in the buried region or on the surface non-interface. To the best of my knowledge, this is 
the first study to thoroughly investigate and quantify the nsSNPs at the interface. 
Previous related studies were more focused on the differences between the core and the 
surface of a protein without considering the interface region specifically. 
The result from the enrichment analysis of the humsavar nsSNPs showed a higher 
tendency for dSNPs to occur at the interface compared to other areas on the protein 
surface. In addition, for pSNPs, an unexpected result was observed where there was a 
high tendency for pSNPs to occur at the interface compared to surface non-interface. 
Similarly, for uSNPs, there was also a high tendency for uSNPs to occur at the interface 
compared to surface non-interface. 
The limiting factor in this study was the number of nsSNPs. With a larger dataset, a 
more accurate and representative result might have been obtained. Additionally, the 
high tendencies of pSNPs and uSNPs at the interface suggest that some of the 
polymorphisms may be deleterious and a structural analysis could provide clarity on 
this issue. 
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5.2 Identification of disease causing and non-disease causing 
nsSNPs 
Three methodologies to assist in the identification of disease-causing and non-disease-
causing nsSNPs were presented. The first methodology, prediction of pathogenicity 
based on SNP server, shows highly significant enrichments of predicted deleterious 
uSNPs in the buried regions and of predicted benign uSNPs in the surface regions. 
However, there was no significant enrichment of either predicted deleterious or 
predicted benign uSNPs at the interface. The prediction for dSNPs at the interface was 
observed to be lacking due to the limited consideration of structural features that could 
affect protein–protein interactions.  
These limited considerations were further shown when performing structural analysis 
on both dSNPs and non-dSNPs. It was observed that dSNPs and uSNPs destabilize 
protein via multiple structural features, and a majority of the predicted deleterious 
nsSNPs at the interface are involved in protein stability. It was also observed that many 
of the dSNPs that Polyphen2 identified to be benign, are actually not (i.e., false 
negative), as they affect changes such as loss of a salt bridge and steric clash. We 
hypothesized that this is due to the exclusion of these two structural features in the 
Polyphen2 algorithm. 
For the last methodology, the GMAF value were assigned and examined. A cut-off of less 
than 10% was used to determine a rare variant. The result showed majority of the 
dSNPs and uSNPs have a low GMAF at the interface, which indicates that they tend to be 
rare variants. The rarity of the nsSNPs could indicate that these amino acids tend to be 
highly conserved, which suggests that they may play a role in pathogenicity.  
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5.3 The 1000 Genomes Project study 
A study on the 1000 Genomes project (1KGP) was performed as an extension of the 
previous two studies. The 1KGP study was comprised of a larger nsSNP and protein 
dataset. Similar methods were used to map nsSNPs to structures and calculate the 
enrichment of nsSNPs at different regions as in the humsavar study. However, changes 
were made in terms of the PDB resolution quality and the definition of protein interface. 
In addition to applying the changes to the new 1KGP dataset, the changes were also 
applied to the humsavar dataset. 
The key result of applying the new resolution cutoff and definition of interface to the 
humsavar dataset (HSVRN) was similar to the earlier study of dSNPs (HSVRO)—a 
higher tendency for dSNPs to occur at the interface compared to surface non-interface. 
However, the pSNPs at the interface compared to surface non-interface in HSVRN was 
less than expected, unlike in HSVRO, where it was more than expected. Similar to 
HSVRN, in the 1KGP study, there was a significantly higher tendency for pSNPs to occur 
at the surface non-interface than the interface. This aligns with the expectation that 
pSNPs should be found more often on the surface non-interface than at the interface, 
since at the new interface, they are less likely to affect protein interactions. For the 
comparison of dSNPs on the interface and surface non-interface in the 1KGP study, the 
conclusion was still similar to the studies in HSVRO and HSVRN, that is, there is a higher 
occurrence at the interface. 
The limiting factor for this study was the number of studied proteins. With a larger 
number of proteins, a more definitive conclusion could be made. Due to time 
constraints, structural analysis on the 1KGP proteins was not performed. 
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5.4 Future studies 
Several future studies can be performed as an extension of the work in this thesis. First, 
a structural analysis of the 1KGP nsSNPs in Chapter 4 can be performed. In addition, all 
1KGP nsSNPs have GMAF values, which should make the result more representative. 
Second, as stated in Chapter 4, the limiting factor for the 1KGP study was the low 
number of studied proteins. By having a larger number of proteins, one could take 
advantage of the huge number of nsSNPs in the 1KGP. This would also give a more 
definitive conclusion as well. One way to solve this problem is by using protein models. 
Recent studies (Gonnelli et al., 2012, Qi et al., 2012) have shown that models with 
reasonable quality could result in reliable predictions of the effect of SNPs. 
Finally, a study could be performed by further differentiating the protein regions to 
include ligand-binding and catalytic regions. The Binding DB (Liu et al., 2007), a 
database of experimentally determined ligand-binding complexes, could be used to 
obtain the coordinates corresponding to ligand-binding residues. Similarly, for catalytic 
sites in proteins, the Catalytic Site Atlas (Porter et al., 2004), a database of enzyme 
active sites and catalytic residues in enzymes of 3D structure, could be used to obtain 
the coordinates. Once the coordinates for both the ligand-binding residues and catalytic 
residues are obtained, they could be mapped together with nsSNPs. Analysis of the 
distribution of nsSNPs on all five types of regions could then be performed. 
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5.5 Impact and conclusion 
In this thesis, three major contributions have been made to the advancement of the 
field. 
First, many previous studies only considered the differences between nsSNPs at the 
core and on the surface. In this thesis, the effects and distribution of nsSNPs at the 
interface region have been addressed systematically. It has been shown throughout the 
thesis that consideration of nsSNPs at the interface could provide new insight into the 
understanding of the molecular etiology of disease. 
Second, we highlighted three methodologies that could assist researchers and clinicians 
in identifying pathogenic variants. Currently, many researchers working to identify 
pathogenic variants, by means such as GWAS, do not consider including the effect of 
nsSNPs on the interface. In this thesis, I have shown that depending on sequence 
conservation alone does not give an optimal result. Similarly, just looking at nsSNPs in 
the core, without considering the structural effect of nsSNP at the interface region, may 
limit the analysis. It was also observed that consideration of the allele frequency of an 
nsSNP could help researchers and clinicians to discriminate between non-important 
and important nsSNP. With the completion of Phase 2 of the 1000 Genome Project and 
the UK 10000 Genome Project, the consideration of allele frequency is vital, especially 
since the current nsSNP data is biased towards the Caucasian population. 
Finally, the nsSNPs from the 1000 Genomes Project were assigned pathogenicity status 
based on predictions by either Polyphen2 or SIFT, since it is impossible to verify all of 
nsSNPs clinically. At the time of our experiment, nsSNPs in the 1000Genome Project 
have not yet been predicted with Polyphen2 or SIFT. Furthermore, neither of these two 
SNP servers considers the effect of a SNP being located at the interface site. In this 
thesis, we show that interface regions can be a hot spot for disease-associated nsSNPs. 
With the use of interactome data, the prediction quality of these SNP servers could be 
improved. In conclusion, the thesis demonstrates the important role that protein–
protein interactions play in disease pathogenesis. 
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Appendices 
Appendix A 
The following phi and psi angles were obtained from Professor George D. Rose’s website 
at the Department of Biophysics, Johns Hopkins University 
(roselab.jhu.edu/~raj/Research/Linus/phipsi.html). The percentages are number of 
occurrences in a set of 42 high-resolution crystal structures. 
ALANINE 
       PHI      PSI       %     
    -164.952  164.234    3.000 
    -158.189  140.234    1.000 
    -132.806  159.171    6.000 
     -99.734  -40.586    1.000 
    -105.095    6.185    4.000 
    -130.396   62.140    1.000 
    -118.125  133.096    8.000 
     -71.528  159.344    4.000 
     -62.819  -40.394   43.000 
     -70.658  -18.416   16.000 
     -66.189  134.878   12.000 
      52.958   53.583    1.000 
      59.827   25.467    1.000 
 
CYSTEINE 
       PHI      PSI       %     
    -161.733  158.848    5.000 
    -121.486  161.795   13.000 
    -111.895  -40.340    2.000 
    -110.835   -9.775    7.000 
    -118.672  127.874   19.000 
     -77.350  157.527    4.000 
     -63.515  -42.342   28.000 
     -72.131  -15.443   12.000 
     -75.319  128.989    8.000 
      55.537   43.017    2.000 
 
ASPARTIC ACID 
       PHI      PSI       %     
    -157.236  178.012    2.000 
    -156.717   74.883    1.000 
    -112.006  170.335    4.000 
    -103.550  -47.863    1.000 
    -106.674    3.821    9.000 
    -117.309   67.459    3.000 
    -112.459  119.135   12.000 
     -72.385  161.420    5.000 
     -64.878  -40.687   28.000 
     -73.279  -15.327   14.000 
     -80.628   68.545    2.000 
     -74.206  122.707   12.000 
      52.636   44.475    3.000 
      61.131   20.041    2.000 
 
GLUTAMIC ACID 
       PHI      PSI       %     
    -161.416  165.956    1.000 
    -152.470  121.715    1.000 
    -125.778  161.771    5.000 
    -110.060  -44.207    2.000 
    -104.389   -1.973    6.000 
    -127.033   73.377    1.000 
    -116.090  130.355   15.000 
     -68.562  155.836    2.000 
     -63.722  -41.183   42.000 
     -68.963  -18.843   13.000 
     -85.957   75.020    1.000 
     -70.107  132.040   10.000 
      59.437   48.093    1.000 
 
PHENYLALANINE 
       PHI      PSI       %     
    -158.471  165.095    5.000 
    -157.573  125.180    1.000 
    -130.697  162.434   11.000 
    -110.205   -6.311    6.000 
    -115.544   70.389    3.000 
GLYCINE 
       PHI      PSI       %     
    -179.133 -178.908    7.000 
    -162.750 -138.547    1.000 
    -174.267  134.280    1.000 
    -115.760 -178.234    4.000 
    -117.934 -137.700    1.000 
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    -112.341  127.542   17.000 
     -71.087  158.065    2.000 
     -62.182  -44.244   34.000 
     -74.501  -18.105    6.000 
     -84.650   68.200    1.000 
     -72.132  135.560   11.000 
      59.263   40.185    2.000 
      70.695   23.570    1.000 
 
    -100.393  -46.830    1.000 
    -103.419   12.468    2.000 
    -110.073   56.547    1.000 
    -112.140  136.351    2.000 
     -79.577  174.917    5.000 
     -62.239  -43.291   11.000 
     -71.531  -16.971    5.000 
     -69.129  140.721    3.000 
     113.166  178.263    8.000 
     106.831  131.468    2.000 
     101.756   -3.787   10.000 
     117.398  -43.767    1.000 
      99.747 -140.978    1.000 
      78.343 -170.608    6.000 
      84.465  133.538    1.000 
      65.712   39.751    5.000 
      77.679    9.403   21.000 
      62.144 -133.911    4.000 
 
HISTIDINE 
       PHI      PSI       %     
    -157.368  161.375    3.000 
    -160.100  144.745    1.000 
    -136.381  159.661    6.000 
    -118.967 -132.687    2.000 
    -114.425  -33.120    1.000 
    -109.203   -2.184   14.000 
    -119.716   63.746    5.000 
    -124.502  127.478   17.000 
     -83.390  159.253    2.000 
     -64.920  -42.403   27.000 
     -74.899  -20.342   10.000 
     -68.685  130.237   11.000 
      51.683   44.750    3.000 
 
ISOLEUCINE 
       PHI      PSI       %     
    -162.075  155.985    1.000 
    -127.553  161.630    9.000 
    -102.414  -55.535    2.000 
    -105.574   -4.043    5.000 
    -121.500   67.405    1.000 
    -115.887  127.303   34.000 
     -68.400  157.150    1.000 
     -62.944  -44.217   33.000 
     -70.286  -16.149    5.000 
     -78.528  129.131    8.000 
 
LYSINE 
       PHI      PSI       %     
    -156.008  163.247    1.000 
    -155.320  136.000    2.000 
    -119.369  163.660    6.000 
    -103.367  -42.442    2.000 
    -104.252   -5.358    8.000 
    -103.550   70.925    1.000 
    -114.266  130.705   15.000 
     -73.365  161.565    3.000 
     -63.806  -41.601   35.000 
     -72.407  -16.293   14.000 
     -71.342  131.546   11.000 
      54.891   45.094    2.000 
 
LEUCINE 
       PHI      PSI       %     
    -118.321  159.889    6.000 
    -105.883  -43.085    2.000 
    -103.013    3.491    5.000 
    -122.938   60.065    1.000 
    -111.371  126.848   21.000 
     -75.858  158.068    4.000 
     -63.817  -42.230   36.000 
     -73.219  -18.056   10.000 
     -83.613   77.960    1.000 
     -73.048  132.018   15.000 
      49.862   40.380    1.000 
 
METHIONINE 
       PHI      PSI       %     
    -153.734  158.196    4.000 
    -156.975  128.430    2.000 
    -129.083  160.034   11.000 
ASPARAGINE 
       PHI      PSI       %     
    -159.376  172.711    3.000 
    -163.325  107.690    1.000 
    -116.772  172.946    7.000 
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    -104.250  -10.296    4.000 
    -124.420   70.723    3.000 
    -115.733  131.295   20.000 
     -63.291  -41.369   35.000 
     -72.916  -20.620    9.000 
     -81.790   77.335    2.000 
     -66.341  124.023    8.000 
      62.115   43.195    2.000 
 
    -109.640  -44.870    1.000 
    -104.783    7.015   11.000 
    -115.615   64.345    4.000 
    -111.682  119.331   15.000 
     -77.673  159.673    2.000 
     -64.672  -40.888   24.000 
     -75.287  -10.537   10.000 
     -84.863   58.717    1.000 
     -71.246  125.952    9.000 
      57.933   41.493    9.000 
      66.388   21.576    2.000 
      47.513 -131.950    1.000 
 
PROLINE 
       PHI      PSI       %     
     -97.575  133.000    1.000 
     -69.689  159.366   25.000 
     -57.344  -37.585   18.000 
     -68.656  -16.377   22.000 
     -78.870   63.673    1.000 
     -63.636  139.180   34.000 
 
GLUTAMINE 
       PHI      PSI       %     
    -160.199  161.083    4.000 
    -154.285  138.450    1.000 
    -120.798  160.903    7.000 
    -109.037  -39.517    2.000 
    -105.794   -5.552    7.000 
    -112.920  132.433   18.000 
     -76.476  161.824    3.000 
     -63.279  -41.526   33.000 
     -74.409  -15.914   12.000 
     -68.259  132.024   10.000 
      51.950   53.606    2.000 
 
ARGININE 
       PHI      PSI       %     
    -157.747  165.405    3.000 
    -156.255  132.295    1.000 
    -122.892  163.442    8.000 
    -106.821   -4.432    8.000 
    -127.889   67.567    3.000 
    -116.087  126.201   13.000 
     -69.493  162.830    2.000 
     -63.681  -41.486   36.000 
     -73.562  -16.844   15.000 
     -70.707  134.316    8.000 
      53.197   39.877    1.000 
      67.685   26.250    1.000 
 
SERINE 
       PHI      PSI       %     
    -159.306  166.898    5.000 
    -164.123  127.848    2.000 
    -121.076  162.135   11.000 
    -122.265 -136.665    0.000 
    -103.510  -50.983    1.000 
    -104.195   -3.659    8.000 
    -122.228   51.539    2.000 
    -118.881  131.621   13.000 
     -76.041  160.364    7.000 
     -63.376  -41.230   20.000 
     -71.840  -15.986   17.000 
     -80.567   34.563    1.000 
     -70.042  134.097   10.000 
      59.310 -167.500    1.000 
      56.653   43.900    1.000 
 
THREONINE 
       PHI      PSI       %     
    -157.738  164.098    1.000 
    -122.951  165.061   16.000 
     -98.647  -41.978    1.000 
    -108.583   -5.427   13.000 
    -125.015   58.727    1.000 
    -116.229  131.576   24.000 
     -80.705  165.912    5.000 
     -62.629  -44.150   22.000 
VALINE 
       PHI      PSI       %     
    -129.423  160.661   11.000 
    -110.477  -46.024    1.000 
    -108.620   -7.082    5.000 
    -125.768   65.503    1.000 
    -116.983  128.441   37.000 
     -77.799  157.447    1.000 
     -64.215  -43.655   30.000 
     -70.339  -20.436    5.000 
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     -74.205  -14.697   10.000 
     -70.229  128.237    6.000 
 
     -74.940  129.293    9.000 
 
TRYPTOPHAN 
       PHI      PSI       %     
    -156.185  174.820    4.000 
    -126.054  163.014    5.000 
    -107.614   15.290    9.000 
    -113.533   61.893    3.000 
    -120.078  138.087   21.000 
     -86.255  155.815    2.000 
     -60.873  -42.896   35.000 
     -71.866  -19.551   10.000 
     -71.255  133.436   11.000 
 
TYROSINE 
       PHI      PSI       %     
    -161.375  161.685    4.000 
    -161.065  142.670    1.000 
    -125.236  163.278   13.000 
    -103.975  -43.903    1.000 
    -107.369   -5.224    8.000 
    -125.934   69.839    3.000 
    -119.263  129.101   24.000 
     -75.326  158.056    3.000 
     -62.351  -44.151   20.000 
     -75.704  -13.476    9.000 
     -81.255   70.405    1.000 
     -69.015  130.959   11.000 
      58.986   41.201    3.000 
Appendix B 
The following are the proteins in the 1000Genomes Project (1KGP) study. 
Identifier PDB model Interface 
Area 
(Å2) 
Resolution 
(Å) 
P62805 1eqz.pdb1 72 3039 2.5 
P28070 1ryp.pdb1 158 5692 1.9 
P25815 2h61.pdb1 66 2872 1.9 
P0C0S5 1f66.pdb1 78 3004 2.6 
P07998 1z7x.pdb1 101 4550 1.95 
P02100 1dxt.pdb1 112 4814 1.7 
P05109 1mr8.pdb1 69 3583 1.9 
P69892 1qxd.pdb2 111 4888 2.25 
P62306 1h64.pdb3 47 1733 1.9 
172 
 
 
P04271 2h61.pdb1 64 2862 1.9 
P06702 3ko0.pdb9 74 4347 2.3 
Q99436 1g65.pdb1 143 5365 2.25 
P42574 2j30.pdb1 172 9812 1.4 
P59768 1gg2.pdb1 40 1858 2.4 
P61326 1p27.pdb1 104 4832 2 
P80511 2h61.pdb1 61 2671 1.9 
P63000 1nf3.pdb2 134 6911 2.1 
P52758 1oni.pdb1 90 3483 1.9 
P61586 1grn.pdb1 134 7297 2.1 
P52657 1nvp.pdb1 64 2379 2.1 
P05451 1umr.pdb3 96 4930 2.4 
P62834 6q21.pdb1 115 6861 1.95 
Q96A08 1eqz.pdb1 74 2960 2.5 
P68431 1eqz.pdb1 84 3249 2.5 
P84243 1eqz.pdb1 84 3249 2.5 
Q6NXT2 1eqz.pdb1 84 3249 2.5 
Q71DI3 1eqz.pdb1 84 3249 2.5 
P02042 1qxd.pdb2 101 4611 2.25 
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Q96A72 1p27.pdb1 99 4426 2 
P63211 1tbg.pdb1 47 2310 2.1 
P30047 1jg5.pdb1 49 1820 2.6 
P14174 2os5.pdb2 67 2152 1.6 
O60814 1eqz.pdb1 72 4130 2.5 
P62807 1eqz.pdb1 72 4130 2.5 
P06899 1eqz.pdb1 72 4207 2.5 
Q9HD89 1rfx.pdb3 63 3853 2 
P61769 1im3.pdb3 70 4318 2.2 
P00709 1f6r.pdb1 74 3134 2.2 
Q8TAA3 1iru.pdb1 171 5957 2.75 
P61956 1y8r.pdb2 55 2693 2.75 
P04908 1eqz.pdb1 80 3487 2.5 
P0C0S8 1eqz.pdb1 80 3487 2.5 
P20671 1eqz.pdb1 80 3487 2.5 
Q6FI13 1eqz.pdb1 80 3487 2.5 
Q7L7L0 1eqz.pdb1 80 3487 2.5 
Q93077 1eqz.pdb1 80 3487 2.5 
Q96QV6 1eqz.pdb1 80 3487 2.5 
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Q99878 1eqz.pdb1 80 3487 2.5 
P01040 1stf.pdb1 56 2856 2.37 
P05113 1hul.pdb1 66 2639 2.4 
P61970 1qma.pdb2 76 3481 2.5 
P60568 1pw6.pdb4 87 6581 2.6 
P68871 1ch4.pdb1 101 4219 2.5 
P25789 1iru.pdb1 168 5792 2.75 
P10114 2ov2.pdb12 106 6023 2.1 
P28066 1ryp.pdb1 150 4954 1.9 
P06703 1k9k.pdb1 48 2697 1.76 
P32320 1zab.pdb2 76 3007 2.36 
P32321 2w4l.pdb1 94 3600 2.1 
P62491 1ukv.pdb1 124 6278 1.5 
P33764 3ko0.pdb4 53 2447 2.3 
P00441 1to5.pdb3 89 4321 2.2 
P57735 1z0a.pdb5 95 4200 2.12 
P63098 1aui.pdb1 101 4130 2.1 
P30041 1prx.pdb1 124 5193 2 
P49720 1iru.pdb1 97 4087 2.75 
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P62942 3mdy.pdb2 60 2719 2.05 
P07954 1jsw.pdb1 263 6930 2.7 
Q9NSA3 1m1e.pdb1 32 1915 2.1 
P49773 1av5.pdb1 48 1534 2 
P15153 1nf3.pdb2 113 5567 2.1 
P00746 2bm2.pdb1 145 8000 2.2 
Q9BPX1 1rwb.pdb1 151 5902 2 
Q15274 2jbm.pdb1 168 5152 2 
P04080 3k9m.pdb1 43 1349 2.61 
O14775 2pbi.pdb2 216 8454 1.95 
O00244 1fe0.pdb1 25 1403 1.75 
Q9BRG1 3htu.pdb2 26 1219 2 
P30626 1hqv.pdb1 121 8185 2.3 
P25786 1iru.pdb1 159 5076 2.75 
P05089 1t4p.pdb1 164 6045 2.6 
P31949 1qls.pdb1 48 2992 2.3 
P55854 2vrr.pdb1 32 1644 2.22 
Q15370 1lm8.pdb1 51 2888 1.85 
O00746 1u8w.pdb1 71 2349 2.4 
176 
 
 
P11177 1ni4.pdb1 141 2736 1.95 
Q8TBC4 3fn1.pdb1 33 1413 2.5 
P60763 1nf3.pdb3 109 5489 2.1 
P55212 2j30.pdb1 141 9325 1.4 
P62330 1hur.pdb1 93 5325 2 
P21953 2j9f.pdb1 143 3547 1.88 
P04406 1i32.pdb2 212 8674 2.6 
P60903 1bt6.pdb2 32 1081 2.4 
P04054 1fx9.pdb1 69 4359 2 
P63167 3dvt.pdb1 26 857 2.3 
P26447 2q91.pdb1 36 4082 1.63 
P84077 1hur.pdb1 91 5456 2 
P43320 3lwk.pdb1 102 5075 1.7 
P04179 3bfr.pdb1 118 6427 2.05 
P78540 1wva.pdb1 156 7013 1.94 
P62877 3dpl.pdb1 31 1312 2.6 
O95166 1eo6.pdb1 48 2275 1.8 
Q15382 1gua.pdb1 83 4331 2 
P61077 2gjd.pdb1 85 5916 1.75 
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Q9Y2X8 2gjd.pdb1 85 5916 1.75 
P08246 1fak.pdb1 125 5498 2.1 
P20231 1bbr.pdb4 134 7785 2.3 
Q15661 1bbr.pdb4 134 7785 2.3 
O14556 1i32.pdb2 208 8591 2.6 
Q04760 1fro.pdb1 90 3115 2.2 
P08134 1grn.pdb1 99 5046 2.1 
P14927 1sqb.pdb1 41 1882 2.69 
O96015 1cmi.pdb3 25 1415 2.5 
P01579 3bes.pdb1 83 6483 2.2 
P09237 1hfs.pdb1 86 5170 1.7 
P30301 3d9s.pdb1 110 2727 2 
P41181 3d9s.pdb1 110 2727 2 
P47224 2fu5.pdb1 32 1131 2 
Q06830 1qmv.pdb1 85 2568 1.7 
P05813 3lwk.pdb1 97 4986 1.7 
P26998 3lwk.pdb1 97 4986 1.7 
P00480 1dxh.pdb1 183 9782 2.5 
P33763 1mho.pdb1 31 2343 2 
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Q8WXG8 1mho.pdb1 31 2343 2 
P02792 1ies.pdb1 83 7480 2.6 
P51148 3clv.pdb1 86 5470 1.89 
P32322 2rcy.pdb1 125 3405 2.3 
Q96C36 2rcy.pdb1 125 3405 2.3 
P01889 1nan.pdb1 172 10376 2.3 
O75531 1ci4.pdb1 17 585 1.9 
P07737 3chw.pdb1 49 1884 2.3 
P49721 1iru.pdb1 83 2237 2.75 
P21673 2b4d.pdb1 84 3925 2 
P62826 1k5d.pdb4 99 6949 2.7 
P61086 1yla.pdb1 107 5431 2.4 
P62873 1tbg.pdb1 180 7299 2.1 
P12544 2bm2.pdb1 122 6787 2.2 
Q13011 1dci.pdb1 126 4802 1.5 
P31151 1psr.pdb1 34 1384 1.05 
P03950 1a4y.pdb1 39 1347 2 
P35080 1hlu.pdb1 48 1994 2.65 
P13804 1efv.pdb1 166 5560 2.1 
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Q96AB3 2b34.pdb2 78 3099 2.14 
O15182 1qx5.pdb2 57 6377 2.54 
Q96F10 2jev.pdb1 82 3651 2.3 
P32119 1qmv.pdb1 75 2352 1.7 
P63104 2b05.pdb4 127 6766 2.55 
P35244 3kdf.pdb1 36 1580 1.98 
P63279 2pe6.pdb1 72 5148 2.4 
Q9NZD4 1z8u.pdb2 20 822 2.4 
P05230 1bar.pdb3 45 5462 2.7 
Q9UKK6 1jkg.pdb1 47 1317 1.9 
P53672 3lwk.pdb1 85 4117 1.7 
P53673 3lwk.pdb1 85 4117 1.7 
Q9UHA4 1vet.pdb1 26 809 1.9 
Q03393 1b66.pdb1 58 3898 1.9 
P61088 2gmi.pdb1 64 2521 2.5 
P31153 2obv.pdb1 204 8529 2.05 
Q05329 2okj.pdb1 244 6421 2.3 
Q99259 2okj.pdb1 244 6421 2.3 
P20618 1g65.pdb1 84 4774 2.25 
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Q9BPX5 1k8k.pdb1 46 2041 2 
Q13257 2qyf.pdb5 88 4630 2.3 
P16104 1s32.pdb1 16 732 2.05 
Q9UHV8 1lcl.pdb1 43 2053 1.8 
O15511 1k8k.pdb1 45 1936 2 
P63208 2e31.pdb1 52 3110 2.4 
P02794 1ies.pdb1 65 5443 2.6 
Q5T215 2c0j.pdb1 70 4297 2.2 
P60891 2h06.pdb1 152 6298 2.2 
P00352 1cw3.pdb2 232 5661 2.58 
P58876 1eqz.pdb1 21 4130 2.5 
Q5QNW6 1eqz.pdb1 21 4130 2.5 
Q93079 1eqz.pdb1 21 4130 2.5 
Q99879 1eqz.pdb1 21 4130 2.5 
P23527 1eqz.pdb1 21 4207 2.5 
P33778 1eqz.pdb1 21 4207 2.5 
P07315 2bb2.pdb1 89 6624 2.1 
P36873 1s70.pdb1 134 6434 2.7 
P30460 2clv.pdb2 153 9657 1.9 
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P30504 2clv.pdb2 153 9657 1.9 
P02766 1eta.pdb2 35 1284 1.7 
P18510 1ira.pdb1 44 1647 2.7 
P11908 2hcr.pdb1 154 6519 2.2 
O14950 2w73.pdb2 58 3880 1.45 
P62745 1ds6.pdb1 64 2904 2.35 
Q9GZQ8 2z0d.pdb1 27 820 1.9 
Q9BRT9 2e9x.pdb1 92 3176 2.3 
P24941 1w98.pdb1 152 7140 2.15 
O43617 1wc8.pdb1 73 4993 1.9 
Q92947 1siq.pdb1 201 10340 2.1 
P27482 1oe9.pdb1 46 1999 2.05 
P51149 1vg9.pdb2 60 1975 2.5 
Q96AT9 2fli.pdb1 69 2210 1.8 
P84090 2nml.pdb1 18 1550 1.55 
Q9Y5R8 2j3t.pdb1 25 704 2.4 
Q9NQR4 2w1v.pdb1 95 3210 1.49 
P51668 2gjd.pdb1 55 4484 1.75 
Q9HAV0 1tbg.pdb1 158 6481 2.1 
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P59998 3dxk.pdb1 29 2945 2.7 
Q13232 1s57.pdb2 40 5623 1.8 
P61204 1hur.pdb1 57 3590 2 
Q9H4E5 2wm9.pdb1 58 1686 2.2 
P24752 2ib7.pdb1 148 3520 2.05 
P04141 1csg.pdb1 20 664 2.7 
P25788 1iru.pdb1 84 4711 2.75 
O14818 1iru.pdb1 84 5556 2.75 
P16520 1tbg.pdb1 158 6599 2.1 
P61160 1u2v.pdb2 206 9149 2.55 
O75293 2wal.pdb1 48 2388 2.4 
O95257 2wal.pdb1 48 2388 2.4 
P24522 2wal.pdb1 48 2388 2.4 
P62158 3g43.pdb1 50 7704 2.1 
P31947 2b05.pdb4 107 6148 2.55 
P36405 1ksg.pdb1 55 2458 2.3 
Q9NRG1 1bzy.pdb1 69 1826 2 
P38117 1efv.pdb1 109 4744 2.1 
P53680 2vgl.pdb1 21 541 2.59 
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P17707 1i72.pdb1 104 4123 2 
P56279 1jsg.pdb1 21 1661 2.5 
P01588 1eer.pdb1 41 1364 1.9 
P29373 1xca.pdb1 41 2436 2.3 
O15392 1e31.pdb1 46 3636 2.71 
O95716 1vg0.pdb1 59 2440 2.2 
Q96EK6 3cxq.pdb1 73 5840 2.3 
Q00526 3f5x.pdb1 150 7655 2.4 
P01009 1ova.pdb2 192 6994 1.95 
Q16548 2voi.pdb1 27 801 2.1 
Q9NR31 2qtv.pdb1 37 1131 2.5 
Q9Y6B6 2qtv.pdb1 37 1131 2.5 
P10144 1op8.pdb3 90 6259 2.5 
P31946 2b05.pdb4 103 6081 2.55 
P62258 2b05.pdb1 104 6154 2.55 
Q04917 2b05.pdb1 104 6154 2.55 
P53597 1euc.pdb1 113 3497 2.1 
O43924 1ksg.pdb1 26 778 2.3 
P05162 1c1f.pdb1 27 2103 1.6 
184 
 
 
P62937 2x2c.pdb1 28 1499 2.41 
P52298 1n52.pdb1 37 1407 2.11 
Q9UL26 3mjh.pdb1 38 2197 2.03 
P47929 1bkz.pdb1 21 734 1.9 
P09417 1hdr.pdb1 103 5673 2.5 
O14921 2gtp.pdb2 24 920 2.55 
O75365 1zck.pdb1 29 1151 1.9 
Q93096 1zck.pdb1 29 1151 1.9 
Q96SL4 1gp1.pdb1 51 2516 2 
O00757 2f3h.pdb1 133 7957 2.7 
P14555 1pod.pdb1 20 6423 2.1 
P36404 1ksg.pdb1 48 2359 2.3 
P61019 1ukv.pdb1 63 3173 1.5 
O75340 2zn9.pdb2 64 5128 2.4 
Q92876 1bth.pdb2 83 4015 2.3 
P05112 1iar.pdb1 19 461 2.3 
Q12974 1zck.pdb1 29 1179 1.9 
Q00534 1w98.pdb1 134 6112 2.15 
P09110 2f2s.pdb2 141 3951 2 
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P04040 7cat.pdb1 301 15006 2.5 
P09382 1w6q.pdb1 16 576 2.1 
Q15631 1key.pdb1 77 3379 2.65 
P09467 1eyj.pdb1 130 7208 2.28 
Q13404 1j7d.pdb1 27 1174 1.85 
Q15819 1j7d.pdb1 27 1174 1.85 
P62166 1s6c.pdb1 48 3113 2 
P40306 1g0u.pdb1 61 2702 2.4 
O75312 2qkd.pdb2 67 5119 2 
P60174 1aw1.pdb2 90 2845 2.7 
P20338 1z0k.pdb1 23 4933 1.92 
Q14558 1dkr.pdb1 128 6238 2.3 
P10809 1dkd.pdb5 16 704 2.1 
P01574 1au1.pdb1 31 1831 2.2 
Q99497 1ucf.pdb1 33 951 1.95 
P84095 1hh4.pdb2 45 2328 2.7 
P10768 3c6b.pdb1 87 4547 2.17 
O60256 1dkr.pdb1 126 6221 2.3 
P05091 1cw3.pdb2 202 5679 2.58 
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Q86SZ2 2j3t.pdb1 26 641 2.4 
P62380 1tbp.pdb1 42 1722 2.6 
P18085 1r8q.pdb4 46 3840 1.86 
O60760 2on5.pdb3 62 2585 1.9 
P31937 2gf2.pdb3 83 1640 2.38 
Q53H96 2ahr.pdb1 123 8147 2.15 
Q9NPJ3 2cy9.pdb1 15 557 2.72 
O00212 2ov2.pdb12 34 2438 2.1 
P02741 1b09.pdb1 56 2430 2.5 
P00568 1z83.pdb1 61 3850 1.9 
Q14232 3ecs.pdb1 112 5096 2.65 
P04181 1oat.pdb1 199 11540 2.5 
Q9Y248 2q9q.pdb1 47 1907 2.36 
O75865 2j3t.pdb1 23 551 2.4 
P02743 1b09.pdb1 56 2425 2.5 
P19623 2o05.pdb1 99 4866 2 
P61020 1s8f.pdb3 32 1864 1.77 
Q9H0T7 1s8f.pdb3 32 1864 1.77 
P36542 2jiz.pdb2 62 2591 2.3 
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P17538 3b9f.pdb1 66 2966 1.6 
P20151 3b9f.pdb1 66 2966 1.6 
P07900 3eko.pdb3 77 5696 1.55 
P61158 1u2v.pdb2 184 8321 2.55 
P11234 1uad.pdb2 26 1587 2.1 
P07741 1ore.pdb1 42 2769 2.1 
Q96LD8 1xt9.pdb1 50 1591 2.2 
P01111 1c1y.pdb1 23 1279 1.9 
P62487 1y14.pdb1 24 670 2.3 
P62070 6q21.pdb1 25 6106 1.95 
Q15669 1hh4.pdb2 36 1632 2.7 
Q9BZX2 1ufq.pdb1 60 2935 2.5 
P09211 1gsy.pdb2 63 2641 2.44 
P15259 1e58.pdb1 90 4118 1.25 
P18669 1e58.pdb1 90 4118 1.25 
Q8N0Y7 1e58.pdb1 90 4118 1.25 
Q9UKU7 1rx0.pdb1 150 4635 1.77 
Q969M7 3fn1.pdb1 22 789 2.5 
Q16613 1ib1.pdb2 34 1202 2.7 
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P24158 1k9o.pdb1 54 2006 2.3 
P62140 1s70.pdb1 98 4345 2.7 
O43745 2bec.pdb1 44 1142 2.7 
Q99653 2bec.pdb1 44 1142 2.7 
P29218 1awb.pdb1 84 2091 2.5 
P68036 1c4z.pdb1 17 552 2.6 
P84085 1r8q.pdb4 35 3116 1.86 
P20340 1ukv.pdb1 44 2591 1.5 
P28161 2f3m.pdb3 56 2260 2.7 
Q9Y3L5 1c1y.pdb1 18 703 1.9 
Q5JXB2 2gmi.pdb1 20 577 2.5 
P19883 2arp.pdb1 32 1168 2 
P80188 1qqs.pdb1 38 2787 2.4 
P09104 1te6.pdb1 147 4941 1.8 
P13929 1te6.pdb1 147 4941 1.8 
P21266 2f3m.pdb3 54 2028 2.7 
P21912 2fbw.pdb2 65 1991 2.1 
Q96C86 1xmm.pdb2 120 4461 2.5 
P01116 1lfd.pdb1 17 646 2.1 
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Q13526 1pin.pdb1 18 1662 1.35 
P06870 1oph.pdb1 50 1846 2.3 
P08311 1oph.pdb1 50 1846 2.3 
P16083 1qr2.pdb1 60 2049 2.1 
P47756 1izn.pdb2 98 3561 2.1 
P52895 1xjb.pdb1 119 6248 1.9 
P51151 2bcg.pdb1 36 1784 1.48 
P20339 1ukv.pdb1 40 8266 1.5 
O43447 1mzw.pdb1 19 628 2 
P61081 1y8x.pdb1 20 743 2.4 
P26440 1ivh.pdb1 131 3690 2.6 
P40313 1oph.pdb2 47 1617 2.3 
Q9Y5K2 1oph.pdb1 47 1617 2.3 
Q30201 2clv.pdb2 108 5656 1.9 
P12694 2j9f.pdb1 135 3718 1.88 
Q9P1U1 1u2v.pdb2 172 7774 2.55 
P17081 1nf3.pdb3 32 1286 2.1 
O15145 1k8k.pdb1 17 764 2 
P01033 1bqq.pdb1 36 1383 2.75 
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P16035 1bqq.pdb1 36 1383 2.75 
P35625 1bqq.pdb1 36 1383 2.75 
Q99727 1bqq.pdb1 36 1383 2.75 
Q9NPB1 1mh9.pdb1 48 3147 1.8 
P47755 1izn.pdb2 91 3553 2.1 
P52907 1izn.pdb2 91 3553 2.1 
Q9BWD1 1dlu.pdb1 114 2910 2.25 
Q99578 6q21.pdb1 12 6780 1.95 
P30086 1bd9.pdb1 21 929 2.05 
P52565 1hh4.pdb1 50 2033 2.7 
P52566 1hh4.pdb1 50 2033 2.7 
P32929 1y4i.pdb1 158 8433 1.9 
P23919 2wwf.pdb2 44 1690 1.89 
O95633 3b4v.pdb1 73 3701 2.48 
P01112 2ov2.pdb12 12 7130 2.1 
P08238 2wer.pdb2 48 3317 1.6 
P04818 2aaz.pdb4 89 2374 2.08 
P49366 1dhs.pdb1 152 10763 2.2 
P15018 1pvh.pdb1 20 823 2.5 
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O75832 2dvw.pdb1 39 1035 2.3 
Q96T66 1nup.pdb1 53 3162 1.9 
O15144 1k8k.pdb1 90 2871 2 
P17612 3idb.pdb1 132 5153 1.62 
P62760 1bjf.pdb1 29 947 2.4 
Q9UM19 1bjf.pdb1 29 947 2.4 
O43708 1fw1.pdb1 45 3021 1.9 
P11310 1ege.pdb1 145 4712 2.75 
P34897 1rv3.pdb1 200 6554 2.4 
P15559 2f1o.pdb4 78 2475 2.75 
O94808 2zj3.pdb1 119 6295 1.9 
P68133 2gwk.pdb1 151 9199 2 
P23526 3h9u.pdb1 166 6365 1.9 
Q8TCD5 2jao.pdb1 41 2740 2 
P18464 2clv.pdb2 98 5778 1.9 
P38919 2hyi.pdb1 136 5435 2.3 
Q9BY32 2car.pdb1 27 935 1.09 
P04424 1u15.pdb1 169 3739 2.5 
P09936 1xd3.pdb1 38 1015 1.45 
192 
 
 
P15374 1xd3.pdb1 38 1015 1.45 
P00414 1v54.pdb1 61 1409 1.8 
Q9NVS9 1nrg.pdb1 61 4920 1.95 
P29972 1j4n.pdb1 73 4856 2.2 
P22612 3idb.pdb1 127 4819 1.62 
P05154 1oph.pdb1 146 6158 2.3 
P03989 1nan.pdb1 98 5676 2.3 
P30491 1nan.pdb1 98 5676 2.3 
P30685 1nan.pdb1 98 5676 2.3 
P07195 1i0z.pdb1 107 9790 2.1 
Q99819 1ds6.pdb1 34 1304 2.35 
P09488 2f3m.pdb3 36 1301 2.7 
P08263 2vct.pdb4 47 2093 2.1 
P27695 2o3c.pdb1 68 4459 2.3 
P01891 2clv.pdb2 94 5343 1.9 
P00966 2nz2.pdb1 175 11137 2.4 
Q15102 1wab.pdb1 29 2168 1.7 
Q14012 2x0g.pdb1 112 5955 2.2 
Q9HAN9 1kqn.pdb1 55 2333 2.2 
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P06744 1iri.pdb2 213 5584 2.4 
P01892 1nan.pdb1 94 5209 2.3 
P06730 2w97.pdb1 15 646 2.29 
Q9Y2Q3 1r4w.pdb2 35 1196 2.5 
P09622 1zy8.pdb2 200 5942 2.59 
P05106 2p28.pdb1 55 2724 2.2 
P05556 2p28.pdb1 55 2724 2.2 
Q9ULA0 3l6s.pdb1 188 12640 2.2 
P00326 1bto.pdb1 116 4916 2 
P49137 2oza.pdb1 122 6367 2.7 
Q99895 1cgi.pdb1 38 799 2.3 
P12532 1u6r.pdb1 129 4875 1.65 
P12004 1axc.pdb1 46 1824 2.6 
P14061 1fdu.pdb2 73 1881 2.7 
P13747 2clv.pdb2 86 4699 1.9 
Q8IU85 2x0g.pdb1 105 4356 2.2 
O15217 1vf1.pdb1 48 3333 1.77 
Q03013 1xwk.pdb2 31 2313 2.3 
P30281 3f5x.pdb1 49 2030 2.4 
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O95749 2q80.pdb1 67 1944 2.7 
O15382 2abj.pdb1 118 4495 2.2 
Q16539 3e7o.pdb1 139 7860 2.14 
Q9BPU6 3dc8.pdb1 166 7860 1.85 
Q13126 1cb0.pdb1 57 4019 1.7 
P40394 1bto.pdb1 108 4377 2 
O14531 3dc8.pdb1 165 7851 1.85 
Q14117 3dc8.pdb1 165 7851 1.85 
Q16555 3dc8.pdb1 165 7851 1.85 
Q16854 1p60.pdb2 54 4276 1.96 
P02679 3bvh.pdb1 85 3755 2.6 
P61011 3dm5.pdb1 187 11799 2.51 
P24855 2a3z.pdb1 28 783 2.08 
Q93088 1umy.pdb1 113 3416 2.5 
P11766 3cos.pdb2 125 4583 2.1 
P04899 1gp2.pdb1 128 7270 2.3 
P63096 1gp2.pdb1 127 7204 2.3 
P52564 3dv3.pdb1 87 5195 2.3 
P27144 1dvr.pdb1 36 1350 2.36 
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P54819 1dvr.pdb1 36 1350 2.36 
P51553 2g4o.pdb3 86 2916 2 
P25787 1g65.pdb1 36 6519 2.25 
P46926 1ne7.pdb1 49 1193 1.75 
P07902 1gup.pdb2 103 3054 1.8 
P60709 1u2v.pdb2 137 6524 2.55 
Q96A44 2fnj.pdb1 15 706 1.8 
P07288 2zeb.pdb1 26 6489 2.5 
Q7LG56 3hf1.pdb1 56 1532 2.6 
Q14749 1bhj.pdb1 76 3478 2.5 
P05121 1oc0.pdb1 108 3881 2.28 
P24385 2w96.pdb1 34 1232 2.3 
P13716 1pv8.pdb1 47 3710 2.2 
Q15119 2pnr.pdb2 145 6173 2.5 
P07947 1k9a.pdb7 197 10980 2.5 
Q92600 2fv2.pdb2 41 1710 2.2 
Q9UK22 2e31.pdb1 40 1519 2.4 
P07451 3iai.pdb2 38 1678 2.2 
P40926 1mld.pdb2 66 2469 1.83 
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P53611 1dce.pdb1 68 2554 2 
P08559 1ni4.pdb1 84 1854 1.95 
P49354 1n4p.pdb6 89 3450 2.65 
P00505 1ajr.pdb1 109 3724 1.74 
P63261 1hlu.pdb1 130 7557 2.65 
Q9GZT4 3l6b.pdb1 67 3173 1.5 
P62879 1tbg.pdb1 79 3944 2.1 
P30279 2w9z.pdb1 30 852 2.45 
P08754 1gp2.pdb1 115 6697 2.3 
Q9UBE0 1y8q.pdb1 65 1773 2.25 
P36959 1eep.pdb1 74 4999 2.4 
O00764 2yxt.pdb1 55 1561 2 
Q9UIK4 2a2a.pdb1 75 3517 1.47 
P53609 1n4p.pdb2 78 2447 2.65 
P17174 1ajr.pdb1 109 3719 1.74 
P45452 1su3.pdb3 176 8434 2.2 
P78330 1l8l.pdb1 16 547 2.51 
Q96GD0 2cfr.pdb1 56 3459 2.4 
P22694 3idb.pdb1 92 3449 1.62 
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Q13253 1m4u.pdb1 35 3466 2.42 
P06576 2jiz.pdb2 160 4547 2.3 
P08254 1su3.pdb3 174 8468 2.2 
P30085 4ake.pdb1 21 933 2.2 
P13995 1b0a.pdb1 55 3394 2.56 
P29803 1ni4.pdb1 73 1453 1.95 
Q7Z4W1 1zem.pdb3 14 5908 1.9 
Q9HAB8 1p9o.pdb1 54 2242 2.3 
O60547 2z1m.pdb1 65 1875 2 
P30040 1ovn.pdb1 22 709 1.9 
P06732 1qh4.pdb3 106 5071 1.41 
P80404 1ohv.pdb2 130 2819 2.3 
P00390 3dgh.pdb1 181 6740 1.75 
Q9UFF9 2d5r.pdb1 17 615 2.5 
Q9UIV1 2d5r.pdb1 17 615 2.5 
P50213 2g4o.pdb3 69 2301 2 
P68032 2gwk.pdb1 108 6450 2 
P40925 4mdh.pdb1 71 2048 2.5 
Q03113 1gp2.pdb1 106 5913 2.3 
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P14618 3gqy.pdb1 182 4950 1.85 
Q9UNI1 1bbr.pdb4 14 10070 2.3 
Q9Y4P1 2z0d.pdb1 43 1113 1.9 
Q9H2U2 2ik2.pdb2 46 3219 1.8 
Q00796 1pl6.pdb1 86 4019 2 
P17540 1qk1.pdb1 115 4380 2.7 
Q14410 2d4w.pdb1 166 6851 2.3 
Q9Y376 2wtk.pdb1 71 3044 2.65 
Q9Y697 3gzd.pdb2 101 3290 1.8 
P62736 2gwk.pdb1 105 7033 2 
P51649 3ifg.pdb2 149 6573 2.7 
P05187 1zeb.pdb1 158 8542 1.9 
P10696 1zeb.pdb1 158 8542 1.9 
P49368 1a6d.pdb1 197 10853 2.6 
O60671 3a1j.pdb1 36 1120 2.5 
P43897 1xb2.pdb1 40 1719 2.2 
Q16775 1qh3.pdb1 10 653 1.9 
P49356 1jcq.pdb1 92 2315 2.3 
Q16836 1f0y.pdb1 38 1106 1.8 
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P49903 3fd5.pdb1 63 1475 1.9 
Q14344 3cx7.pdb1 63 2944 2.25 
Q99832 1a6d.pdb1 191 10684 2.6 
Q96KP4 2zof.pdb1 147 4351 2.3 
Q9UGM6 1i6k.pdb1 66 4288 1.72 
P00439 1toh.pdb1 72 5617 2.3 
P30566 1yis.pdb1 138 9207 2.4 
P12955 2iw2.pdb1 143 5092 1.82 
Q06520 3f3y.pdb1 45 3116 2.2 
Q13867 2dzy.pdb1 170 12227 2.57 
P45381 2gu2.pdb2 40 1375 1.8 
O15143 1u2v.pdb2 77 4612 2.55 
Q92747 1u2v.pdb2 77 4625 2.55 
P01008 2b5t.pdb2 118 5825 2.1 
O60921 3a1j.pdb1 30 1172 2.5 
Q8NHY5 3a1j.pdb1 30 1172 2.5 
P12277 1qh4.pdb2 90 4541 1.41 
Q96HD9 2gu2.pdb1 40 1389 1.8 
P04075 1zah.pdb1 77 2679 1.8 
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Q9NPH2 1la2.pdb1 179 4761 2.65 
Q96DX5 2xai.pdb1 20 740 2.58 
P63267 2gwk.pdb1 90 5632 2 
P50053 2hqq.pdb1 32 2804 1.86 
Q14376 1ek6.pdb1 62 2167 1.5 
P68400 3h30.pdb3 63 2640 1.56 
P11488 1got.pdb1 83 4866 2 
Q96I99 2fp4.pdb1 97 3081 2.08 
P30838 1ad3.pdb1 112 3368 2.6 
P51648 1ad3.pdb1 112 3368 2.6 
O75695 3bh7.pdb1 34 1114 1.9 
Q16515 2qts.pdb2 145 5424 1.9 
P17735 1bw0.pdb1 81 2096 2.5 
P42025 1d4x.pdb2 82 5069 1.75 
P61163 1d4x.pdb2 82 5069 1.75 
Q9P2R7 1euc.pdb1 97 3392 2.1 
P00387 1qx4.pdb1 16 601 1.8 
P50613 1unh.pdb1 22 1244 2.35 
P06126 2akr.pdb3 44 1641 1.9 
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P45983 3e7o.pdb1 90 5322 2.14 
P50440 1jdw.pdb1 37 2718 1.9 
P06132 1r3q.pdb1 51 2962 1.7 
Q00266 2obv.pdb1 79 4087 2.05 
P15813 2akr.pdb4 44 1677 1.9 
P28482 1o9u.pdb1 88 5075 2.4 
P25705 2jiz.pdb2 141 4560 2.3 
P22830 2hre.pdb2 67 3024 2.5 
P09471 1gp2.pdb1 80 5017 2.3 
Q14195 1kcx.pdb1 110 3441 2.12 
P54619 2v8q.pdb1 43 1424 2.1 
O43837 1x0l.pdb1 49 1947 1.85 
P29016 2h26.pdb1 57 1743 1.8 
P16444 3k5x.pdb2 69 3364 1.4 
P19087 1got.pdb1 72 3525 2 
P49448 3etd.pdb1 139 4447 2.5 
P37837 1f05.pdb1 20 682 2.45 
P36222 1hjv.pdb1 39 1694 2.75 
P00367 3etd.pdb1 139 4456 2.5 
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Q9UJ70 2ch5.pdb1 53 1752 1.9 
P50148 1cul.pdb2 58 3437 2.4 
P52292 1wa5.pdb1 126 5532 2 
O75530 2qxv.pdb1 45 1597 1.82 
P18754 1i2m.pdb2 52 1865 1.76 
O43488 1gve.pdb1 24 779 1.38 
O95154 1gve.pdb1 24 779 1.38 
Q16773 3fvs.pdb1 74 2010 1.5 
O00338 1z28.pdb1 16 1132 2.3 
P63092 1azt.pdb1 72 3910 2.3 
Q15118 3crk.pdb1 78 3862 2.3 
P19784 3h30.pdb3 44 2262 1.56 
P19086 1gp2.pdb1 68 4296 2.3 
A8MTJ3 1got.pdb1 62 3122 2 
O60701 2qg4.pdb2 103 4538 2.1 
P12956 1jeq.pdb1 220 8350 2.7 
P05120 1ova.pdb1 60 2308 1.95 
Q96P63 1hle.pdb1 23 1364 1.95 
P29992 1cul.pdb2 49 3044 2.4 
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O96019 1d4x.pdb1 60 2182 1.75 
P52209 1pgn.pdb1 145 9742 2.3 
Q9H0R6 3h0l.pdb5 39 492 2.3 
Q8IUF8 2xdv.pdb1 100 7707 2.57 
P30038 1uzb.pdb1 110 4947 1.4 
P15121 2hdj.pdb3 20 1715 2 
Q9NWT6 1h2k.pdb1 45 1192 2.15 
P68104 1ije.pdb1 109 4440 2.4 
P11926 7odc.pdb1 62 4099 1.6 
P27361 3e7o.pdb1 63 3932 2.14 
P28838 2ewb.pdb1 102 6746 1.85 
P13489 1a4y.pdb1 84 2211 2 
Q13303 1exb.pdb1 13 867 2.1 
P14091 2iko.pdb1 28 11516 1.9 
P30520 1j4b.pdb1 84 5352 2.5 
Q8N142 1j4b.pdb1 84 5352 2.5 
P22695 1sqb.pdb1 61 2312 2.69 
O75390 1cts.pdb1 92 6858 2.7 
P17987 1a6d.pdb1 142 8875 2.6 
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P15169 1qmu.pdb1 28 1962 2.7 
P00395 1v54.pdb1 66 1131 1.8 
P29622 1oph.pdb2 45 2789 2.3 
P20839 1jcn.pdb1 74 5022 2.5 
Q9Y230 2c9o.pdb1 97 7912 2.2 
Q9Y265 2c9o.pdb1 97 7912 2.2 
P53778 3e7o.pdb1 50 3206 2.14 
Q15759 3e7o.pdb1 50 3206 2.14 
P05166 1xnv.pdb1 115 13026 2.3 
P31939 1p4r.pdb1 158 3946 2.55 
P31930 1pp9.pdb1 67 1924 2.1 
P49748 3b96.pdb1 180 10284 1.91 
P53602 3d4j.pdb1 30 869 2.4 
O15533 3f8u.pdb3 52 2325 2.6 
Q96QU6 1b8g.pdb1 69 1811 2.37 
Q96KN2 3dlj.pdb3 99 2502 2.26 
P50990 1a6d.pdb1 129 7903 2.6 
P29460 3duh.pdb1 20 526 2.3 
P00558 2cun.pdb1 30 1060 2.1 
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P51817 3a8w.pdb3 23 835 2.1 
P48637 2hgs.pdb1 98 5371 2.1 
P07205 2cun.pdb1 30 1100 2.1 
P05062 1fdj.pdb1 26 937 2.1 
P01011 1oph.pdb1 26 1515 2.3 
P10619 1ivy.pdb1 55 1522 2.2 
P49841 1j1b.pdb1 39 1574 1.8 
Q9BYC2 1m3e.pdb2 74 2476 2.5 
O94810 2pbi.pdb2 101 4183 1.95 
P49758 2pbi.pdb2 101 4183 1.95 
Q15120 3crk.pdb1 26 1261 2.3 
P07093 1k9o.pdb1 17 633 2.3 
P30740 1k9o.pdb1 17 633 2.3 
Q99574 1k9o.pdb1 17 633 2.3 
P27338 2z5x.pdb2 118 6726 2.2 
Q03426 2r3v.pdb6 24 716 2.5 
P45984 3e7o.pdb1 17 1497 2.14 
Q13882 1k9a.pdb7 87 5516 2.5 
P19971 2wk6.pdb1 37 1361 2.5 
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O75879 3h0l.pdb5 34 564 2.3 
P50395 1ukv.pdb1 47 1719 1.5 
O00629 1wa5.pdb1 55 2797 2 
P21397 2z5x.pdb2 107 5921 2.2 
P14868 1eov.pdb1 116 7782 2.3 
P23141 2h7c.pdb1 74 2591 2 
P41240 1k9a.pdb7 73 4716 2.5 
P23368 1gq2.pdb3 100 3562 2.5 
P15289 1n2k.pdb1 38 2225 2.75 
P05546 1jmo.pdb1 37 1681 2.2 
P42679 1k9a.pdb7 66 4987 2.5 
P00156 1pp9.pdb1 27 669 2.1 
Q9UBT2 3kyc.pdb1 112 3852 2.45 
P07686 1o7a.pdb1 36 1328 2.25 
P16118 1k6m.pdb2 53 3686 2.4 
Q15172 3fga.pdb1 13 638 2.7 
P11413 2bh9.pdb1 79 6531 2.5 
P49902 2jc9.pdb1 51 4237 1.5 
P31040 1zoy.pdb1 97 2082 2.4 
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Q16222 1jvd.pdb1 63 2718 2.4 
Q9NRF8 1vco.pdb1 64 4532 2.15 
P22303 3bix.pdb2 73 2793 1.8 
P17812 1vco.pdb1 62 4441 2.15 
P30101 3f8u.pdb1 56 3273 2.6 
P06276 3bix.pdb1 72 3882 1.8 
Q16526 1tez.pdb4 36 1796 1.8 
P02774 1lot.pdb1 48 1426 2.5 
P08236 1bhg.pdb1 117 7764 2.53 
Q13614 1m7r.pdb1 21 1015 2.6 
P08107 2qxl.pdb1 140 7759 2.41 
P34947 2acx.pdb1 43 1510 2.6 
P43250 2acx.pdb1 43 1510 2.6 
P23219 1q4g.pdb1 62 1628 2 
P36871 1c47.pdb1 18 782 2.7 
P02786 3kas.pdb1 64 4729 2.4 
Q92696 1dce.pdb2 69 2726 2 
Q15835 3c4w.pdb1 27 1362 2.7 
P23921 2wgh.pdb1 37 1652 2.3 
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P27487 1r9m.pdb3 140 6767 2.1 
Q12884 1r9m.pdb3 139 6632 2.1 
P30153 2ie4.pdb1 27 944 2.6 
P06737 1fa9.pdb1 174 13916 2.4 
P07384 1kfu.pdb1 141 4749 2.5 
P17655 1kfu.pdb1 141 4749 2.5 
P00488 1evu.pdb1 79 3007 2.01 
P22033 3bic.pdb3 82 2360 2.6 
P21980 1l9m.pdb1 39 2410 2.1 
P00751 3hrz.pdb1 67 2860 2.2 
P06681 3hrz.pdb1 67 2860 2.2 
Q15436 2qtv.pdb1 59 2483 2.5 
Q9ULD0 2jgd.pdb1 78 1993 2.6 
Q15437 2qtv.pdb1 41 1178 2.5 
Q09161 1n52.pdb1 49 1801 2.11 
Q14974 1qgk.pdb1 136 6419 2.5 
P55060 1wa5.pdb1 115 4765 2 
P43246 2o8b.pdb1 77 3307 2.75 
O14980 3gjx.pdb1 130 4684 2.5 
209 
 
 
P14735 2g54.pdb1 42 904 2.25 
A0AVT1 3cmm.pdb2 53 1872 2.7 
P22314 3cmm.pdb2 53 1872 2.7 
P41226 3cmm.pdb2 53 1872 2.7 
P16615 1wpg.pdb1 15 1277 2.3 
O14983 1wpg.pdb1 15 1212 2.3 
 
